10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from  to

Commission file number 000-56021

ACREAGE HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada			98-1463868
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)
366 Madison Ave, 14th floor	New York	New York	10017
(Address of Principal Executive Offices)			(Zip Code)

(646) 600-9181

Registrant’s telephone number, including area code

Securities registered pursuant to Section 12(b) of the Act: None.

Securities registered pursuant to section 12(g) of the Act: Class D Subordinate Voting Shares, no par value; Class E Subordinate Voting Shares, no par value.

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes  x   No  o 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	☒
Non-accelerated filer	o	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes ☐   No  x

The Company has three classes of issued and outstanding shares: the Class E subordinate voting shares (the “Fixed Shares”), the Class D subordinate voting shares (the “Floating Shares”) and the Class F multiple voting shares (the “Fixed Multiple Shares”). The Fixed Shares and Floating Shares each entitle the holders to notice of and to attend at any meeting of the shareholders of the Company, except a meeting of which only holders of another particular class or series of shares of the Company have the right to vote. Each Fixed Share is entitled to one vote per Fixed Share, each Floating Share is entitled to one vote per Floating Share and each Fixed Multiple Share is entitled to 4,300 votes per Fixed Multiple Share on all matters upon which the holders of shares are entitled to vote. As of November 2, 2023, there were 80,682,114 Fixed shares, 36,019,462 Floating Shares, and 117,600 Fixed Multiple Shares, in each case, issued and outstanding.

TABLE OF CONTENTS

Acreage Holdings, Inc.

Form 10-Q

For the Three and Nine Months Ended September 30, 2023

PART I	Financial Information
Item 1.	Unaudited Condensed Consolidated Statements of Financial Position as of September 30, 2023 (unaudited) and December 31, 2022 (audited)	1
	Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022	2
	Unaudited Condensed Consolidated Statements of Shareholders’ Equity for the three and nine months ended September 30, 2023 and 2022	3
	Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022	5
	Notes to the Unaudited Condensed Consolidated Financial Statements	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	42
Item 4.	Controls and Procedures	42
PART II	Other Information
Item 1.	Legal Proceedings	44
Item 1A.	Risk Factors	44
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	44
Item 3.	Defaults Upon Senior Securities	44
Item 4.	Mine Safety Disclosures	44
Item 5.	Other Information	44
Item 6.	Exhibits	45
	SIGNATURES	46

PART I

Item 1. Financial Statements and Supplementary Data.

ACREAGE HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(in thousands)	September 30, 2023		December 31, 2022
	(unaudited)		(audited)
ASSETS
Cash and cash equivalents	$	15,142	$	24,067
Restricted cash	9,651		—
Accounts receivable, net	8,242		10,512
Inventory	51,050		49,446
Notes receivable, net	—		29,191
Other current assets	5,594		4,977
Total current assets	89,679		118,193
Long-term investments	33,176		34,046
Capital assets, net	136,866		133,405
Operating lease right-of-use assets	18,699		22,443
Intangible assets, net	35,124		35,124
Goodwill	38,721		13,761
Other non-current assets	3,519		3,601
Total non-current assets	266,105		242,380
TOTAL ASSETS	$	355,784	$	360,573
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable and accrued liabilities	$	35,431	$	29,566
Taxes payable	40,445		24,226
Interest payable	5,676		2,575
Operating lease liability, current	2,535		2,443
Debt, current	3,336		1,584
Other current liabilities	9,244		11,939
Total current liabilities	96,667		72,333
Debt, non-current	231,402		213,496
Operating lease liability, non-current	18,298		21,692
Deferred tax liability	10,654		9,623
Other liabilities	2,961		3,250
Total non-current liabilities	263,315		248,061
TOTAL LIABILITIES	359,982		320,394
Commitments and contingencies
Common stock, no par value - unlimited authorized, 115,965 and 112,437 issued and outstanding, respectively	—		—
Additional paid-in capital	758,918		760,529
Treasury stock, 842 common stock held in treasury	(21,054)		(21,054)
Accumulated deficit	(716,829)		(678,091)
Total Acreage Shareholders' equity	21,035		61,384
Non-controlling interests	(25,233)		(21,205)
TOTAL EQUITY (DEFICIT)	(4,198)		40,179
TOTAL LIABILITIES AND EQUITY	$	355,784	$	360,573

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

F-1

ACREAGE HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended September 30,				Nine Months Ended September 30,
(in thousands, except per share amounts)	2023		2022		2023		2022
REVENUE
Retail revenue, net	$	43,857	$	48,314	$	130,651	$	136,426
Wholesale revenue, net	12,645		12,810		39,845		42,342
Other revenue, net	—		295		84		881
Total revenues, net	56,502		61,419		170,580		179,649
Cost of goods sold, retail	(23,247)		(26,097)		(67,145)		(70,331)
Cost of goods sold, wholesale	(11,981)		(14,096)		(34,454)		(27,968)
Total cost of goods sold	(35,228)		(40,193)		(101,599)		(98,299)
Gross profit	21,274		21,226		68,981		81,350
OPERATING EXPENSES
General and administrative	8,036		9,727		25,621		27,036
Compensation expense	13,524		15,271		38,930		42,045
Equity-based compensation expense	745		3,156		2,423		8,970
Marketing	542		735		1,942		2,396
Impairments, net	—		506		—		2,973
Loss on notes receivable	—		7,219		—		7,219
Write down of assets held-for-sale	—		—		3,557		874
Legal recoveries	—		—		—		(335)
Depreciation and amortization	928		1,047		2,919		6,019
Total operating expenses	23,775		37,661		75,392		97,197
Net operating loss	$	(2,501)	$	(16,435)	$	(6,411)	$	(15,847)
Income from investments, net	248		17		228		154
Interest income from loans receivable	—		474		10		1,256
Interest expense	(9,207)		(5,688)		(26,143)		(15,989)
Other income, net	10,021		4,743		9,823		5,019
Total other income (loss)	1,062		(454)		(16,082)		(9,560)
Loss before income taxes	$	(1,439)	$	(16,889)	$	(22,493)	$	(25,407)
Income tax expense	(6,420)		(8,109)		(19,763)		(24,105)
Net loss	$	(7,859)	$	(24,998)	$	(42,256)	$	(49,512)
Less: net loss attributable to non-controlling interests	(234)		(2,784)		(3,885)		(4,675)
Net loss attributable to Acreage Holdings, Inc.	$	(7,625)	$	(22,214)	$	(38,371)	$	(44,837)
Net loss per share attributable to Acreage Holdings, Inc. - basic and diluted:	$	(0.07)	$	(0.20)	$	(0.34)	$	(0.41)
Weighted average shares outstanding - basic and diluted	114,171		111,200		113,181		108,795

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

F-2

ACREAGE HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

			Attributable to shareholders of the parent
(in thousands)	LLC Membership Units	Pubco Shares (as converted)	Share Capital		Treasury Stock		Accumulated Deficit		Shareholders’ Equity		Non-controlling Interests		Total Equity
December 31, 2021	3,861	106,903	$	756,536	$	(21,054)	$	(538,215)	$	197,267	$	7,003	$	204,270
NCI adjustments for changes in ownership	—	—	5		—		—		5		(5)		—
Equity-based compensation expense and related issuances	—	508	4,159		—		—		4,159		—		4,159
Net loss	—	—	—		—		(12,694)		(12,694)		(1,217)		(13,911)
March 31, 2022	3,861	107,411	$	760,700	$	(21,054)	$	(550,909)	$	188,737	$	5,781	$	194,518
NCI adjustments for changes in ownership	—	—	(4,524)		—		—		(4,524)		4,524		—
Capital distributions, net	—	—	—		—		—		—		(5,534)		(5,534)
Equity-based compensation expense and related issuances	—	1,778	1,655		—		—		1,655		—		1,655
Net loss	—	—	—		—		(9,929)		(9,929)		(674)		(10,603)
June 30, 2022	3,861	109,189	$	757,831	$	(21,054)	$	(560,838)	$	175,939	$	4,097	$	180,036
NCI adjustments for changes in ownership	—	—	697		—		—		697		(697)		—
Other equity transactions	—	378	—		—		—		—		—		—
Equity-based compensation expense and related issuances	—	2,580	3,156		—		—		3,156		—		3,156
Net loss	—	—	—		—		(22,214)		(22,214)		(2,784)		(24,998)
September 30, 2022	3,861	112,147	$	761,684	$	(21,054)	$	(583,052)	$	157,578	$	616	$	158,194

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

F-3

ACREAGE HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

			Attributable to shareholders of the parent
(in thousands)	LLC Membership Units	Pubco Shares (as converted)	Share Capital		Treasury Stock		Accumulated Deficit		Shareholders’ Equity		Non-controlling Interests		Total Equity (Deficit)
December 31, 2022	3,861	112,437	$	760,529	$	(21,054)	$	(678,091)	$	61,384	$	(21,205)	$	40,179
Cumulative effect of change in accounting principle for current expected credit losses, net of tax	—	—			—		(367)		(367)		—		(367)
NCI adjustments for changes in ownership	—	—	14		—		—		14		(14)		—
Equity-based compensation expense and related issuances	—	287	984		—		—		984		—		984
Net loss	—	—	—		—		(14,590)		(14,590)		(1,567)		(16,157)
March 31, 2023	3,861	112,724	$	761,527	$	(21,054)	$	(693,048)	$	47,425	$	(22,786)	$	24,639
NCI adjustments for changes in ownership	—	—	(3,389)		—		—		(3,389)		3,389		—
Capital distributions, net	—	—	—		—		—		—		(3,968)		(3,968)
Other equity transactions	—	—	(130)		—		—		(130)		—		(130)
Equity-based compensation expense and related issuances	—	479	694		—		—		694		—		694
Net loss	—	—	—		—		(16,156)		(16,156)		(2,084)		(18,240)
June 30, 2023	3,861	113,203	$	758,702	$	(21,054)	$	(709,204)	$	28,444	$	(25,449)	$	2,995
NCI adjustments for changes in ownership	—	—	(450)		—		—		(450)		450		—
Other equity transactions	—	—	(79)		—		—		(79)		—		(79)
Equity-based compensation expense and related issuances	—	2,762	745		—		—		745		—		745
Net loss	—	—	—		—		(7,625)		(7,625)		(234)		(7,859)
September 30, 2023	3,861	115,965	$	758,918	$	(21,054)	$	(716,829)	$	21,035	$	(25,233)	$	(4,198)

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

F-4

ACREAGE HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended September 30,
(in thousands)	2023		2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(42,256)	$	(49,512)
Adjustments for:
Depreciation and amortization	2,919		6,019
Depreciation and amortization included in COGS	6,058		4,840
Equity-based compensation expense	2,423		8,970
Inventory write-off and provision	8,824		6,286		(1)
Gain on business divestiture	(47)		(3,490)
Loss on disposal of capital assets	34		49
Loss on impairment	—		2,973
Loss on notes receivable	—		7,219
Recovery on notes receivable	—		(1,107)
Bad debt expense	320		22
Non-cash interest expense	3,743		2,301
Non-cash operating lease expense (income)	(18)		223
(Gain) Loss on lease termination	(200)		297
Deferred tax (income) expense	16		(889)
Non-cash loss from investments, net	870		895
Write-down of assets held-for-sale	3,557		874
Change, net of acquisitions in:
Accounts receivable, net	(3,427)		(2,787)
Inventory	(12,572)		(15,001)		(1)
Other assets	(597)		(1,240)
Interest receivable	(756)		(1,125)
Accounts payable and accrued liabilities	(2,628)		(279)
Taxes payable	15,026		4,668
Interest payable	3,101		(265)
Other liabilities	(3,119)		(414)
Net cash used in operating activities	$	(18,729)	$	(30,473)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of capital assets	$	(5,345)	$	(12,582)
Collection of notes receivable	2,150		7,106
Business acquisitions, net of cash acquired	516		—
Purchases of intangible assets	(27)		(900)
Distributions from investments	—		1,048
Cash paid for short-term investment	—		(3,400)
Proceeds from disposal of short-term investments	—		3,400
Proceeds from business divestiture	500		—
Net cash used in investing activities	$	(2,206)	$	(5,328)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds (payments) from equity transactions	(79)		—
Proceeds from financing (refer to Note 14 for related party financing)	$	27,121	$	25,000
Deferred financing costs paid	(500)		(511)
Repayment of debt	(913)		(1,084)

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

F-5

ACREAGE HOLDINGS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Capital distributions - non-controlling interests	(3,968)		(5,534)
Net cash provided by financing activities	$	21,661	$	17,871
Net increase (decrease) in cash, cash equivalents, restricted cash, and cash held for sale	$	726	$	(17,930)
Cash, cash equivalents, and restricted cash - Beginning of period	24,067		44,501
Cash, cash equivalents, and restricted cash - End of period	$	24,793	$	26,571
RECONCILIATION OF CASH FLOW INFORMATION:
Cash and cash equivalents	$	15,142	$	26,476
Restricted cash	9,651		95
Total cash, cash equivalents, restricted cash, and cash held for sale at end of period	$	24,793	$	26,571

[1]Presentation of September 30, 2022 figures have been revised, refer to Note 2 for further discussion.

	Nine Months Ended September 30,
(in thousands)	2023		2022
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid - non-lease	$	19,266	$	12,730
Income taxes paid	5,933		21,742
OTHER NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capital assets not yet paid for	$	5,040	$	6,242
Non-cash proceeds from business divestiture	—		7,850
Non-cash proceeds from finance lease	—		5,785
Cumulative effect of change in accounting principle for current expected credit losses, net of tax	121		—
NCI adjustments for changes in ownership	(14)		—

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements

F-6

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

1.    NATURE OF OPERATIONS

Acreage Holdings, Inc. (the “Company”, “Pubco” or “Acreage”) is a vertically integrated, multi-state operator in the United States (“U.S.”) cannabis industry. The Company’s operations include (i) cultivating and processing cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing cannabis products to patients and consumers. The Company’s products appeal to medical and adult recreational use customers through brand strategies intended to build trust and loyalty.

The Company’s Class E subordinate voting shares (“Fixed Shares”) and Class D subordinate voting shares (“Floating Shares”) are listed on the Canadian Securities Exchange under the symbols “ACRG.A.U” and “ACRG.B.U”, respectively, quoted on the OTCQX under the symbols “ACRHF” and “ACRDF”, respectively, and traded on the Frankfurt Stock Exchange under the symbols “0VZ1” and “0VZ2”, respectively.

High Street Capital Partners, LLC (“HSCP”) was formed on April 29, 2014. The Company became the indirect parent of HSCP on November 14, 2018 in connection with the reverse takeover (“RTO”) transaction described below.

The Company’s principal place of business is located at 366 Madison Ave, 14th floor, New York, New York in the U.S. The Company’s registered and records office address is Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia in Canada.

The RTO transaction

On September 21, 2018, the Company, HSCP, HSCP Merger Corp. (a wholly-owned subsidiary of the Company), Acreage Finco B.C. Ltd. (a special purpose corporation) (“Finco”), Acreage Holdings America, Inc. (“USCo”) and Acreage Holdings WC, Inc. (“USCo2”) entered into a business combination agreement (the “Business Combination Agreement”) whereby the parties thereto agreed to combine their respective businesses, which would result in the RTO of Pubco by the security holders of HSCP, which was deemed to be the accounting acquiror. On November 14, 2018, the parties to the Business Combination Agreement completed the RTO.

Canopy Growth Corporation transaction

On June 27, 2019, the Company and Canopy Growth Corporation (“Canopy Growth” or “CGC”) implemented the Prior Plan of Arrangement (as defined in Note 13) contemplated by the Original Arrangement Agreement (as defined in Note 13). Pursuant to the Prior Plan of Arrangement, Canopy Growth was granted an option to acquire all of the issued and outstanding shares of the Company in exchange for the payment of 0.5818 of a common share in the capital of Canopy Growth for each Class A subordinate voting share (each, a “SVS”) held (with the Class B proportionate voting shares (the “PVS”) and Class C multiple voting shares (the “MVS”) being automatically converted to SVS immediately prior to consummation of the Acquisition (as defined in Note 13), which original exchange ratio was subject to adjustment in accordance with the Original Arrangement Agreement. Canopy Growth was required to exercise the option upon a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and, subject to the satisfaction or waiver of certain closing conditions set out in the Original Arrangement Agreement, Canopy Growth was required to acquire all of the issued and outstanding SVS (following the mandatory conversion of the PVS and MVS into SVS).

On June 24, 2020, Canopy Growth and the Company entered into an agreement to, among other things, amend the terms of the Original Arrangement Agreement and the terms of the Prior Plan of Arrangement (the “Amended Arrangement”). On September 16, 2020, the Company’s shareholders voted in favor of a special resolution authorizing and approving the terms of, among other things, the Amended Arrangement. Subsequently, on September 18, 2020, the Company obtained a final order from the Supreme Court of British Columbia approving the Amended Arrangement, and on September 23, 2020 the Company and Canopy Growth entered into the Amending Agreement (as defined in Note 13) and implemented the Amended Arrangement. Pursuant to the Amended Arrangement, the Company’s articles were amended to create the Fixed Shares, the Floating Shares and the Class F multiple voting shares (the “Fixed Multiple Shares”), and each outstanding SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share, each outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and each outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share. Pursuant to the Amended Arrangement, Canopy Growth was granted the option to acquire all of the issued and outstanding Fixed Shares on the basis of 0.3048 (the “Fixed Exchange Ratio”) of a common share of Canopy Growth (each, a “Canopy Share”) for each Fixed Share held at the time of the acquisition of the Fixed Shares (the “Acquisition” or “Acquisition Time”), subject to adjustment in accordance with the terms of the Amended Arrangement (the “Canopy Call Option”), which Canopy Growth is

F-7

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

required to exercise upon the occurrence, or waiver (at the discretion of Canopy Growth), of a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event” and the date on which the Triggering Event occurs, the “Triggering Event Date”). Refer to Note 13 for further discussion.

Pursuant to the implementation of the Amended Arrangement, on September 23, 2020, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 to Universal Hemp, LLC, an affiliate of the Company. The debenture bears interest at a rate of 6.1% per annum. Refer to Note 10 for further discussion.

On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. On March 15, 2023, the Company received the required approval of the holders of Floating Shares in connection with the Floating Share Arrangement at its special meeting of holders of Floating Shares. On March 21, 2023, the Corporation obtained a final order form from the Supreme Court of British Columbia approving the Floating Share Arrangement. Upon the satisfaction or waiver of all other conditions set out in the Floating Share Arrangement Agreement, which the parties continue to work towards, the parties will complete the Floating Share Arrangement. Refer to Note 13 for further discussion.

2.    SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and going concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other period.

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of September 30, 2023, as well as a net loss and negative cash flow from operating activities for the nine months ended September 30, 2023. Additionally, subsequent to quarter end the Company was temporarily in default of the Universal Hemp 6.1% Loan. Refer to Note 10 for further discussion. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, and (iv) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company’s need to raise additional capital on an immediate basis.

These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023, as filed with the Securities and Exchange Commission (the “2022 Form 10-K”).

F-8

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Use of estimates

Preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the dates presented and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include the fair value of assets acquired and liabilities assumed in business combinations, assumptions relating to equity-based compensation expense, estimated useful lives for property, plant and equipment and intangible assets, the valuation allowance against deferred tax assets and the assessment of potential charges on goodwill, intangible assets and investments in equity and notes receivable.

Emerging growth company

The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.

Functional and presentation currency

The unaudited condensed consolidated financial statements and the accompanying notes are expressed in U.S. dollars. Financial metrics are presented in thousands. Other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.

Basis of consolidation

The Company’s unaudited condensed consolidated financial statements include the accounts of Acreage, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in business entities in which Acreage lacks control but is able to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations.

Non-controlling interests (“NCI”)

Non-controlling interests represent ownership interests in consolidated subsidiaries by parties that are not shareholders of Pubco. They are shown as a component of Total equity in the Unaudited Condensed Consolidated Statements of Financial Position, and the share of loss attributable to non-controlling interests is shown as a component of Net loss in the Unaudited Condensed Consolidated Statements of Operations. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.

Cash and cash equivalents

The Company defines cash equivalents as highly liquid investments held for the purpose of meeting short-term cash commitments that are readily convertible into known amounts of cash, with original maturities of three months or less. The Company maintains cash with various U.S. banks and credit unions with balances in excess of the Federal Deposit Insurance Corporation and National Credit Union Share Insurance Fund limits, respectively. The failure of a bank or credit union where the Company has significant deposits could result in a loss of a portion of such cash balances in excess of the insured limit, which could materially and adversely affect the Company’s business, financial condition, results of operations and the market price of the Company’s Fixed Shares and Floating Shares. Cash and cash equivalents belonging to entities the Company has classified as held-for-sale have been reclassified to Assets held-for-sale on the Unaudited Condensed Consolidated Statements of Financial Position. Refer to Note 3 for further discussion.

Restricted cash

Restricted cash represents funds contractually held for specific purposes and, as such, not available for general corporate purposes.

Cash and restricted cash, as presented on the Unaudited Condensed Consolidated Statements of Cash Flows, consists of $15,142 and $9,651 as of September 30, 2023, respectively, and $26,476 and $95 as of September 30, 2022, respectively.

F-9

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Accounts receivable and notes receivable valuations

The Company reports accounts receivable at their net realizable value, which is management’s best estimate of the cash that will ultimately be received from customers. The Company's notes receivable represent notes due from various third parties. The Company maintains an allowance for expected credit losses to reflect the expected uncollectability of accounts receivable and notes receivable based on historical collection data and specific risks identified among uncollected accounts, as well as management’s expectation of future economic conditions. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the companies receivables and the expected future losses. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Trade accounts receivable and notes receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. As of September 30, 2023 and December 31, 2022, the Company’s allowance for doubtful accounts was $339 and $953, respectively, all of which relates to the allowance for credit losses over accounts receivable. As of September 30, 2023 and December 31, 2022, the allowance on loans receivable was $15,340 and $14,875, respectively, of which the allowance for credit losses over notes receivable was nil as the receivables were fully reserved for. Refer to Note 6 for further discussion.

Net loss per share

Net loss per share represents the net loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis. Basic and diluted loss per share are the same as of September 30, 2023 and 2022 as the issuance of shares upon conversion, exercise or vesting of outstanding units would be anti-dilutive in each period. There were 51,006 and 47,999 anti-dilutive shares outstanding as of September 30, 2023 and 2022, respectively.

Change in presentation

Note that certain items presented on the nine months ended September 30, 2022, Unaudited Condensed Consolidated Statement of Cash Flows, includes a change in presentation to conform to the current year presentation. There was no impact to our Consolidated Financial Statements as a result of this reclassification.

Accounting Pronouncements Recently Adopted

As of January 1, 2023, the Company adopted Accounting Standards Update (“ASU”) 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which was subsequently revised by ASU 2018-19 and ASU 2020-02. This standard applies to financial assets, measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases and trade accounts receivable. The guidance must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The adoption of ASU 2016-13 did not have a material effect on the Company’s unaudited condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08 - Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The new standard requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers. The ASU will be effective for the Company’s first interim period of fiscal 2024. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company does not anticipate a material impact on the Company’s unaudited condensed consolidated financial statements upon adoption.

3.    ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE

Acquisitions

On January 2, 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine. Under the terms of the agreement, the consideration paid consisted of the settlement of a pre-existing relationship, which included a line-of credit, other advances and the related interest receivable, all totaling $25,160, which were previously recorded in Notes receivable, net on the Statements of Financial Position.

F-10

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

The purchase price allocation is based upon preliminary valuations, estimates and assumptions which are subject to change within the measurement period, generally one year from the acquisition date. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the capital assets, tangible assets acquired and the residual goodwill resulting from the transaction.

Purchase Price Allocation	Northeast Patients Group
Assets acquired:
Cash and cash equivalents	$	361
Accounts Receivable	25
Inventory	384
Other current assets	173
Capital assets	2,377
Financing lease right-of-use asset	416
Operating lease right-of-use asset	1,279
Goodwill	24,960
Liabilities assumed:
Accounts payable and accrued liabilities	(672)
Taxes payable	(1,112)
Finance lease liability, current	(87)
Finance lease liability, non-current	(459)
Operating lease liability, current	(73)
Operating lease liability, non-current	(1,385)
Notes payable	(11)
Deferred tax liability	(1,016)
Fair value of net assets acquired	$	25,160
Consideration paid:
Settlement of pre-existing relationship	25,160
Total consideration	$	25,160

During the year ended December 31, 2022, the Company did not complete any business acquisitions.

Divestitures

During the three and nine months ended September 30, 2023 management committed to a plan to sell CWG Botanicals, Inc. (“CWG”) as of June 30, 2023. At this point all assets and liabilities were classified as held for sale on the balance sheet and written down to the fair value of the expected sale price. On September 12, 2023 the company effectively sold 100% of its ownership interest in CWG for an aggregate sales price of $500 and recognizing a gain of $47 on the Unaudited Condensed Consolidated Statements of Operations in Other income, net.

During the three and nine months ended September 30, 2022, the Company completed the divestitures of six properties as outlined in the following paragraphs. In February 2021, a subsidiary of the Company entered into a definitive agreement and management services agreement to sell an indoor cultivation facility in Medford, Oregon ("Medford"), and a retail dispensary in Powell, Oregon ("Powell"), for total consideration of $3,000. In March 2022, the total consideration was reduced to $2,000. In April 2022, the Company sold all equity interests in Medford for an aggregate sale price of $2,000 and recognized a gain on sale of $290 for the nine months ended September 30, 2022 which was recorded in Other income, net in the Unaudited Condensed Consolidated Statements of Operations. The aggregate sales price consisted of $750 paid to the Company in February 2021 and $1,250 of promissory notes (refer to Note 6 for further discussion). In conjunction with the sale, the Company closed its dispensary in Powell. Further, the Company derecognized deferred tax liabilities of $375 related to Medford.

F-11

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

In September 2021, a subsidiary of the Company entered into a definitive agreement and management services agreements to sell, upon regulatory approval, four retail dispensaries in Oregon for total consideration of $6,500. In July 2022, the Company executed and closed an amendment to its previously announced asset purchase and services agreement for the sale of its four Oregon retail dispensaries (the “Amended Agreement”). Under the terms of the Amended Agreement, the sale price was reduced to $6,200 and the Company recognized a gain on sale of $3,189 for the nine months ended September 30, 2022 which was recorded in Other income, net in the Unaudited Condensed Consolidated Statements of Operations. The aggregate sales price consisted of a $250 payment previously made at the signing of the Original Agreement, plus an additional $100 in cash at closing. The remaining amount of $5,850 has been satisfied by a 36-month secured promissory note bearing interest at a rate of 12% per annum (the “Note”). Under the terms of the Note, quarterly interest payments commence on January 1, 2023, principal payments of $1,000 are due on January 1, 2024 and January 1, 2025, and the remaining principal is due on January 1, 2026.

Assets Held for Sale

The Company determined certain businesses and assets met the held-for-sale criteria. As such, the related assets and liabilities within these disposal groups were transferred into Assets held-for-sale and Liabilities related to assets held for sale on the Unaudited Condensed Consolidated Statements of Financial Position. As of September 30, 2023 and December 31, 2022, the Company did not have any business or assets that met the held-for-sale criteria.

Previously, the Company determined certain businesses and assets met the held-for-sale criteria. Upon classification of the disposal groups as held for sale, the Company tested each disposal group for impairment and recognized charges of $— and $3,557 within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations related to CWG for three and nine months ended September 30, 2023, respectively.

During the three and nine months ended September 30, 2022, the Company recognized a write down of assets held-for-sale of $— and $874 related to its Oregon operations within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations.

4.    INTANGIBLE ASSETS AND GOODWILL

Intangible assets

The following table details the intangible asset balances by major asset classes:

Intangibles	September 30, 2023		December 31, 2022
Finite-lived intangible assets:
Customer relationships	—		1,000
Total finite-lived intangible assets	—		1,000
Accumulated amortization on finite-lived intangible assets:
Customer relationships	—		(1,000)
Total accumulated amortization on finite-lived intangible assets	—		(1,000)
Finite-lived intangible assets, net	—		—
Indefinite-lived intangible assets
Cannabis licenses	35,124		35,124
Total intangibles, net	$	35,124	$	35,124

During the year ended December 31, 2022, the Company amended the purchase price allocation related to its acquisition of certain Ohio operations based upon final valuations within the measurement period. As a result, $17,000 was re-allocated from Goodwill to Intangible assets, net on the Unaudited Condensed Consolidated Statements of Financial Position.

There was no amortization expense recorded for the three and nine months ended September 30, 2023, respectively. Amortization expense associated with the Company’s intangible assets was $296 and $1,288 for the three and nine months ended September 30, 2022, respectively.

F-12

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Goodwill

The following table details the changes in the carrying amount of goodwill:

Goodwill	Total
December 31, 2022	$	13,761
Acquisitions	24,960
September 30, 2023	$	38,721

During the nine months ended September 30, 2023, the Company recognized $24,960 of goodwill based on the preliminary purchase price allocation related to the acquisition of Northeast Patients Group. Refer to Note 3 for further discussion.

5.    INVESTMENTS

The carrying values of the Company’s investments in the Unaudited Condensed Consolidated Statements of Financial Position as of September 30, 2023 and December 31, 2022 are as follows:

Investments	September 30, 2023		December 31, 2022
Investments held at FV-NI	$	33,176	$	34,046
Total long-term investments	$	33,176	$	34,046

Income from investments, net in the Unaudited Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2023 and 2022 is as follows:

Investment income	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Short-term investments	$	—	$	1	$	—	$	4
Investments held at FV-NI	248		16		228		150
Income from investments, net	$	248	$	17	$	228	$	154

Investments held at FV-NI

The Company has investments in equity of other companies that do not result in significant influence or control. These investments are carried at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.

As further described under the “6.10% Secured debenture due September 2030” in Note 10, on September 23, 2020, a subsidiary of the Company, Universal Hemp, LLC ("Universal Hemp"), was advanced gross proceeds of $50,000 (less transaction costs) pursuant to the terms of a secured debenture. The Company subsequently engaged an investment advisor, which under the investment advisor's sole discretion, on September 28, 2020 invested $34,019 of these proceeds on behalf of Universal Hemp. As a result, Universal Hemp acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the institutional investor holds Class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The Class B units are held by the Investment Advisor as an agent for Universal Hemp.

Universal Hemp, through its investment with the Investment Advisor, was originally determined to hold significant influence in the Investment Partnership in accordance with ASC 810 - Consolidations due to (1) the economic financial interest, and (2) the entitlement to matters as they pertain to ‘Extraordinary Resolution’ items as defined within the Investment Partnership Agreement. As a result, the Company accounted for the investment in the Investment Partnership under the equity method until December 2020. Refer to Note 10 for further discussion. In December 2020, the Company no longer held significant influence due to the removal of the Extraordinary Resolution entitlements and other revisions in the Investment Partnership Agreement. As a result, the Company changed its accounting for the Investment Partnership to recognize the investment at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.

F-13

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

6.     NOTES RECEIVABLE, NET

Notes receivable as of September 30, 2023 and December 31, 2022 consisted of the following:

	September 30, 2023		December 31, 2022
Promissory notes receivable	$	7,062	$	34,088
Line of credit receivable	4,331		5,831
Interest receivable	3,947		4,147
Allowance for notes and interest receivable	(15,340)		(14,875)
Total notes receivable, net	$	—	$	29,191
Less: Notes receivable, current	—		29,191
Notes receivable, non-current	$	—	$	—

Interest income from loans receivable during the three and nine months ended September 30, 2023 was $— and $10, respectively, and during the three and nine months ended September 30, 2022 was $474 and $1,256, respectively.

At each reporting date, the Company applies its judgment to evaluate the collectability of the note receivable and makes a provision based on the assessed amount of expected credit loss. This judgment is based on parameters such as interest rates, market conditions and creditworthiness of the creditor.

The Company determined that the collectability of certain notes receivables is doubtful based on information available. As of September 30, 2023 and December 31, 2022, the Company’s allowance for notes receivable of $15,340 and $14,875, respectively, included $11,393 and $12,041 of principal outstanding and $3,947 and $2,834 of accrued interest, respectively, and represents the full value of such loan balances.

Activity during the nine months ended September 30, 2023

In January 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine and the amounts outstanding under the promissory notes receivable were converted into equity in Northeast Patients Group. Refer to Note 3 for further discussion.

In April 2023, the Company’s subsidiary Prime Alternative Treatment Center Consulting, LLC (“NH-PATCC”) received $1,500 from Prime Alternative Treatment Center, Inc. (“PATC”) in settlement of the principal balance related to a promissory note that was extended to “PATC”.

In May 2023, the Company received a $500 cash payment towards the principal balance on a promissory note receivable from Grown Rogue.

In August 2023, the Company received a $150 cash payment towards the principal balance on a promissory note receivable from Grown Rogue.

Activity during the nine months ended September 30, 2022

In February 2022, the Company received a $5,279 cash payment in full on a line of credit due from Patient Centric Martha’s Vineyard, and subsequently closed the line of credit.

In April 2022, the Company executed and closed its previously announced asset purchase agreement for the sale of Medford and Powell in Oregon. Part of the total consideration was satisfied by a 12-month $1,250 secured promissory note bearing interest at a rate of 12.5% per annum. Refer to Note 3 for further discussion. In August 2022, the secured promissory note was replaced with a $500 secured promissory note bearing interest at a rate of 12.5% per annum and a $750 non-interest bearing secured promissory note, with both secured promissory notes due on May 1, 2023.

F-14

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

In July 2022, the Company executed and closed an amendment to its previously announced asset purchase and services agreement for the sale of its four Oregon retail dispensaries. Part of the total consideration was satisfied by a 36-month $5,850 secured promissory note bearing interest at a rate of 12% per annum. Refer to Note 3 for further discussion.

7.    CAPITAL ASSETS, NET

Net property, plant and equipment consisted of:

	September 30, 2023		December 31, 2022
Land	$	9,778	$	9,605
Building	58,524		58,334
Right-of-use asset, finance leases	6,297		5,077
Furniture, fixtures and equipment	40,701		46,811
Leasehold improvements	49,611		6,178
Construction in progress	14,883		34,435
Capital assets, gross	$	179,794	$	160,440
Less: accumulated depreciation and amortization	(42,928)		(27,035)
Capital assets, net	$	136,866	$	133,405

Depreciation of capital assets for the three and nine months ended September 30, 2023 is comprised of $928 and $2,919 of depreciation expense, respectively, and $2,116 and $6,493 that was capitalized to inventory, respectively. Depreciation of capital assets for the three and nine months ended September 30, 2022 is comprised of $751 and $4,731 of depreciation expense, respectively, and $1,963 and $5,679 that was capitalized to inventory, respectively.

During the nine months ended September 30, 2022, the Company determined that it was unable to find a satisfactory buyer for the held-for-sale assets related to its Michigan operations and, as such, these assets were reclassified as held-and-used. This conclusion was considered a triggering event for capital asset impairment testing. Upon assessment, these specific capital assets were not considered to have future economic value. As such, the fair value of the assets was considered to be nil and the Company recognized an impairment charge of $1,907 within Impairments, net on the Unaudited Condensed Consolidated Statements of Operations during the nine months ended September 30, 2022. Refer to Note 3 for further discussion on changes in held-for-sale entities.

F-15

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

8.    LEASES

The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments and accounts for non-lease components separately from leases.

Statements of Financial Position Information	Classification	September 30, 2023		December 31, 2022
Right-of-use assets
Operating	Operating lease right-of-use assets	$	18,699	$	22,443
Finance	Capital assets, net	4,597		4,269
Total right-of-use assets		$	23,296	$	26,712
Lease liabilities
Current
Operating	Operating lease liability, current	$	2,535	$	2,443
Financing	Debt, current	112		1
Non-current
Operating	Operating lease liability, non-current	18,298		21,692
Financing	Debt, non-current	5,846		5,305
Total lease liabilities		$	26,791	$	29,441

		Three Months Ended September 30,				Nine Months Ended September 30,
Statement of Operations Information	Classification	2023		2022		2023		2022
Short-term lease expense	General and administrative	$	102	$	(28)	$	311	$	190
Operating lease expense	General and administrative	1,238		1,221		3,853		3,613
Finance lease expense:
Amortization of right of use asset	Depreciation and amortization	93		63		278		190
Interest expense on lease liabilities	Interest expense	213		314		633		855
Net operating and finance lease cost		$	1,544	$	1,598	$	4,764	$	4,658

		Nine Months Ended September 30,
Statement of Cash Flows Information	Classification	2023		2022
Cash paid for operating leases	Net cash used in operating activities	$	3,871	$	3,390
Cash paid for finance leases - interest	Net cash used in operating activities	$	718	$	843

F-16

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of September 30, 2023:

Maturity of lease liabilities	Operating Leases		Finance Leases
2023	$	1,085	$	228
2024	4,285		923
2025	4,104		946
2026	4,314		969
2027	3,897		992
Thereafter	13,276		11,705
Total lease payments	$	30,961	$	15,763
Less: interest	10,128		9,805
Present value of lease liabilities	$	20,833	$	5,958
Weighted average remaining lease term (years)	8		11
Weighted average discount rate	10%		12%

As of September 30, 2023, there have been no leases entered into that have not yet commenced.

9.    INVENTORY

The Company’s inventory balance consists of the following:

	September 30, 2023		December 31, 2022
Retail inventory	$	5,305	$	3,255
Wholesale inventory	36,129		35,885
Cultivation inventory	6,491		7,133
Supplies & other	3,125		3,173
Total	$	51,050	$	49,446

Inventory is valued at the lower of cost and net realizable value (“NRV”), defined as estimated selling price in the ordinary course of business, less estimated costs of disposal. During the nine months ended September 30, 2023, the Company analyzed its inventory balances, and recorded wholesale inventory adjustments as a result of (i) having excess or obsolete inventory and (ii) reducing the carrying value to ensure inventory balances are properly recorded at the lower of cost and NRV. The Company recognized $2,103 and $8,824 during the three and nine months ended September 30, 2023, respectively, and $6,286 during the three and nine months ended September 30, 2022 of wholesale inventory adjustments within Cost of goods sold, wholesale on the Unaudited Condensed Consolidated Statements of Operations.

F-17

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

10.    DEBT

The Company’s debt balances consist of the following:

Debt balances	September 30, 2023		December 31, 2022
Financing liability (failed sale-leaseback)	$	15,253	$	15,253
Finance lease liabilities	5,958		5,306
7.50% Loan due April 2026	31,682		31,288
6.10% Secured debenture due September 2030	46,841		46,502
Note due December 2024	2,375		3,167
Prime rate credit facilities due January 2026, as amended	130,989		113,564
Note backed by ERTC	1,640		—
Total debt	$	234,738	$	215,080
Less: current portion of debt	3,336		1,584
Total long-term debt	$	231,402	$	213,496

Scheduled maturities of debt, excluding amortization of discount and issuance costs, are as follows:

2023	$	2,432
2024	1,584
2025	—
2026	173,011
2027	39
Thereafter	71,160
Total payments (excluding amortization of discount and issuance costs)	$	248,226

During the three and nine months ended September 30, 2023, the Company incurred interest expense of $9,207 and $26,143, respectively, and $5,688 and $15,989 during the three and nine months ended September 30, 2022, respectively, on the Unaudited Condensed Consolidated Statements of Operations. Interest expense for the three and nine months ended September 30, 2023 included debt discount amortization of $547 and $1,562, respectively, and amortization of debt issuance costs of $706 and $2,094, respectively. Interest expense for the three and nine months ended September 30, 2022 included debt discount amortization of $381 and $1,132, respectively, and amortization of debt issuance costs of $297 and $849, respectively. As of September 30, 2023 and December 31, 2022, the Company had unamortized discount $5,030 and $6,093, respectively, and debt issuance costs of $8,458 and $10,522, respectively, which is netted against the gross carrying value of long-term debt in Debt, non-current on Unaudited Condensed Unaudited Condensed Consolidated Statements of Financial Position. Additionally, as of September 30, 2023 and December 31, 2022, the Company had accrued interest of $5,676 and $2,575, respectively, within Interest payable on the Unaudited Condensed Consolidated Statements of Financial Position.

Financing liability (failed sales leaseback)

In connection with the Company’s failed sale-leaseback transaction in November 2020, a financing liability was recognized equal to the cash proceeds received. The Company will recognize the cash payments made on the lease as interest expense, and the principal will be de-recognized upon expiration of the lease.

6.10% Secured debenture due September 2030

On September 23, 2020, pursuant to the implementation of the Amended Arrangement (Refer to Note 13 for further discussion), a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture (“6.1% Loan”). In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. An additional $50,000 may be advanced pursuant to the debenture subject to the satisfaction of certain conditions by Universal Hemp. The debenture bears interest at a rate of 6.1% per annum, matures 10 years from the date hereof or such earlier date in accordance with the terms of the debenture and all interest payments made pursuant to the debenture are payable in cash by Universal Hemp. Subsequent to quarter end, Universal Hemp received a reservations of rights letter for

F-18

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

failure to make the annual cash interest payment within 10 business days of September 23, 2023 (October 10, 2023). The parties agreed on November 14, 2023 to waive the default and that the cash interest payment would be satisfied through a partial cash payment of $1,400 by year end 2023, an obligation of Universal Hemp to deliver proceeds from the sale of certain real property held by Universal Hemp and an agreement between the parties to offset potential future expenses that may be payable by Canopy Growth. The debenture is secured by substantially all of the assets of Universal Hemp and its subsidiaries and, further, is not convertible and is not guaranteed by Acreage.

With a portion of the proceeds for the 6.1% Loan received by Universal Hemp, Acreage engaged an Investment Advisor which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp $34,019 on September 28, 2020. As a result, Universal Hemp acquired 34,019 class B units, at $1.00 par value per unit, which represented 100% financial interest in the Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Investment Advisor as an agent for Universal Hemp. Upon execution of the limited partnership agreement, $1,019 was distributed to the class A unit holders of the Investment Partnership.

7.50% Loan due April 2026

On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Investor (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note (as described above) and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The loan is unsecured, matures in 3 years and bears interest at a 7.5% annual interest rate. The Lender is controlled by the Institutional Investor. The Investment Partnership is the investor in the Lender. On December 16, 2021, the Company paid an amendment fee of $413 to extend the maturity date from September 28, 2023 to April 2, 2026. The amendment was treated as a debt extinguishment.

Note due December 2024

In November 2020, the Company issued a promissory note with a third party, which is non-interest bearing and payable based on a payment schedule with ten payments in the aggregate amount of $7,750 through December 31, 2024, as a result of a settlement described under the “CanWell Dispute” in Note 13.

Prime rate credit facilities due January 2026, as amended

On December 16, 2021, the Company entered into a $150,000 senior secured credit facility with a syndicate of lenders consisting of a $75,000 initial draw, a $25,000 delayed draw that must be advanced within 12 months and a $50,000 committed accordion facility that is available after December 1, 2022, provided certain financial covenants are met, and with a maturity of January 1, 2026. Upon closing, gross proceeds of $75,000 were drawn (before origination discounts and issuance costs of approximately $4,000 and $1,500, respectively, which were capitalized). In April 2022, the Company drew down on the $25,000 delayed draw. Refer to Note 14 for further discussion of the syndicated related party lender.

The Company obtained a waiver of the financial covenants for the three month periods ended March 31, 2022 and June 30, 2022. This waiver included a $500 waiver fee that was paid to the lenders

On October 24, 2022, the Company amended the senior secured credit facility such that $25,000 of the committed accordion was available for immediate draw by Acreage, which was drawn down in the fourth quarter of 2022, with the remaining $25,000 available from January 1, 2023, provided certain predetermined milestones are achieved. The Company paid an amendment fee of $1,250 to the syndicate of lenders and the amendment was treated as a debt modification.

On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further $15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to limit the total amounts outstanding under the Credit Agreement to $140,000 and to at all times subsequent to the amendment, maintain collateral (as defined in the Credit Agreement) equal to or greater than the outstanding amount under the Credit Agreement.

The loan is secured by pledged equity interests and substantially all of the assets of the Company. Advances under the facility bear interest at a variable rate of U.S. prime (“Prime”) plus 5.75% per annum, payable monthly in arrears, with a Prime floor of 5.50% plus an additional 1.0% per annum until certain collateral assignment agreements are delivered.

F-19

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

The facility has a maturity date of January 1, 2026 and the Company has the option to extend the maturity date to January 1, 2027 prior to January 1, 2024, for a fee equal to 1.0% of the total loan amount. If the Company chooses to extend the maturity date, it will also be required to make monthly installment payments, each of which shall be an amount equal to five percent per year of the outstanding amount of the loan.

The loan is subject to various financial covenants, including (i) a fixed charge coverage ratio and two leverage ratios in respect of all periods beginning on or after December 31, 2023 and (ii) a minimum cash requirement of $9.0 million at each quarter end of the Company. Finally, the Amended Credit Facility includes approval for Canopy USA to acquire control of Acreage without requiring repayment of all amounts outstanding under the Amended Credit Facility, provided certain conditions are satisfied. As of September 30, 2023 the Company was in compliance with all covenants.

ERTC Factoring Agreement

On April 11, 2023, the Company received $12,113 pursuant to a financing agreement with a third-party lender (the “Financing Agreement”), which was included in “Debt, current” as of June 30, 2023. The Company assigned to the lender its interests in Employee Retention Tax Credits (“ERTC”) that it submitted for a claim of approximately $14,251. If the Company does not receive the ERTC, in whole or in part, the Company is required to repay the related portion of the funds received plus 10% interest accrued from the date of the Financing Agreement through the repayment date. The Financing Agreement does not have a stated maturity date and the discount is being accreted to interest expense over an expected term. The Company’s obligations under the Financing Agreement will be satisfied upon receipt of the ERTC or other full repayment. Finally, the Company determined the ERTC did not meet the criteria to record as a receivable as of June 30, 2023 due to the uncertain nature of such claims.

During the three and nine months ended September 30, 2023, the Company received $10,472 of the ERTC claims which was remitted to the lender per the terms of the Financing Agreement, extinguishing an equal portion of the debt included in “Debt, current” as of September 30, 2023.

11.    SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS

The table below details the change in Pubco shares outstanding by class for the nine months ended September 30, 2023:

Shareholders’ Equity	Fixed Shares	Floating Shares	Fixed Shares Held in Treasury	Floating Shares Held in Treasury	Fixed Multiple Shares	Total Shares Outstanding
December 31, 2022	79,047	34,114	(589)	(253)	118	112,437
Issuances	1,626	1,902	—	—	—	3,528
September 30, 2023	80,673	36,016	(589)	(253)	118	115,965

Warrants

A summary of the warrants activity outstanding is as follows:

Warrants	Fixed Shares	Floating Shares
December 31, 2022	5,817	2,524
Expired	—	—
September 30, 2023	5,817	2,524

The exercise price of each Fixed Share warrants ranged from $3.15 to $4.00, respectively, and the exercise price of each Floating Share warrants ranged from $3.01 to $4.00, respectively. The warrants are exercisable for a period of 4 years. The weighted-average remaining contractual life of the warrants outstanding is approximately 1.3 years. There was no aggregate intrinsic value for warrants outstanding as of September 30, 2023.

Non-controlling interests - convertible units

The Company has NCIs in consolidated subsidiaries USCo2 and HSCP. The non-voting shares of USCo2 and HSCP units make up substantially all of the NCI balance as of September 30, 2023 and are convertible for either 0.7 of a Fixed Share and

F-20

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

0.3 of a Floating Share of Pubco or cash, as determined by the Company. Summarized financial information of HSCP is presented below. USCo2 does not have discrete financial information separate from HSCP.

HSCP net asset reconciliation	September 30, 2023			December 31, 2022
Current assets	$	89,448		$	118,193
Non-current assets	261,389			237,665
Current liabilities	(15,172)			(9,141)
Non-current liabilities	(254,751)			(239,525)
Other NCI balances	(726)			(725)
Accumulated equity-settled expenses	(243,182)			(240,760)
Net assets	$	(162,994)		$	(134,293)
HSCP/USCo2 ownership % of HSCP	15.93		%	16.33		%
Net assets allocated to USCo2/HSCP	$	(25,959)		$	(21,930)
Net assets attributable to other NCIs	726			725
Total NCI	$	(25,233)		$	(21,205)

	Three Months Ended September 30,						Nine Months Ended September 30,
HSCP Summarized Statement of Operations	2023			2022			2023			2022
Net loss allocable to HSCP/USCo2	$	(1,521)		$	(16,549)		$	(23,924)		$	(27,589)
HSCP/USCo2 weighted average ownership % of HSCP	15.37		%	16.84		%	16.23		%	16.96		%
Net loss allocated to HSCP/USCo2	$	(234)		$	(2,787)		$	(3,884)		$	(4,679)
Net loss allocated to other NCIs	—			3			(1)			4
Net loss attributable to NCIs	$	(234)		$	(2,784)		$	(3,885)		$	(4,675)

As of September 30, 2023, USCo2’s non-voting shares owned approximately 0.22% of HSCP units. USCo2’s capital structure is comprised of voting shares, all of which are held by the Company, and of non-voting shares held by certain former HSCP members. Certain executive employees and profits interests holders own approximately 16.01% of HSCP non-voting units. The remaining 83.77% interest in HSCP is held by USCo and represents the members’ equity attributable to shareholders of the parent.

A reconciliation of the beginning and ending amounts of convertible units is as follows:

Convertible Units	September 30, 2023	December 31, 2022
Beginning balance	22,698	23,076
NCI units converted to Pubco	—	(378)
Ending balance	22,698	22,698

12.    EQUITY-BASED COMPENSATION EXPENSE

Amended Arrangement with Canopy Growth

On September 23, 2020, the Company announced the implementation of the Amended Arrangement (as defined in Note 13). Pursuant to the Amended Arrangement, the Company’s articles have been amended to create new Fixed Shares, Floating Shares and Fixed Multiple Shares. Consequently, the Company’s equity-based compensation was modified into new equity awards of the Company. Refer to Note 13 for further discussion.

Equity-based compensation - Plan (Acreage Holdings, Inc. Omnibus Incentive Plan)

In connection with the RTO transaction, the Company’s Board of Directors adopted an Omnibus Incentive Plan, as amended September 23, 2020 (the “Plan”), which permits the issuance of stock options, stock appreciation rights, stock awards, share units, performance shares, performance units and other stock-based awards up to an amount equal to 15% of the issued and outstanding Subordinate Voting Shares of the Company.

F-21

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Pursuant to the Amended Arrangement, the Company retained the Plan described above, the upper limit of issuances being up to an amount equal to 15% of the issued and outstanding Fixed Shares and Floating Shares of the Company. As of September 30, 2023, the Company had 959 shares authorized and available for grant under the Plan.

Restricted Share Units (“RSUs”)

	Fixed Shares			Floating Shares
Restricted Share Units (Fair value information expressed in whole dollars)	RSUs	Weighted Average Grant Date Fair Value		RSUs	Weighted Average Grant Date Fair Value
Unvested, January 1, 2023	6,324	$	1.80	464	$	6.68
Granted	3,646	$	0.15	7,870	$	0.23
Forfeited	(1,642)	$	0.90	(135)	$	1.15
Vested	(2,201)	$	1.29	(1,973)	$	0.60
Unvested, September 30, 2023	6,127	$	1.24	6,226	$	0.58
Vested and unreleased(1)	40	$	8.52	11	$	17.35
Outstanding, September 30, 2023	6,167	$	1.29	6,237	$	0.61

(1) RSUs that are vested and unreleased represent RSUs that are pending delivery.

RSUs of the Company generally vest over a period of three years and RSUs granted to certain executives vest based on achievement of specific performance conditions. In certain situations for specified individuals, RSUs vest on an accelerated basis on separation. The fair value for RSUs is based on the Company’s share price on the date of the grant. The Company recorded $791 and $2,019 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2023, respectively, and $2,256 and $7,645 during the three and nine months ended September 30, 2022, respectively. The fair value of RSUs vested during the three and nine months ended September 30, 2023 was $890 and $1,489, respectively, and $1,427 and $4,760 during the three and nine months ended September 30, 2022, respectively.

The total weighted average remaining contractual life and aggregate intrinsic value of unvested RSUs as of September 30, 2023 was approximately 0.9 years and $4,612, respectively. Unrecognized compensation expense related to these awards at September 30, 2023 was $10,436 and is expected to be recognized over a weighted average period of approximately 1.0 year.

Stock options

	Fixed Shares			Floating Shares
Stock Options (Exercise price expressed in whole dollars)	Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price
Options outstanding, January 1, 2023	7,337	$	2.75	2,267	$	3.10
Forfeited	(1,875)	$	0.66	(131)	$	3.16
Expired	—	$	—	(35)	$	2.55
Options outstanding, September 30, 2023	5,462	$	3.46	2,101	$	3.10
Options exercisable, September 30, 2023	3,400	$	5.21	2,101	$	3.10

Stock options of the Company generally vest over a period of three years and options granted to certain executives vest based on achievement of specific performance conditions. Stock options of the Company have an expiration period of 5 or 10 years from the date of grant. The weighted average contractual life remaining for Fixed Share options outstanding and exercisable as of September 30, 2023 was approximately 4.3 and 4.7 years, respectively. The weighted average contractual life remaining for Floating Share options outstanding and exercisable as of September 30, 2023 was approximately 6.2 and 6.2 years, respectively. The Company recorded $(46) and $404 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2023 and $300 and $725 during the three and nine months ended September 30, 2022, respectively, in connection with these awards.

F-22

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

As of September 30, 2023, unamortized expense related to stock options totaled $596 and is expected to be recognized over a weighted-average period of approximately 2 years. As of September 30, 2023, the aggregate intrinsic value for unvested options and for vested and exercisable options was nil, respectively.

13.    COMMITMENTS AND CONTINGENCIES

Commitments

The Company provides revolving lines of credit to certain of its portfolio companies. As of September 30, 2023, only one revolving line of credit remained outstanding and the maximum obligation under this arrangement was equal to the balance advanced of $4,331. Refer to Note 6 for further discussion).

Prior Plan of Arrangement with Canopy Growth

On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the proposed plan of arrangement (the “Prior Plan of Arrangement”) involving the two companies, and on June 21, 2019, the Supreme Court of British Columbia granted a final order approving the Prior Plan of Arrangement. Effective June 27, 2019, the articles of the Company were amended pursuant to the Prior Plan of Arrangement to provide that, upon the occurrence (or waiver by Canopy Growth) of the Triggering Event, subject to the satisfaction of the conditions set out in the arrangement agreement entered into between Acreage and Canopy Growth on April 18, 2019, as amended on May 15, 2019 (the “Original Arrangement Agreement”), Canopy Growth will acquire (the “Acquisition”) all of the issued and outstanding shares in the capital of the Company (each, an “Acreage Share”).

Second Amendment to the Arrangement Agreement with Canopy Growth

On September 23, 2020, Acreage and Canopy Growth entered into an amending agreement (the “Amending Agreement” or “Amended Arrangement”) (and together with the Original Arrangement Agreement and any further amendments thereto, the “Amended Plan of Arrangement”) and the Amended Arrangement became effective at 12:01 a.m. (Vancouver time) (the “Amendment Time”) on September 23, 2020 (the “Amendment Date”). Pursuant to the Amended Plan of Arrangement, Canopy Growth made a cash payment of $37,500 which was delivered to Acreage’s shareholders and certain holders of securities convertible or exchangeable into shares of Acreage. Acreage also completed a capital reorganization (the “Capital Reorganization”) effective as of the Amendment Time whereby: (i) each existing SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share; (ii) each issued and outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and (iii) each issued and outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share.

At the Amendment Time, each option, restricted share unit, compensation option, and warrant to acquire existing SVS (each a “Security”) that was outstanding immediately prior to the Amendment Time, was exchanged for a replacement Security to acquire Fixed Shares (a “Fixed Share Replacement Security”) and a replacement Security to acquire Floating Shares (a “Floating Share Replacement Security”) to account for the Capital Reorganization.

Pursuant to the Amended Plan of Arrangement, upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event (the “Triggering Event Date”), Canopy Growth will, subject to the satisfaction or waiver of certain closing conditions set out in the Arrangement Agreement: (i) acquire all of the issued and outstanding Fixed Shares (following the mandatory conversion of the Fixed Multiple Shares into Fixed Shares) on the basis of 0.3048 of a common share of Canopy Growth (each whole common share, a “Canopy Growth Share”) for each Fixed Share held (the “Fixed Exchange Ratio”) at the time of the acquisition of the Fixed Shares (the “Acquisition Time”), subject to adjustment in accordance with the terms of the Amended Plan of Arrangement (the “Canopy Call Option”). The Canopy Call Option will expire 10 years from the Amendment Time.

At the Acquisition Time, on the terms and subject to the conditions of the Amended Plan of Arrangement, each Fixed Share Replacement Security will be exchanged for a replacement Security from Canopy Growth equal to: (i) the number of Fixed Shares that were issuable upon exercise of such Fixed Share Replacement Security immediately prior to the Acquisition Time, multiplied by (ii) the Fixed Exchange Ratio in effect immediately prior to the Acquisition Time (provided that if the foregoing would result in the issuance of a fraction of a Canopy Growth Share, then the number of Canopy Growth Shares to be issued will be rounded down to the nearest whole number).

The Amended Plan of Arrangement provides for, among other things, Amendments to the definition of Purchaser Approved Share Threshold (as defined therein) to change the number of shares of Acreage available to be issued by Acreage without an adjustment in the Fixed Exchange Ratio such that Acreage may issue a maximum of 32,700 shares. Furthermore, Acreage

F-23

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

generally may not issue any equity securities without Canopy Growth’s prior consent. Additionally, the Amended Plan of Arrangement allows for various Canopy Growth rights that extend beyond the Acquisition Date, including, among others: (i) rights to nominate a majority of Acreage’s Board of Directors following the Acquisition Time; (ii) restrictive covenants in respect of the business conduct in favor of Canopy Growth; (iii) termination of non-competition and exclusivity rights granted to Acreage by Canopy Growth in the event that Acreage does not meet certain specified financial targets; (iv) implementation of further restrictions on Acreage’s ability to operate its business in the event that Acreage does not meet certain specified financial targets; and (v) termination of the Amended Plan of Arrangement in the event that Acreage does not meet certain specified financial targets in the trailing 12 month period. Each of the financial targets referred to above is specified in the Amending Agreement and related to the performance of Acreage relative to a business plan for Acreage for each fiscal year ended December 31, 2020 through December 31, 2029 set forth in the Proposal Agreement (the “Initial Business Plan”).

Further, the Amended Plan of Arrangement imposes restrictions on Acreage entering into any contracts in respect of Company Debt if: (i) such contract would be materially inconsistent with market standards for companies operating in the United States cannabis industry; (ii) such contract prohibits a prepayment of the principal amount of such Company Debt; and (iii) such contract would provide for interest payments to be paid through the issuance of securities as opposed to cash, among other restrictions. The Amended Plan of Arrangement also provides for the following: (i) certain financial reporting obligations to Canopy Growth; (ii) certain specified criteria related to any new directors or officers of Acreage, and (iii) a limit to Acreage’s operations to the Identified States (as defined therein).

Third Amendment to the Arrangement Agreement with Canopy Growth

On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. A special meeting of the holders of Floating Shares was held on March 15, 2023, where the holders of Floating Shares approved the Floating Share Arrangement (the “Special Meeting”).

Concurrently with entering the Floating Share Agreement, Canopy Growth irrevocably waived its option to acquire the Floating Shares pursuant to the Amended Arrangement.

Subject to the provisions of the Floating Share Agreement, Canopy Growth has agreed to exercise the fixed option pursuant to the Amended Agreement to acquire all outstanding Fixed Shares, representing approximately 70% of the total shares of Acreage as at the date hereof, at a fixed exchange ratio of 0.3048 of a Canopy Share for each Fixed Share.

Acreage expects the Floating Share Arrangement to close upon the satisfaction or waiver of all conditions under the Floating Share Agreement and the Amended Arrangement. It is anticipated that the acquisition by Canopy USA of the Fixed Shares pursuant to the Fixed Option will be completed immediately following closing of the Floating Share Agreement. In the event that Canopy USA exercises the Fixed Option and acquires the Floating Shares pursuant to the Floating Share Arrangement, Acreage will be wholly-owned subsidiary of Canopy USA.

On March 17, May 31, August 31, 2023, and October 31, 2023 Acreage, Canopy and Canopy USA entered into amendments to the Floating Share Arrangement Agreement (collectively, the “FSA Amendments”). Pursuant to the terms of the FSA Amendments, Acreage, Canopy and Canopy USA agreed to multiple extensions to the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement) from its initial date of March 31, 2023 to its current date of December 31, 2023.

Tax Receivable Agreement and Tax Receivable Bonus Plans

The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the “Tax Receivable Agreement”) between the Company and certain current and former unit holders of HSCP and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the “Tax Receivable Bonus Plans”) between the Company and certain directors, officers and consultants of the Company (together the “Tax Receivable Recipients”). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan. Although the actual timing and amount of any payments that the Company makes to the Tax Receivable Recipients cannot be estimated, it expects those payments will be

F-24

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

significant. Any payments made by the Company to the Tax Receivable Recipients may generally reduce the amount of overall cash flow that might have otherwise been available to it. Payments under the Tax Receivable Agreement are not conditioned on any Tax Receivable Recipient’s continued ownership of Units or our shares after the completion of the RTO. Payments under the Tax Receivable Bonus Plan may, at times, be conditioned on the Tax Receivable Recipient’s continued employment by the Company. As of September 30, 2023, the Company has not made any payments in relation to the Tax Receivable Agreement or the Tax Receivable Bonus Plans.

Concurrently with the execution of the Floating Share Arrangement Agreement, Canopy Growth, Canopy USA, High Street, Acreage Holdings America, Inc. and certain individuals party to the Tax Receivable Agreement, amended the Tax Receivable Agreement in accordance with the Floating Share Agreement. Pursuant to the Floating Share Agreement, Canopy Growth, on behalf of Canopy USA agreed to: (i) issue Canopy Shares with a value of approximately $30,500 to the Tax Receivable Agreement Members in exchange for each such individual executing an assignment of rights agreement assigning such individual’s rights under the Tax Receivable Agreement to Canopy USA, such that following assignment, Canopy USA is the sole member and beneficiary under the Tax Receivable Agreement; and (ii) fund a payment with a value of approximately $19,500 to be made by the Company in Canopy Shares to certain eligible participants pursuant to the Tax Receivable Bonus Plans, as amended on October 24, 2022, both in order to reduce a potential liability of approximately $121,000 under the Tax Receivable Agreement and the Tax Receivable Bonus Plans. In connection with the foregoing, Canopy Growth issued 5,648,927 Canopy Shares on or about November 4, 2022 and 7,102,081 Canopy Shares on or about March 17, 2023 to the Tax Receivable Agreement Members. In addition, the Tax Receivable Agreement Bonuses with an aggregate value of approximately $19,500 in Canopy Shares will be issued by Canopy to certain eligible participants under the Tax Receivable Bonus Plans on the closing of the Floating Share Arrangement or, if the Floating Share Arrangement does not close or is terminated but the Amended Arrangement closes, then on the closing of the acquisition. The Tax Receivable Agreement Bonuses will be paid to recipients to be determined by Kevin Murphy, the administrator of the Tax Receivable Bonus Plans, and may include one or more directors of Acreage and other current and former officers or consultants of Acreage as may be determined by Kevin Murphy. Canopy Growth has also agreed to register the resale of such Canopy Shares under the Securities Act of 1933, as amended.

Debenture

In connection with the implementation of the Amended Arrangement, pursuant to a secured debenture dated September 23, 2020 (the “Debenture”) issued by Universal Hemp, LLC, an affiliate of Acreage that operates solely in the hemp industry in full compliance with all applicable laws (the “Borrower”), to 11065220 Canada Inc., an affiliate of Canopy Growth (the “Lender”), the Lender agreed to provide a loan of up to $100,000 (the “Loan”), $50,000 of which was advanced on the Amendment Date (the “Initial Advance”), and $50,000 of the Loan will be advanced in the event that the following conditions, among others, are satisfied: (a) the Borrower’s EBITDA (as defined in the Debenture) for any 90 day period is greater than or equal to 2.0 times the interest costs associated with the Initial Advance; and (b) the Borrower’s business plan for the 12 months following the applicable 90 day period supports an Interest Coverage Ratio (as defined in the Debenture) of at least 2.00:1. On October 24, 2022, the Debenture was assigned by the Lender to Canopy USA.

The principal amount of the Loan will bear interest from the date of advance, compounded annually, and be payable on each anniversary of the date of the Debenture in cash in U.S. dollars at a rate of 6.1% per annum. The Loan will mature 10 years from the date of the Initial Advance.

The Loan must be used exclusively for U.S. hemp-related operations and on the express condition that such amount will not be used, directly or indirectly, in connection with or for the operation or benefit of any of the Borrower’s affiliates other than subsidiaries of the Borrower exclusively engaged in U.S. hemp-related operations and not directly or indirectly, towards the operation or funding of any activities that are not permissible under applicable law. The Loan proceeds must be segregated in a distinct bank account and detailed records of debits to such distinct bank account will be maintained by the Borrower.

No payment due and payable to the Lender by the Borrower pursuant to the Debenture may be made using funds directly or indirectly derived from any cannabis or cannabis-related operations in the United States, unless and until the Triggering Event Date.

The Debenture includes usual and typical events of default for a financing of this nature, including, without limitation, if: (i) Acreage is in breach or default of any representation or warranty in any material respect pursuant to the Arrangement Agreement; (ii) operations deemed to be non-core must cease within 18 months from the Amendment Date; and (iii) Acreage fails to perform or comply with any covenant or obligation in the Arrangement Agreement which is not remedied within 30 days after written notice is given to the Borrower by the Lender. The Debenture also includes customary representations and warranties, positive covenants and negative covenants of the Borrower.

F-25

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

Advisor fee

In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of $7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of $3,000 in cash, less a $500 initial payment, and $2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of $5,000 as of September 30, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.

The Company is subject to other capital commitments and similar obligations. As of September 30, 2023 and 2022, such amounts were not material.

CanWell Settlement

In November 2020, the Company entered into a final confidential settlement agreement with CanWell, LLC for certain outstanding proceedings. As part of that agreement, the Company accrued for $7,750 in Legal settlements, net on the Statements of Operations for the year ended December 31, 2020. In connection with this settlement agreement, the Company issued a promissory note in the amount of $7,750 to CanWell, which is non-interest bearing and is payable in periodic payments through December 31, 2024. Through September 30, 2023, the Company has paid $5,375 of the promissory note.

Contingencies

The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company’s applicable subsidiaries ceasing operations. While management of the Company believes that the Company’s subsidiaries are in compliance with applicable local and state regulations as of September 30, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company’s subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.

The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated.

New York outstanding litigation

On November 2, 2018, EPMMNY LLC (“EPMMNY”) filed a complaint in the Supreme Court of the State of New York, County of New York, asserting claims against 16 defendants, including NYCANNA, Impire State Holdings LLC (“Impire”), NY Medicinal Research & Caring, LLC (“NYMRC”) (each, a wholly owned subsidiary of High Street) and High Street. The Index Number for the action is 655480/2018. EPMMNY alleges that it was wrongfully deprived of a minority equity interest and management role in NYCANNA by its former partner, New Amsterdam Distributors, LLC (“New Amsterdam”), which attempted to directly or indirectly sell or transfer EPMMNY’s alleged interest in NYCANNA to other entities in 2016 and 2017, including Impire, NYMRC and High Street.

EPMMNY alleges that it is entitled to the value of its alleged minority interest in NYCANNA or minority ownership in NYCANNA. EPMMNY also alleges that certain defendants misused its alleged intellectual property and/or services, improperly solicited its employees, and aided and abetted or participated in the transfer of equity and/or business opportunities from EPMMNY.

High Street, along with the other Defendants, filed motions to dismiss on April 1, 2019. The motions were fully briefed and submitted to the Court as of July 18, 2019, and oral argument was heard on September 6, 2019. Following a hearing held during April 2022, in ruling on one dismissal argument advanced by several Defendants, the Court ruled that Plaintiff had the capacity to bring this action on behalf of EPMMNY. On July 13, 2023, the Court ruled on the remaining dismissal arguments, granting the vast majority of them. As part of its ruling, the Court dismissed without prejudice every claim against NYCANNA, Impire,

F-26

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

NYMRC, and High Street, except the claims for unjust enrichment and quantum meruit (which also were permitted to proceed against other Defendants). The only other claim that the Court did not dismiss was for breach of contract against New Amsterdam.

On July 24, 2023, EPMMNY moved for leave to file a proposed amended complaint. The proposed amended complaint names several defendants, including NYCANNA, Impire, NYMRC, High Street, and Kevin Murphy, and contains similar allegations to those in the original complaint. High Street intends to oppose the motion for leave to amend and,if necessary, move to dismiss the new complaint.

High Street intends to continue vigorously defend this action, which the Company firmly believes is without merit. High Street also believes it is entitled to full indemnity from the claims asserted against it by EPMMNY pursuant to the purchase agreement pertaining to its acquisition of NYCANNA and personal guarantee by the largest shareholders of the seller.

Health Circle, Inc. litigation

On April 13, 2023, Health Circle, Inc., a licensed cannabis dispensary operator in Massachusetts, initiated a civil action against the Company and MA RMD SVCS, LLC in Plymouth County, Massachusetts for alleged breaches of that certain Revolving Line of Credit, dated October 31, 2017, by and between Health Circle, Inc. and MA RMD SVCS, LLC (the “HCI Credit Agreement”) and certain torts. High Street has filed a second civil action against Michael Westort, individually, in the Business Litigation Section, located in Boston, MA, predicated upon that certain Membership Interest Purchase Agreement, dated June 30, 2018, by and between Mr. Westort and High Street. The Company has moved to partially dismiss the complaint in Plymouth County, and the court has scheduled a hearing on February 1, 2024 to hear argument on this motion. The Company is assessing the amended complaint, and will ultimately file counterclaims against Health Circle, Inc. based on the outstanding debt under the HCI Credit Agreement. High Street intends to vigorously defend against this action, which the Company believes is without merit, and to pursue its claims against Mr. Westort and Health Circle, Inc.

Alfred’s Finest, Inc. arbitration

On June 22, 2023, Alfred’s Finest, Inc. (“AFI”) filed a demand for arbitration relating to that certain Asset Purchase Agreement, dated June 24, 2021, by and between Alfred’s Finest, Inc., Robert M. Andrews, Jr and The Botanist, Inc., a wholly owned subsidiary of High Street, and the Company (the “AFI APA”). The AFI APA provided for the payment of $2,000 to AFI upon closing and an additional $3,000 payable on or before the 18-month anniversary of the closing date. Pursuant to its termination rights provided under the APA, the Company sent a notice of termination of the AFI APA on June 29, 2022 before the closing occurred. AFI alleges that the Company breached the terms of the APA and claims that the notice of termination sent by the Company has no basis in the language of the AFI APA. AFI is seeking relief from the Company consisting of specific performance of the AFI APA and recovery of its damages, including arbitration fees and costs. The Company believes the plain language of the AFI APA supports its position and intends to vigorously defend this action, which the Company believes is without merit. The Company has filed a counterclaim against AFI for breach of the AFI APA based on AFI’s failure to act in good faith as required by the AFI APA.

On June 28, 2023, in response to AFI’s demand for arbitration, the Company asserted its right under the AFI APA to submit the dispute to mediation before it proceeds to arbitration. The parties are in the process of scheduling the mediation and identifying a mediator.

14.    RELATED PARTY TRANSACTIONS

Transactions with related parties are entered into in the normal course of business and are measured at the amount established and agreed to by the parties.

6.10% Secured debenture due September 2030

As disclosed in Note 10, “6.10% Secured debenture due September 2030”, on September 23, 2020, pursuant to the implementation of the Amended Arrangement, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture. In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. Acreage then engaged an investment advisor (the “Investment Advisor”) which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp, $34,019 of the proceeds on September 28, 2020. During the three and nine months ended September 30, 2023, the Company incurred interest expense attributable to the 6.10% Secured debenture due September 2030 of $763 and $2,289, respectively.

F-27

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

As a result of the transaction described above, Universal Hemp, a subsidiary of the Company, acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds Class A Units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Institutional Investor as agent for Universal Hemp. On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Lender (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The Lender is controlled by the Institutional Lender. The Investment Partnership is the investor in the Lender.

Prime rate credit facilities due January 2026, as amended

On December 16, 2021, the Company entered into the Prime rate credit facilities due January 2026 with a syndicate of lenders, including Viridescent Realty Trust, Inc. (“Viridescent”), an entity controlled by Kevin Murphy. Refer to Note 10 for further discussion. On October 24, 2022, the Company amended these credit facilities and the Company paid an amendment fee of $1,250 to the lenders, with $375 paid to Viridescent. On April 28, 2023, the Company and the lenders further amended the Prime rate credit facilities. Refer to Note 10 for further discussion.

Viridescent has committed $42,000 of the $140,000 drawn down under the Credit Facility, with third-party syndicated affiliates committing the additional $98,000. During the three and nine months ended September 30, 2023, the Company incurred interest expense attributable to Viridescent of $1,522 and $4,212, respectively. The loan is secured by first-lien mortgages on Acreage’s wholly owned real estate and other commercial security interests. A third-party syndicate served as Administrative Agent for the transaction.

15.    REPORTABLE SEGMENTS

The Company prepares its segment reporting on the same basis that its Chief Operating Decision Maker manages the business, and makes operating decisions. The Company operates under one operating segment, which is its only reportable segment: the production and sale of cannabis products. The Company’s measure of segment performance is net income, and derives its revenue primarily from the sale of cannabis products, as well as related management or consulting services which were not material in all periods presented. All of the Company’s operations are located in the United States.

16.    EARNINGS PER SHARE

Basic earnings per share are computed by dividing net loss attributable to common shareholders of the Company by the weighted average number of outstanding shares for the period. Diluted earnings per share are calculated based on the weighted number of outstanding common shares plus the dilutive effect of stock options and warrants, as if they were exercised, and restricted stock units and profits interests, as if they vested and NCI convertible units, as if they converted.

Basic and diluted loss per share is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Net loss attributable to common shareholders of the Company	$	(7,625)	$	(22,214)	$	(38,371)	$	(44,837)
Weighted average shares outstanding - basic	114,171		111,200		113,181		108,795
Effect of dilutive securities	—		—		—		—
Weighted average shares - diluted	114,171		111,200		113,181		108,795
Net loss per share attributable to common shareholders of the Company - basic	$	(0.07)	$	(0.20)	$	(0.34)	$	(0.41)
Net loss per share attributable to common shareholders of the Company - diluted	$	(0.07)	$	(0.20)	$	(0.34)	$	(0.41)

F-28

ACREAGE HOLDINGS, INC.

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

During the nine months ended September 30, 2023, 5,817 Fixed warrants, 2,524 Floating warrants, 6,167 Fixed Share RSUs, 6,237 Floating Share RSUs, 5,462 Fixed Share stock options, 2,101 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive. During the nine months ended September 30, 2022, 5,817 Fixed warrants, 2,524 Floating warrants, 6,786 Fixed Share RSUs, 534 Floating Share RSUs, 7,337 Fixed Share stock options, 2,303 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive.

17.    SUBSEQUENT EVENTS

On October 31, 2023, Acreage, Canopy and Canopy USA entered into a fourth amendment to the Floating Share Arrangement Agreement (the “Floating Share Amendment”). Pursuant to the terms of the Floating Share Amendment, Acreage, Canopy and Canopy USA agreed to amend the Exercise Outside Date from October 31, 2023, to December 31, 2023.

F-29

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to assist in the understanding and assessing the trends and significant changes in our results of operations and financial condition. Historical results may not be indicative of future performance. This discussion includes forward-looking statements that reflect our plans, estimates and beliefs. Such statements involve risks and uncertainties. Our actual results may differ materially from those contemplated by these forward-looking statements as a result of various factors, including those set forth in “Risk Factors” in Part I, Item 1A of the Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”), and “Cautionary Statement Regarding Forward-Looking Statements” set forth below.

This MD&A should be read in conjunction with the Company’s unaudited condensed consolidated financial statements for the three and nine month period ended September 30, 2023 and related notes appearing elsewhere in this Quarterly Report on Form 10-Q (this “Quarterly Report” or “Form 10-Q) and the 2022 Form 10-K. Financial information presented in this MD&A is presented in thousands of U.S. dollars, unless otherwise indicated.

Cautionary Statement Regarding Forward Looking-Statements

This Quarterly Report of the Company contains statements that include forward-looking information and are forward-looking statements within the meaning of applicable Canadian and United States securities legislation (“forward-looking statements”), including the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. All statements, other than statements of historical fact, included herein are forward-looking statements, including, for greater certainty, statements regarding the proposed transactions with Canopy Growth Corporation (“Canopy Growth” or “Canopy”), including the anticipated benefits and likelihood of completion thereof.

Generally, forward-looking statements may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. There can be no assurance that such forward-looking statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking statements. Forward-looking statements reflect Acreage’s current beliefs and are based on information currently available to Acreage and on assumptions Acreage believes are reasonable. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Acreage to be materially different from those expressed or implied by such forward-looking statements. Such risks and other factors may include, but are not limited to:

•The US Federal Illegality of the Company’s business activities;

•the anticipated benefits of the Floating Share Arrangement with Canopy Growth;

•the likelihood of Canopy Growth completing the acquisition of the Fixed Shares and/or Floating Shares;

•risks related to the ability to finance Acreage’s business and fund its obligations;

•other expectations and assumptions concerning the transactions contemplated between Canopy Growth and Acreage;

•in the event that the Floating Share Arrangement is completed, the likelihood of Canopy completing the Acquisition in accordance with the Existing Arrangement Agreement;

•the risk of a change of control of either Canopy or Canopy USA;

•the impact of material non-recurring expenses in connection with the Floating Share Arrangement on Acreage’s future results of operations, cash flows and financial condition;

•the ability of Canopy, Canopy USA and Acreage to leverage each other’s respective capabilities and resources;

•the available funds of Acreage and the anticipated use of such funds;

•the availability of financing opportunities for Acreage and the risks associated with the completion thereof;

•regulatory and licensing risks;

•changes in general economic, business and political conditions, including changes in the financial and stock markets;

•legal and regulatory risks inherent in the cannabis industry;

•risks associated with economic conditions, dependence on management and currency risk;

•risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks;

•risks relating to anti-money laundering laws and regulation;

•other governmental and environmental regulation;

•public opinion and perception of the cannabis industry;

•risks related to contracts with third-party service providers;

•risks related to the enforceability of contracts and lack of access to U.S. bankruptcy protections;

•reliance on the expertise and judgment of senior management of Acreage;

•risks related to proprietary intellectual property and potential infringement by third parties;

•the concentrated voting control of Acreage’s founder and the unpredictability caused by Acreage’s capital structure;

F-30

•the dual structure of the Fixed and Floating Shares

•risks relating to the management of growth;

•increasing competition in the industry;

•risks inherent in an agricultural business;

•risks relating to energy costs;

•risks associated with cannabis products manufactured for human consumption including potential product recalls;

•reliance on key inputs, suppliers and skilled labor;

•cybersecurity risks;

•ability and constraints on marketing products;

•fraudulent activity by employees, contractors and consultants;

•tax and insurance related risks;

•risks related to the economy generally;

•risk of litigation;

•conflicts of interest;

•risks relating to certain remedies being limited and the difficulty of enforcement judgments and effecting service outside of Canada;

•risks related to future acquisitions or dispositions;

•sales by existing shareholders; and

•limited research and data relating to cannabis.

A description of additional assumptions used to develop such forward-looking statements and a description of additional risk factors that may cause actual results to differ materially from forward-looking statements can be found in Part I, Item 1A of the Company’s Annual Report on Form 10-K, under the heading “Risk Factors”, dated May 1, 2023, as filed with the Securities and Exchange Commission. Although Acreage has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking statements contained in this Form 10-Q are expressly qualified by this cautionary statement. The forward-looking statements contained in this Form 10-Q represent the expectations of Acreage as of the date of this Form 10-Q and, accordingly, are subject to change after such date. However, Acreage expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Management’s discussion and analysis of financial condition and results of operations is intended to help provide an understanding of the Company’s financial condition, changes in financial condition and results of operations. This discussion is organized as follows:

•Overview—This section provides a general description of the Company’s businesses, its strategic objectives, as well as developments that occurred during the three and nine months ended September 30, 2023 and 2022 that the Company believes are important in understanding its results of operations and financial condition or to disclose known trends.

•Results of Operations—This section provides an analysis of the Company’s results of operations for the three and nine months ended September 30, 2023 and 2022. This analysis is presented on a consolidated basis. In addition, a brief description is provided of significant transactions and events that impact the comparability of the results being analyzed.

•Liquidity and Capital Resources—This section provides an analysis of the Company’s cash flows for the three and nine months ended September 30, 2023 and 2022, as well as a discussion on the Company’s outstanding debt and commitments that existed as of September 30, 2023. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to fund the Company’s future commitments and obligations, as well as a discussion of other financing arrangements.

F-31

Overview

Acreage Holdings, Inc. (“Acreage” or the “Company”), a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S, was continued into the Province of British Columbia under the Business Corporations Act (British Columbia). Acreage Fixed Shares and Floating Shares (as such terms are defined at Note 13 of the unaudited condensed consolidated financial statements) are each listed on the Canadian Securities Exchange under the symbols “ACRG.A.U” and “ACRG.B.U”, respectively, and are quoted on the OTCQX® Best Market by OTC Markets Group under the symbols “ACRHF” and “ACRDF”, respectively and on the Open Market of the Frankfurt Stock Exchange under the symbols “0VZ1” and “0VZ2”, respectively. Acreage operates through its consolidated subsidiary High Street Capital Partners, LLC (“HSCP”), a Delaware limited liability company. HSCP, which does business as “Acreage Holdings”, was formed on April 29, 2014. The Company became an indirect parent of HSCP on November 14, 2018 in connection with a reverse takeover (“RTO”) transaction. The Company’s operations include (i) cultivating cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing high-quality, effective cannabis products to patients and consumers. The Company appeals to medical patients and adult-use customers through brand strategies intended to build trust and loyalty.

As of September 30, 2023, Acreage owned and operated a total of twenty-three dispensaries - four in New York, three in New Jersey, three in Connecticut, two in Massachusetts, two in Illinois, five in Ohio, and four in Maine. As of September 30, 2023, Acreage owned and operated a total of eight cultivation and processing facilities, one each in Illinois, Maine, New Jersey, New York, Ohio and Pennsylvania, respectively, and two in Massachusetts.

Strategic Priorities

The Company believes its focused strategy is the key to continued improvements in its financial results and shareholder value. For the past few years, the Company was focused on three key strategic objectives - accelerating growth in its core markets, driving profitability, and strengthening the balance sheet. For 2023 and onwards, the Company has modified its strategic objectives in response to Company and industry developments - focus on cash, accelerate growth in core markets with core brands and prepare for Canopy USA.

Focus on Cash: A combination of economic conditions, lack of regulatory change and industry competition impacting pricing have negatively impacted the Company’s ability to generate cash flow to support operational requirements and capital activities. Additionally, these factors have likely limited the additional capital that might be available to the Company. While these factors continue, the Company will focus on maximizing the cash flow generated by operating activities and limit capital expenditures to only those projects that can be funded from existing resources and are expected to generate near-term returns.

Accelerating Growth in Core Markets with Core Brands: Through prior acquisitions and capital expenditures, management believes Acreage is well positioned for future success in several key markets as regulations regarding the use of cannabis continue to evolve. The Company will continue to focus its growth in its core markets where it can take advantage of and expand on the presence already established. Additionally, the Company has developed a portfolio of core brands that resonate with its customers. The Company will focus on ensuring that these core brands feature prominently in the markets where they are available.

Prepare for Canopy USA: During the fourth quarter of 2022, the Company entered into a new strategic arrangement with Canopy Growth that would allow Canopy Growth to acquire 100% of Acreage by (i) waiving its existing Floating Share option and entering into a new Floating Share arrangement agreement; and (ii) committing to exercise its Fixed Share option, all subject to required approvals and terms of the related agreements. Throughout 2023, the Company has taken all steps necessary to date to prepare for the eventual closing of these transactions, including holding a special meeting of shareholders to approve the Floating Share arrangement agreement.

Highlights from the three and nine months ended September 30, 2023:

•The Company ended the quarter with a cash balance of $24,793, including $15,142 of cash and cash equivalents and $9,651 of restricted cash, respectively.

•The Company’s total consolidated revenue declined 8% and 5% as compared with the three and nine months ended September 30, 2022, respectively. After adjusting for acquisitions and divestitures, revenue for the three and nine months ended September 30, 2023 declined by 7% and 3%, respectively. On a sequential basis, revenue decreased by 3% for the three months ended September 30, 2023 as compared to the prior three months period ended June 30, 2023.

•Adjusted EBITDA for the three and nine months ended September 30, 2023 was $6.6 million and $24.0 million, respectively, compared to adjusted EBITDA of $8.8 million and $27.9 million, respectively during the same period in 2022. This marks eleven consecutive quarters of positive adjusted EBITDA. Refer to section “Non-GAAP Information” for a discussion of Adjusted EBITDA as a non-GAAP measure.

F-32

•On January 2, 2023, the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine.

•On January 10, 2023, the Company commenced adult-use operations in Connecticut, offering a range of products from our flagship brand The Botanist for adult-use sales in Montville.

•On January 31, 2023, the Company launched “Fast-Acting Gummies” or “TiME Gummies” under its flagship brand The Botanist in Illinois, Maine, Massachusetts, and Ohio.

•The Floating Share Arrangement was approved at a special meeting of the holders of Floating Shares held on March 15, 2023. Refer to Note 13 for further discussion.

•On April 11, 2023, the Company sold, for total proceeds of $12,113, the rights to receive certain Employee Retention Tax Credits (“ERTC”) with an aggregate receivable value of $14,251.

•On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further $15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company has agreed to limit the total amounts outstanding under the Credit Agreement to $140,000.

•On September 12, 2023 the Company finalized the sale of CWG Botanicals, Inc, completing our exit of the California market, which is consistent with its overall strategy to focus on its core states.

Operational and Regulation Overview (all amounts in thousands, except per share amounts)

The Company believes its operations are in material compliance with all applicable state and local laws, regulations and licensing requirements in the states in which it operates. However, cannabis is illegal under U.S. federal law. Substantially all of the Company’s revenue is derived from U.S. cannabis operations. For information about risks related to U.S. cannabis operations, please refer to Item 1A of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Results of Operations

The following table presents selected financial data derived from the unaudited condensed consolidated financial statements of the Company for the three and nine months ended September 30, 2023 and 2022. The selected financial information set out below may not be indicative of the Company’s future performance.

Summary Results of Operations

					Better/(Worse)								Better/(Worse)
in thousands, except per share amounts	Three Months Ended September 30,				2023 vs. 2022				Nine Months Ended September 30,				2023 vs. 2022
	2023		2022		$		%		2023		2022		$		%
Revenues, net	$	56,502	$	61,419	$	(4,917)	(8)	%	$	170,580	$	179,649	$	(9,069)	(5)	%
Net operating loss	(2,501)		(16,435)		13,934		85		(6,411)		(15,847)		9,436		60
Net loss attributable to Acreage	(7,625)		(22,214)		14,589		66		(38,371)		(44,837)		6,466		14
Basic and diluted loss per share attributable to Acreage	$	(0.07)	$	(0.20)	$	0.13	65	%	$	(0.34)	$	(0.41)	$	0.07	17	%

Revenues, Cost of goods sold and Gross profit

The Company derives its revenues from sales of cannabis and cannabis-infused products through retail dispensary, wholesale and manufacturing and cultivation businesses, as well as from management or consulting fees from entities for whom the Company provides management or consulting services.

Gross profit is revenue less cost of goods sold. Cost of goods sold includes costs directly attributable to inventory sold such as direct material, labor, and overhead, including depreciation. Such costs are further affected by various state regulations that limit the sourcing and procurement of cannabis and cannabis-related products, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes.

F-33

							Better/(Worse)										Better/(Worse)
in thousands	Three Months Ended September 30,						2023 vs. 2022				Nine Months Ended September 30,						2023 vs. 2022
	2023			2022			$		%		2023			2022			$		%
Retail revenue, net	$	43,857		$	48,314		$	(4,457)	(9)	%	$	130,651		$	136,426		$	(5,775)	(4)	%
Wholesale revenue, net	12,645			12,810			(165)		(1)		39,845			42,342			(2,497)		(6)
Other revenue, net	—			295			(295)		n/m		84			881			(797)		(90)
Total revenues, net	$	56,502		$	61,419		$	(4,917)	(8)	%	$	170,580		$	179,649		$	(9,069)	(5)	%
Cost of goods sold, retail	(23,247)			(26,097)			2,850		11		(67,145)			(70,331)			3,186		5
Cost of goods sold, wholesale	(11,981)			(14,096)			2,115		15		(34,454)			(27,968)			(6,486)		(23)
Total cost of goods sold	$	(35,228)		$	(40,193)		$	4,965	12	%	$	(101,599)		$	(98,299)		$	(3,300)	(3)	%
Gross profit	$	21,274		$	21,226		$	48	—	%	$	68,981		$	81,350		$	(12,369)	(15)	%
Gross margin	38		%	35		%			3	%	40		%	45		%			(5)	%
n/m - Not Meaningful

Three months ended September 30, 2023 vs. 2022

Total revenues for the three months ended September 30, 2023 declined by $4,917, or 8%, compared to the three months ended September 30, 2022. The decline in total revenue was primarily due to continued competitive pressure across most of the Company’s markets and was somewhat offset by revenue growth in Connecticut after commencement of adult use sales.

Retail revenue for the three months ended September 30, 2023 declined by $4,457, or 9%, compared to the three months ended September 30, 2022. This decline was primarily driven by increased retail competition and pricing pressures in key markets and was partially offset by the commencement of adult use sales in Connecticut in January 2023.

.

Wholesale revenue for the three months ended September 30, 2023 decreased by $165, or 1%, compared to the three months ended September 30, 2022. The decline in wholesale revenue was primarily due to price compression and decreased wholesale demand in key markets, particularly in those markets where integrated operators put a greater focus on the sales of their own internally produced products.

Retail cost of goods sold decreased $2,850 or 11% for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. This decrease was driven by lower volumes and cost efficiencies.

Wholesale cost of goods sold decreased $2,115, or 15%, for the three months ended September 30, 2023 compared to the three months ended September 30, 2022. The Company recognized $2,103 of wholesales inventory adjustments during the three months ended September 30, 2023 and $6,286 during the three months ended September 30, 2022, as a result of excess inventory in select markets and reducing the carrying value of wholesale inventory to reflect the lower of cost and net realizable value. Excluding these non-cash inventory adjustments, wholesale costs of goods sold for the three months ended September 30, 2023 increased $2,068 or 26% compared to 2022 due to increased volumes and product mix shifts.

Gross profit increased $48, for the three months ended September 30, 2023 to $21,274 from $21,226 in the three months ended September 30, 2022, gross margin increased to 38% of revenue in the three months ended September 30, 2022 from 35% of revenue for the three months ended September 30, 2022. Efficiencies gained from further economies of scale were unable to offset (i) overall selling price declines, (ii) cost increases due to inflation, (iii) volume declines relative to a portion of the expenditures that are fixed in nature and, (iv) the aforementioned wholesale non-cash inventory adjustments. Excluding these non-cash inventory adjustments, margin increased to 41%.

Nine months ended September 30, 2023 vs. 2022

Total revenues for the nine months ended September 30, 2023 decreased by $9,069, or 5%, compared to the nine months ended September 30, 2022. The decline in total revenue was, in part, due to a decrease of $2,111 related to the divestiture of the Company’s operations in Oregon, offset by an increase of $430 due to the acquisitions of a Maine dispensary in 2022. Excluding these acquisitions and divestitures, total revenue decreased by $7,387, or 4% for the nine months ended September 30, 2023, as compared to 2022. Continued competitive pressure across most of the Company’s markets was somewhat offset by revenue growth in both New Jersey and Connecticut after the commencement of adult use sales.

Retail revenue for the nine months ended September 30, 2023 decreased by $5,775, or 4%, compared to the nine months ended September 30, 2022. Excluding the impact of acquisitions and divestitures, retail revenue decreased by $4,094 or 3% for the nine months ended September 30, 2023 compared to the nine months ended September 30, 2022. Revenue decreased due to increased retail competition and pricing pressures in key markets that was partially offset by the commencement of adult use sales in New Jersey in April 2022 and Connecticut in January 2023.

F-34

Wholesale revenue for the nine months ended September 30, 2023 decreased by $2,497, or 6%, compared to the nine months ended September 30, 2022. The decline in wholesale revenue was primarily due to price compression and decreased wholesale demand in select markets, particularly in those markets where integrated operators put a greater focus on the sales of their own internally produced products.

Retail cost of goods sold decreased $3,186, or 5%, for the nine months ended September 30, 2023 compared to the nine months ended 2022, which was generally consistent with the 4% decrease in retail revenue. Inflation-driven cost increases were generally offset by cost efficiencies.

Wholesale cost of goods sold increased $6,486, or 23%, for the nine months ended September 30, 2023 compared to the nine months ended 2022. The growth in wholesale cost of goods sold contrasted with an 6% decrease in wholesale revenue. Wholesale cost of goods sold increased due to $8,824 of non-cash inventory adjustments made during the nine months ended September 30, 2023 compared to $6,826 of non-cash inventory adjustments during the nine months ended September 30, 2022. Excluding these non-cash inventory adjustments, wholesale costs of goods sold increased $4,488 or 21%. Inflation driven cost increases and product mix shifts, which were greater than the cost reductions associated with lower volumes, drove the increase in wholesale cost of goods sold.

Gross profit decreased $12,369, or 15%, for the nine months ended September 30, 2023 to $68,981 from $81,350 in the nine months ended 2022, and Gross margin decreased from 45% of revenue for the nine months ended September 30, 2022 to 40% of revenue in 2023, or 5%, due to the factors discussed above. Efficiencies gained from further economies of scale were unable to offset (i) overall selling price declines, (ii) cost increases due to inflation, (iii) volume declines relative to a portion of the expenditures that are fixed in nature, and (iv) the aforementioned wholesale non-cash inventory adjustments. Excluding the non-cash inventory adjustments, margin improved slightly to 46%.

Revenue by geography

While the Company operates under one operating segment for the production and sale of cannabis products, the below revenue breakout by geography is included as management believes it provides relevant and useful information to investors.

Revenue by region					Better/(Worse)					Better/(Worse)
in thousands	Three Months Ended September 30,				2023 vs. 2022			Nine Months Ended September 30,		2023 vs. 2022
	2023		2022		$	%		2023	2022	$	%
New England	$	18,186	$	16,481	1,705	10	%	50,845	49,293	1,552	3	%
Mid-Atlantic	19,672		21,235		(1,563)	(7)	%	61,047	56,125	4,922	9	%
Midwest	18,575		23,096		(4,521)	(20)	%	58,102	70,059	(11,957)	(17)	%
West	69		607		(538)	(89)	%	586	4,172	(3,586)	(86)	%
Total revenues, net	$	56,502	$	61,419	(4,917)	(8)	%	170,580	179,649	(9,069)	(5)	%

Total operating expenses

Total operating expenses consist primarily of loss on impairments, compensation expense at our corporate offices as well as operating subsidiaries, professional fees, which includes, but is not limited to, legal and accounting services, depreciation and other general and administrative expenses.

F-35

Operating expenses					Better/(Worse)								Better/(Worse)
in thousands	Three Months Ended September 30,				2023 vs. 2022				Nine Months Ended September 30,				2023 vs. 2022
	2023		2022		$		%		2023		2022		$		%
General and administrative	$	8,036	$	9,727	$	1,691	17	%	$	25,621	$	27,036	$	1,415	5	%
Compensation expense	13,524		15,271		1,747		11		38,930		42,045		3,115		7
Equity-based compensation expense	745		3,156		2,411		76		2,423		8,970		6,547		73
Marketing	542		735		193		26		1,942		2,396		454		19
Impairments, net	—		506		506		n/m		—		2,973		2,973		n/m
Loss on notes receivable	—		7,219		7,219		n/m		—		7,219		7,219		n/m
Write down (recovery) of assets held-for-sale	—		—		—		n/m		3,557		874		(2,683)		(307)
Legal settlements (recoveries)	—		—		—		n/m		—		(335)		(335)		n/m
Depreciation and amortization	928		1,047		119		11		2,919		6,019		3,100		52
Total operating expenses	$	23,775	$	37,661	$	13,886	37	%	$	75,392	$	97,197	$	21,805	22	%
n/m - Not Meaningful

Three months ended September 30, 2023 vs. 2022

Total operating expenses for the three months ended September 30, 2023 were $23,775, a decrease of $13,886, or 37%, compared to the three months ended 2022. The primary drivers of the decrease in operating expenses were as follows:

•General and administrative expenses decreased $1,691 during the three months ended September 30, 2023 compared to 2022, primarily due to (i) decreases in professional fees as the Company has become less reliant on consultants as the organization has matured and (ii) decreases in both office expenses and other expenses, which was driven by measures put in place by management to reduce costs.

•Compensation expense decreased $1,747 during the three months ended September 30, 2023 as compared to 2022, primarily due to decreased human capital costs and employee benefits.

•Equity-based compensation expense decreased $2,411, or 76%, during the three months ended September 30, 2023 as compared to 2022, primarily due to staffing reductions and changes made to the Company’s long-term incentive compensation plans.

•Impairments, net expense decreased $506 during the three months ended September 30, 2023 as compared to 2022, primarily due to non-recurrence of the impairments from 2022.

•Loss on notes receivable expense decreased $7,219 during the three months ended September 30, 2023 as compared to 2022, primarily due to the prior year loss being a one-time determination that the payment for certain notes receivables was doubtful as of prior-year’s quarter-end.

•Depreciation and amortization expenses decreased by $119 during the three months ended September 30, 2023 compared to 2022, primarily due to the impairment of certain intangible assets in 2022.

Nine months ended September 30, 2023 vs. 2022

Total operating expenses for the nine months ended September 30, 2023 were $75,392, a decrease of $21,805, or 22%, compared to the nine months ended September 30, 2022. The primary drivers of the increase in operating expenses were as follows:

•Compensation expense decreased $3,115 during the nine months ended September 30, 2023 as compared to 2022, primarily due to the reversal of bonus provisions related to the prior year along with lower human capital costs and employee benefits.

•Equity-based compensation expense decreased $6,547, or 73%, during the nine months ended September 30, 2023 as compared to 2022, primarily due to the fully vesting, prior to the three months ended March 31, 2023 of certain historic equity-based compensation grants.

•There were no impairments in the nine months ended September 30, 2023. Impairments, net of $2,973 for the nine months ended September 30, 2022 was primarily driven by an impairment of $1,907 related to certain Michigan locations during the nine months ended September 30, 2022.

•Write down (recovery) of assets held-for-sale of $3,557 for the nine months ended September 30, 2023 related to the Company’s adult-use cannabis cultivation and processing operations in the state of California. The write downs of assets held-for-sale in the comparative period of 2022 relate to the Company’s Oregon operations which were disposed of in the year ended December 31, 2022.

F-36

•Depreciation and amortization expenses decreased by $3,100 during the nine months ended September 30, 2023 compared to 2022, primarily due to an acceleration of the amortization of certain intangible assets as a result of a reduction in the expected useful lives of such assets during the nine months ended September 30, 2023 and due to the impairment of certain intangible assets in the year ended December 31, 2022.

Total other income (loss)

Other income (loss)					Better/(Worse)							Better/(Worse)
in thousands	Three Months Ended September 30,				2023 vs. 2022			Nine Months Ended September 30,				2023 vs. 2022
	2023		2022		$		%	2023		2022		$		%
Income from investments, net	$	248	$	17	$	231	n/m	$	228	$	154	$	74	48
Interest income from loans receivable	—		474		(474)		n/m	10		1,256		(1,246)		(99)	%
Interest expense	(9,207)		(5,688)		(3,519)		(62)	(26,143)		(15,989)		(10,154)		(64)
Other income, net	10,021		4,743		5,278		111	9,823		5,019		4,804		96
Total other income (loss)	$	1,062	$	(454)	$	1,516	n/m	$	(16,082)	$	(9,560)	$	(6,522)	(68)	%
n/m - Not Meaningful

Three months ended September 30, 2023 vs. 2022

Total other income (loss) for the three months ended September 30, 2023 was $1,062, an increase of $1,516 compared to the three months ended September 30, 2022. The primary drivers of the increase in total other income (loss) were as follows:

•Income from investments, net of $248 for the three months ended September 30, 2023 has increased $231 as compared to 2022 due to fair value adjustments to the investment in equity in other companies.

•Interest expense for the three months ended September 30, 2023 of $9,207, increased by $3,519 as a result of the Company having a larger debt balance as compared to 2022 and due to an increased interest rate on a substantial portion of the Company’s debt.

•Other income, net for the three months ended September 30, 2023 of $10,021, increased by $5,278 as compared to 2022, which was primarily due to income provided from Employee Retention Tax Credits.

Nine months ended September 30, 2023 vs. 2022

Total other income (loss) for the nine months ended September 30, 2023 was $16,082, an increase of $6,522 compared to the nine months ended September 30, 2022. The primary drivers of the increase in Total other loss were as follows:

•Interest income from loans receivable of $10 for the nine months ended September 30, 2023 has decreased $1,246 as compared to 2022 due to a reduction in loans receivable outstanding during the comparative period.

•Interest expense for the nine months ended September 30, 2023 of $26,143 increased by $10,154 as a result of the Company having a larger debt balance as compared to 2022 and due to an increased interest rate on a substantial portion of the Company’s debt.

•Other income, net for the nine months ended September 30, 2023 of $9,823, increased by $4,804 as compared to 2022, which was primarily due to income provided from Employee Retention Tax Credits.

Net loss

Net loss					Better/(Worse)								Better/(Worse)
in thousands	Three Months Ended September 30,				2023 vs. 2022				Nine Months Ended September 30,				2023 vs. 2022
	2023		2022		$		%		2023		2022		$		%
Net loss	$	(7,859)	$	(24,998)	$	17,139	69	%	$	(42,256)	$	(49,512)	$	7,256	15	%
Less: net loss attributable to non-controlling interests	(234)		(2,784)		2,550		92		(3,885)		(4,675)		790		17	%
Net loss attributable to Acreage Holdings, Inc.	$	(7,625)	$	(22,214)	$	14,589	66	%	$	(38,371)	$	(44,837)	$	6,466	14	%

The changes in net loss are driven by the factors discussed above.

F-37

Non-GAAP Information

This statement includes Adjusted EBITDA, which is a non-GAAP performance measure that we use to supplement our results presented in accordance with U.S. GAAP. The Company uses Adjusted EBITDA to evaluate its actual operating performance and for planning and forecasting future periods. The Company believes that the adjusted results presented provide relevant and useful information for investors because they clarify the Company’s actual operating performance, make it easier to compare our results with those of other companies and allow investors to review performance in the same way as our management. Since these measures are not calculated in accordance with U.S. GAAP, they should not be considered in isolation of, or as a substitute for, net loss or our other reported results of operations as reported under U.S. GAAP as indicators of our performance, and they may not be comparable to similarly named measures from other companies.

The Company defines Adjusted EBITDA as net income before interest, income taxes and, depreciation and amortization and excluding the following: (i) income from investments, net (the majority of the Company's investment income relates to remeasurement to net asset value of previously-held interests in connection with our roll-up of affiliates, and the Company expects income from investments to be a non-recurring item as its legacy investment holdings diminish), (ii) equity-based compensation expense, (iii) non-cash impairment losses, (iv) transaction costs, (v) non-cash inventory adjustments and (vi) other non-recurring expenses (other expenses and income not expected to recur).

Adjusted EBITDA					Better/(Worse)								Better/(Worse)
in thousands	Three Months Ended September 30,				2023 vs. 2022				Nine Months Ended September 30,				2023 vs. 2022
	2023		2022		$		%		2023		2022		$		%
Net loss (U.S. GAAP)	$	(7,859)	$	(24,998)					$	(42,256)	$	(49,512)
Income tax expense	6,420		8,109						19,763		24,105
Interest expense, net	9,207		5,214						26,133		14,733
Depreciation and amortization(1)	2,427		2,583						8,976		9,930
EBITDA (non-GAAP)	$	10,195	$	(9,092)	$	19,287	212	%	$	12,616	$	(744)	$	13,360	1,796	%
Adjusting items:
Income from investments, net	(248)		(17)						(228)		(154)
Impairments, net	—		506						—		2,596
Non-cash inventory adjustments	2,103		6,286						8,824		6,286
Loss on extraordinary events(2)	—		—						1,692		376
Loss on notes receivable	—		7,219						—		7,219
Write down (recovery) of assets held-for-sale	—		—						3,557		874
Legal settlements, net	—		—						—		(335)
Gain on business divestiture	(47)		(3,200)						(47)		(3,496)
Equity-based compensation expense	745		3,156						2,423		8,970
Other non-recurring income and expenses(3)	(6,174)		3,989						(4,835)		6,267
Adjusted EBITDA (non-GAAP)	$	6,574	$	8,847	$	(2,273)	(26)	%	$	24,002	$	27,859	$	(3,857)	(14)	%

(1) Depreciation and amortization for the three and nine months ended September 30, 2023 and 2022 contains depreciation and amortization included in cost of goods sold.

(2) Extraordinary items are events and transactions that are distinguished by their unusual nature and by the infrequency of their occurrence.

(3) Other non-recurring income and expenses relates to certain compensation, general and administrative, and other miscellaneous income and expenses. The Company excludes these items as they are not expected to recur.

The increases in adjusted EBITDA are driven by the factors discussed above.

F-38

LIQUIDITY AND CAPITAL RESOURCES

Liquidity

Sources and uses of cash (all amounts in thousands, except per share amounts)

The Company’s primary uses of capital include operating expenses, income taxes, capital expenditures and the servicing of outstanding debt. The Company’s primary sources of capital include funds generated by cannabis sales as well as financing activities. Through September 30, 2023, the Company had primarily used private financing as a source of liquidity for short-term working capital needs and general corporate purposes.

As of September 30, 2023, the Company had cash of $24,793, including $15,142 of cash and cash equivalents and $9,651 of restricted cash, respectively, on the Unaudited Condensed Consolidated Statements of Financial Position. The Company’s ability to fund its operations, capital expenditures, acquisitions, and other obligations depends on its future operating performance and ability to obtain financing, which are subject to prevailing economic conditions, as well as financial, business and other factors, some of which are beyond the Company’s control.

The Company’s future contractual obligations include the following:

Leases

As of September 30, 2023, the Company had future operating lease obligations and future finance lease obligations of $30,961 and $15,763, respectively, with $1,085 and $228 payable within the next three months, respectively. The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments, and accounts for non-lease components separately from leases. Refer to Note 8 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Debt

As of September 30, 2023, the Company had outstanding debt with varying maturities for an aggregate principal amount of $234,738 (net of $13,488 of unamortized discounts and debt issuance costs), with $2,432 payable within the remaining three months. The Company has related future interest payments of $67,457, with $6,184 payable within the remaining three months. In April 2023, the Company reached an agreement with its lenders that would allow it to draw a further $15,000 under its current credit agreement, but such funds would be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to not draw additional funds under the Credit Agreement. Refer to Notes 10 and 17 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

The Company expects that its Cash and cash equivalents of $15,142 as of September 30, 2023, will be adequate to support the future obligations discussed above as well as the capital needs of the existing operations and expansion plans over the next twelve months.

Going Concern

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of September 30, 2023, as well as a net loss and negative cash flow from operating activities for the nine months ended September 30, 2023. Additionally, subsequent to quarter end the Company was temporarily in default of the Universal Hemp 6.1% Loan. Refer to Note 10 for further discussion. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, (iv) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans.

F-39

Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company’s need to raise additional capital on an immediate basis.

Cash flows

Cash and cash equivalents and restricted cash were $24,793 as of September 30, 2023, which represents a net increase of $726 for the nine months ended September 30, 2023 as compared to 2022. The following table details the change in cash, cash equivalents, restricted cash and cash related to assets held for sale for the nine months ended September 30, 2023 and 2022.

Cash flows					Better/(Worse)
in thousands	Nine Months Ended September 30,				2023 vs. 2022
	2023		2022		$		%
Net cash used in operating activities	$	(18,729)	$	(30,473)	$	11,744	39	%
Net cash used in investing activities	(2,206)		(5,328)		3,122		59
Net cash provided by financing activities	21,661		17,871		3,790		21
Net increase (decrease) in cash, cash equivalents, restricted cash, and cash held for sale	$	726	$	(17,930)	$	18,656	n/m
n/m - Not Meaningful

Net cash used in operating activities

During the nine months ended September 30, 2023, the Company used $18,729 of net cash in operating activities compared to $30,473 of net cash provided through operating activities in the same period for 2022, which represented an improvment of $11,744, or 39%, when compared with 2022. The Company’s reported net loss decreased by $7,256 during the nine months ended September 30, 2023 when compared to the same period of 2022.

Net cash used in investing activities

During the nine months ended September 30, 2023, the Company used $2,206 of net cash through investing activities compared to $5,328 of net cash used in investing activities in the same period for 2022, which represented an improvement of $3,122. Net cash used in investing activities for the nine months ended September 30, 2023 included $5,345 on the purchase of capital assets and intangibles which was partially offset by collection of notes receivable of $2,150.

Net cash provided by financing activities

During the nine months ended September 30, 2023, the Company had $21,661 of net cash provided through financing activities compared to $17,871 of net cash provided through financing activities in the same period for 2022, which represented an improvement of $3,790. Net cash used in financing activities for the nine months ended September 30, 2023 included $913 of debt repayments.

F-40

Capital Resources

Capital structure and debt

Our debt outstanding as of September 30, 2023 and December 31, 2022 is as follows:

Debt balances	September 30, 2023		December 31, 2022
Financing liability (failed sale-leaseback)	$	15,253	$	15,253
Finance lease liabilities	5,958		5,306
7.50% Loan due April 2026	31,682		31,288
6.10% Secured debenture due September 2030	46,841		46,502
Note due December 2024	2,375		3,167
Prime rate credit facilities due January 2026, as amended	130,989		113,564
Note backed by ERTC	1,640		—
Total debt	$	234,738	$	215,080
Less: current portion of debt	3,336		1,584
Total long-term debt	$	231,402	$	213,496

Commitments and contingencies

Commitments

The Company provides revolving lines of credit to several third parties. Refer to Note 6 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Arrangement with Canopy Growth

On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the Prior Plan of Arrangement involving the two companies. Subsequently, on September 23, 2020, Acreage and Canopy Growth entered into an amending agreement and the Amended Arrangement became effective on September 23, 2020.

During the fourth quarter of 2022, the Company entered into a new strategic arrangement with Canopy Growth that, would allow Canopy Growth to acquire 100% of Acreage by (i) waiving its existing Floating Share option and entering into a new Floating Share acquisition agreement; and (ii) committing to exercise its Fixed Share option, all subject to required approvals and terms of the related agreements.

Refer to Note 13 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Advisor fee

In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of $7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of $3,000 in cash, less a $500 initial payment, and $2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Tax Receivable Agreement

The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the “Tax Receivable Agreement”) between the Company, certain current and former unit holders of HSCP and, Canopy Growth and Canopy USA and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the “Tax Receivable Bonus Plans”) between the Company and certain directors, officers, consultants of the Company, Canopy Growth and Canopy USA (together the “Tax Receivable Recipients”). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan.

F-41

Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of $5,000 as of September 30, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.

The Company is subject to other capital commitments and similar obligations. As of September 30, 2023, such amounts were not material.

Contingencies

The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company’s applicable subsidiaries ceasing operations. While management of the Company believes that the Company’s subsidiaries are in compliance with applicable local and state regulations as of September 30, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company’s subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.

The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated. Refer to Note 13 of the Unaudited Condensed Consolidated Financial Statements for further discussion.

Critical accounting policies and estimates

We have adopted various accounting policies to prepare the Unaudited Condensed Consolidated Financial Statements in accordance with GAAP. Certain of our accounting policies require the application of significant judgment by management in selecting the appropriate assumptions for calculating financial estimates. In our 2022 Annual Report on Form 10-K, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements.

As of September 30, 2023 there have been no material changes to our critical accounting policies and estimates from those previously disclosed in our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.

Item 3. Quantitative and Qualitative Disclosures About Market Risk (presented in thousands, except share amounts).

The Company has exposure to certain risks, including market, credit, liquidity, asset forfeiture, banking and interest rate risk, and assesses the impact and likelihood of those risks. However, there have been no material changes in our market risk during the three and nine months ended September 30, 2023. For additional information, refer to our 2022 Annual Report on Form 10-K for the year ended December 31, 2022.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Based on an evaluation under the supervision and with the participation of the Company’s management, and due to the material weakness in internal controls over financial reporting described below, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act were not effective for the period ending September 30, 2023 to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Inherent Limitations Over Internal Controls

The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. The Company’s internal control over financial reporting includes those policies and procedures that:

F-42

(i)    pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company’s assets;

(ii)    provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that the Company’s receipts and expenditures are being made only in accordance with authorizations of the Company’s management and directors; and

(iii)    provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

Management, including the Company’s Chief Executive Officer and Chief Financial Officer, does not expect that the Company’s internal controls will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of internal controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Also, any evaluation of the effectiveness of controls in future periods are subject to the risk that those internal controls may become inadequate because of changes in business conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Material Weaknesses in Internal Control Over Financial Reporting

A material weakness in internal controls over financial reporting is a deficiency, or a combination of deficiencies, in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

The review, testing and evaluation of key internal controls over financial reporting completed by the Company resulted in the Company’s principal executive officer and principal financial officer concluding that a material weakness in the Company’s internal controls over financial reporting remained present as of September 30, 2023. Specifically, as a result of turnover and the availability of resources with the appropriate level of technical capabilities (including the impacts on staffing and recruiting and the general global labor shortage brought about by the global COVID-19 pandemic), the Company did not have effective staffing levels and adequate segregation of duties within several finance and accounting processes. Further, and as a result of this material weakness, the Company’s financial disclosures for the quarterly period ending June 30, 2021 incorrectly disclosed certain debt that was due 11 months after the balance sheet date as long-term rather than as current liabilities. Additionally, and as a result of this material weakness, the Company’s financial disclosures for the quarterly and annual periods ended June 30, 2020, September 30, 2020, December 31, 2020, March 31, 2021, June 30, 2021, and September 30, 2021 incorrectly reported the weighted average shares outstanding which resulted in an incorrect determination of earnings per share and diluted earnings per share. Finally, for the year ended December 31, 2022, the Company did not have adequate processes or sufficient resources to adequately assess the impairment of goodwill and intangible assets and cutoff over inventory.

The Company has begun to address the material weaknesses described above through the following actions. Although the Company previously believed the material weaknesses would be addressed by the second half of 2023, due to continued staff turnover and the availability of resources with appropriate levels of technical capabilities, the Company now expects to complete these actions in 2024:

a.Engaging third-party consultants with appropriate expertise to assist the finance and accounting department on an interim basis until key roles are filled;

b.Assessing finance and accounting resources to identify the areas and functions that lack sufficient personnel and recruiting for experienced personnel to assume these roles;

c.Further centralization of key accounting processes to enable greater segregation of duties;

d.Developing further training on segregation of duties; and

e.Designing and implementing additional compensating controls where necessary.

The Company is working diligently to remediate this material weakness by hiring qualified and capable personnel. Further, we will continue to evaluate and assess the staffing needs of the Company as the landscape and needs of the Company continue to evolve. While we are working diligently to remediate this material weakness, there is no assurance that this material weakness will be fully remediated by December 31, 2024, given continuing lasting impacts of COVID-19 on staffing and labor for companies within our industry and otherwise.

Changes in Internal Control Over Financial Reporting

F-43

During the third quarter of 2023, we implemented a new Enterprise Resource Planning (“ERP”) system. As a result of this implementation, we revised existing internal controls, processes and procedures where necessary.

Other than the changes discussed above in connection with our implementation of a new ERP system and remediation plan relating to our material weakness, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a–15(f) and 15d–15(f) under the Exchange Act) that occurred during our most recent quarter, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

Item 1. Legal Proceedings.

For information on legal proceedings, refer to Note 13 to the Unaudited Condensed Consolidated Financial Statements included this report.

Item 1A. Risk Factors.

There have been no material changes to the risk factors described in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.

None.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

Not applicable.

F-44

Item 6. Exhibits.

		Incorporated by Reference
Exhibit No.	Description of Document	Schedule Form	File Number	Exhibit/Form	Filing Date	Filed or Furnished Herewith
10.1	Third Amendment to Arrangement Agreement, dated August 31, 2023, by and among Acreage Holdings, Inc., Canopy Growth Corporation and Canopy USA, LLC	8-K	000-56021	10.1	9/6/2023
10.2	Fourth Amendment to Arrangement Agreement, dated October 31, 2023, by and among Acreage Holdings, Inc., Canopy Growth Corporation and Canopy USA, LLC	8-K	000-56021	10.1	11/3/2023
31.1	Certification of Periodic Report by Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.					X
31.2	Certification of Periodic Report by Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.					X
32.1	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*					X
101	Attached as Exhibit 101 to this report are the following documents formatted in iXBRL (Extensible Business Reporting Language):): (i) Consolidated Statements of Financial Position as of September 30, 2023 (unaudited) and December 31, 2022 (audited), (ii) Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and September 30, 2022, (iii) Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and September 30, 2022, (iv) Unaudited Condensed Consolidated Statements of Shareholders’ Equity for the three and nine months ended September 30, 2023 and September 30, 2022 and (v) Notes to Unaudited Condensed Consolidated Financial Statements.					X

* Document has been furnished, is not deemed filed and is not to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in any such filing.

F-45

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 14, 2023

Acreage Holdings, Inc.
By:	/s/ Carl Nesbitt
	Carl Nesbitt
	Chief Financial Officer (Principal Financial and Accounting Officer)

F-46

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer Pursuant to Section 302 of the

Sarbanes-Oxley Act and Rule 13a-14(a) or 15d-14(a)

Under the Securities and Exchange Act of 1934

I, Dennis Curran, certify that:

1.    I have reviewed this Quarterly report on Form 10-Q for the period ended September 30, 2023 of Acreage Holdings, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2023

By: /s/ Dennis Curran

Dennis Curran

Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer Pursuant to Section 302 of the

Sarbanes-Oxley Act and Rule 13a-14(a) or 15d-14(a)

Under the Securities and Exchange Act of 1934

I, Carl Nesbitt, certify that:

1.    I have reviewed this Quarterly report on Form 10-Q for the period ended September 30, 2023 of Acreage Holdings, Inc.;

2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)     Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)     Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and

(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2023

By: /s/ Carl Nesbitt

Carl Nesbitt

Chief Financial Officer

EX-32.1

Exhibit 32.1

Certifications of the

Chief Executive Officer and Chief Financial Officer

Pursuant to 18 U.S.C. Section 1350

Solely for the purposes of complying with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, we, the undersigned Chief Executive Officer and Chief Financial Officer of Acreage Holdings, Inc. (the “Company”), hereby certify, based on our knowledge, that the Quarterly Report on Form 10-Q of the Company for the period ended September 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Dennis Curran

Dennis Curran

Chief Executive Officer

/s/ Carl Nesbitt

Carl Nesbitt

Chief Financial Officer

Date: November 14, 2023

XML

COVER - shares	9 Months Ended
	Sep. 30, 2023	Nov. 02, 2023
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	000-56021
Entity Registrant Name	ACREAGE HOLDINGS, INC.
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	98-1463868
Entity Address, Address Line One	366 Madison Ave, 14th floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10017
City Area Code	646
Local Phone Number	600-9181
Title of 12(g) Security	Class D Subordinate Voting Shares, no par value; Class E Subordinate Voting Shares, no par value.
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Entity Central Index Key	0001762359
Fixed Shares
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		80,682,114
Floating Shares
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		36,019,462
Fixed Multiple Shares
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		117,600

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
ASSETS
Cash and cash equivalents	$ 15,142	$ 24,067
Restricted cash	9,651	0
Accounts receivable, net	8,242	10,512
Inventory	51,050	49,446
Notes receivable, net	0	29,191
Other current assets	5,594	4,977
Total current assets	89,679	118,193
Long-term investments	33,176	34,046
Capital assets, net	136,866	133,405
Operating lease right-of-use assets	18,699	22,443
Intangible assets, net	35,124	35,124
Goodwill	38,721	13,761
Other non-current assets	3,519	3,601
Total non-current assets	266,105	242,380
TOTAL ASSETS	355,784	360,573
LIABILITIES AND SHAREHOLDERS’ EQUITY
Accounts payable and accrued liabilities	35,431	29,566
Taxes payable	40,445	24,226
Interest payable	5,676	2,575
Operating lease liability, current	2,535	2,443
Debt, current	3,336	1,584
Other current liabilities	9,244	11,939
Total current liabilities	96,667	72,333
Debt, non-current	231,402	213,496
Operating lease liability, non-current	18,298	21,692
Deferred tax liability	10,654	9,623
Other liabilities	2,961	3,250
Total non-current liabilities	263,315	248,061
TOTAL LIABILITIES	359,982	320,394
Commitments and contingencies
Common stock, no par value - unlimited authorized, 115,965 and 112,437 issued and outstanding, respectively	0	0
Additional paid-in capital	758,918	760,529
Treasury stock, 842 common stock held in treasury	(21,054)	(21,054)
Accumulated deficit	(716,829)	(678,091)
Total Acreage Shareholders' equity	21,035	61,384
Non-controlling interests	(25,233)	(21,205)
TOTAL EQUITY (DEFICIT)	(4,198)	40,179
TOTAL LIABILITIES AND EQUITY	$ 355,784	$ 360,573

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - shares shares in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, issued (in shares)	115,965	112,437
Common stock, shares, outstanding (in shares)	115,965	112,437
Treasury stock (in shares)	842	842

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
REVENUE
Total revenues, net	$ 56,502	$ 61,419	$ 170,580	$ 179,649
Total cost of goods sold	(35,228)	(40,193)	(101,599)	(98,299)
Gross profit	21,274	21,226	68,981	81,350
OPERATING EXPENSES
General and administrative	8,036	9,727	25,621	27,036
Compensation expense	13,524	15,271	38,930	42,045
Equity-based compensation expense	745	3,156	2,423	8,970
Marketing	542	735	1,942	2,396
Impairments, net	0	506	0	2,973
Loss on notes receivable	0	7,219	0	7,219
Write down of assets held-for-sale	0	0	3,557	874
Legal recoveries	0	0	0	(335)
Depreciation and amortization	928	1,047	2,919	6,019
Total operating expenses	23,775	37,661	75,392	97,197
Net operating loss	(2,501)	(16,435)	(6,411)	(15,847)
Income from investments, net	248	17	228	154
Interest income from loans receivable	0	474	10	1,256
Interest expense	(9,207)	(5,688)	(26,143)	(15,989)
Other income, net	10,021	4,743	9,823	5,019
Total other income (loss)	1,062	(454)	(16,082)	(9,560)
Loss before income taxes	(1,439)	(16,889)	(22,493)	(25,407)
Income tax expense	(6,420)	(8,109)	(19,763)	(24,105)
Net loss	(7,859)	(24,998)	(42,256)	(49,512)
Less: net loss attributable to non-controlling interests	(234)	(2,784)	(3,885)	(4,675)
Net loss attributable to Acreage Holdings, Inc.	$ (7,625)	$ (22,214)	$ (38,371)	$ (44,837)
Net loss per share attributable to Acreage Holdings, Inc. - basic (in USD per share)	$ (0.07)	$ (0.20)	$ (0.34)	$ (0.41)
Net loss per share attributable to Acreage Holdings, Inc. - diluted (in USD per share)	$ (0.07)	$ (0.20)	$ (0.34)	$ (0.41)
Weighted average shares outstanding - basic (in share)	114,171	111,200	113,181	108,795
Weighted average shares outstanding - diluted (in shares)	114,171	111,200	113,181	108,795
Retail
REVENUE
Total revenues, net	$ 43,857	$ 48,314	$ 130,651	$ 136,426
Total cost of goods sold	(23,247)	(26,097)	(67,145)	(70,331)
Wholesale
REVENUE
Total revenues, net	12,645	12,810	39,845	42,342
Total cost of goods sold	(11,981)	(14,096)	(34,454)	(27,968)
Other
REVENUE
Total revenues, net	$ 0	$ 295	$ 84	$ 881

XML

UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Share Capital	Treasury Stock	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Shareholders’ Equity	Shareholders’ Equity Cumulative Effect, Period of Adoption, Adjustment	Non-controlling Interests	LLC Membership Units	Pubco Shares (as converted)
Beginning balance (in shares) at Dec. 31, 2021										3,861	106,903
Beginning balance at Dec. 31, 2021	$ 204,270		$ 756,536	$ (21,054)	$ (538,215)		$ 197,267		$ 7,003
Increase (Decrease) in Stockholders' Equity
NCI adjustments for changes in ownership	0		5				5		(5)
Equity-based compensation expense and related issuances (in shares)											508
Equity-based compensation expense and related issuances	4,159		4,159				4,159
Net loss	(13,911)				(12,694)		(12,694)		(1,217)
Ending balance (in shares) at Mar. 31, 2022										3,861	107,411
Ending balance at Mar. 31, 2022	194,518		760,700	(21,054)	(550,909)		188,737		5,781
Beginning balance (in shares) at Dec. 31, 2021										3,861	106,903
Beginning balance at Dec. 31, 2021	204,270		756,536	(21,054)	(538,215)		197,267		7,003
Increase (Decrease) in Stockholders' Equity
Net loss	(49,512)
Ending balance (in shares) at Sep. 30, 2022										3,861	112,147
Ending balance at Sep. 30, 2022	158,194		761,684	(21,054)	(583,052)		157,578		616
Beginning balance (in shares) at Mar. 31, 2022										3,861	107,411
Beginning balance at Mar. 31, 2022	194,518		760,700	(21,054)	(550,909)		188,737		5,781
Increase (Decrease) in Stockholders' Equity
NCI adjustments for changes in ownership	0		(4,524)				(4,524)		4,524
Capital contributions, net	(5,534)								(5,534)
Equity-based compensation expense and related issuances (in shares)											1,778
Equity-based compensation expense and related issuances	1,655		1,655				1,655
Net loss	(10,603)				(9,929)		(9,929)		(674)
Ending balance (in shares) at Jun. 30, 2022										3,861	109,189
Ending balance at Jun. 30, 2022	180,036		757,831	(21,054)	(560,838)		175,939		4,097
Increase (Decrease) in Stockholders' Equity
NCI adjustments for changes in ownership	0		697				697		(697)
Other equity transactions (in shares)											378
Equity-based compensation expense and related issuances (in shares)											2,580
Equity-based compensation expense and related issuances	3,156		3,156				3,156
Net loss	(24,998)				(22,214)		(22,214)		(2,784)
Ending balance (in shares) at Sep. 30, 2022										3,861	112,147
Ending balance at Sep. 30, 2022	158,194		761,684	(21,054)	(583,052)		157,578		616
Beginning balance (in shares) at Dec. 31, 2022										3,861	112,437
Beginning balance at Dec. 31, 2022	40,179	$ (367)	760,529	(21,054)	(678,091)	$ (367)	61,384	$ (367)	(21,205)
Increase (Decrease) in Stockholders' Equity
NCI adjustments for changes in ownership	0		14				14		(14)
Equity-based compensation expense and related issuances (in shares)											287
Equity-based compensation expense and related issuances	984		984				984
Net loss	(16,157)				(14,590)		(14,590)		(1,567)
Ending balance (in shares) at Mar. 31, 2023										3,861	112,724
Ending balance at Mar. 31, 2023	24,639		761,527	(21,054)	(693,048)		47,425		(22,786)
Beginning balance (in shares) at Dec. 31, 2022										3,861	112,437
Beginning balance at Dec. 31, 2022	40,179	$ (367)	760,529	(21,054)	(678,091)	$ (367)	61,384	$ (367)	(21,205)
Increase (Decrease) in Stockholders' Equity
Net loss	(42,256)
Ending balance (in shares) at Sep. 30, 2023										3,861	115,965
Ending balance at Sep. 30, 2023	(4,198)		758,918	(21,054)	(716,829)		21,035		(25,233)
Beginning balance (in shares) at Mar. 31, 2023										3,861	112,724
Beginning balance at Mar. 31, 2023	24,639		761,527	(21,054)	(693,048)		47,425		(22,786)
Increase (Decrease) in Stockholders' Equity
NCI adjustments for changes in ownership	0		(3,389)				(3,389)		3,389
Capital contributions, net	(3,968)								(3,968)
Other equity transactions	(130)		(130)				(130)
Equity-based compensation expense and related issuances (in shares)											479
Equity-based compensation expense and related issuances	694		694				694
Net loss	(18,240)				(16,156)		(16,156)		(2,084)
Ending balance (in shares) at Jun. 30, 2023										3,861	113,203
Ending balance at Jun. 30, 2023	2,995		758,702	(21,054)	(709,204)		28,444		(25,449)
Increase (Decrease) in Stockholders' Equity
NCI adjustments for changes in ownership	0		(450)				(450)		450
Other equity transactions	(79)		(79)				(79)
Equity-based compensation expense and related issuances (in shares)											2,762
Equity-based compensation expense and related issuances	745		745				745
Net loss	(7,859)				(7,625)		(7,625)		(234)
Ending balance (in shares) at Sep. 30, 2023										3,861	115,965
Ending balance at Sep. 30, 2023	$ (4,198)		$ 758,918	$ (21,054)	$ (716,829)		$ 21,035		$ (25,233)

XML

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2023		Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$ (42,256)		$ (49,512)
Adjustments for:
Depreciation and amortization		2,919		6,019
Depreciation and amortization included in COGS		6,058		4,840
Equity-based compensation expense		2,423		8,970
Inventory write-off and provision		8,824	[1]	6,286
Gain on business divestiture		(47)		(3,490)
Loss on disposal of capital assets		34		49
Loss on impairment		0		2,973
Loss on notes receivable		0		7,219
Recovery on notes receivable		0		(1,107)
Bad debt expense		320		22
Non-cash interest expense		3,743		2,301
Non-cash operating lease expense (income)		(18)		223
(Gain) Loss on lease termination		(200)		297
Deferred tax (income) expense		16		(889)
Non-cash loss from investments, net		870		895
Write-down of assets held-for-sale		3,557		874
Change, net of acquisitions in:
Accounts receivable, net		(3,427)		(2,787)
Inventory	[1]	(12,572)		(15,001)
Other assets		(597)		(1,240)
Interest receivable		(756)		(1,125)
Accounts payable and accrued liabilities		(2,628)		(279)
Taxes payable		15,026		4,668
Interest payable		3,101		(265)
Other liabilities		(3,119)		(414)
Net cash used in operating activities		(18,729)		(30,473)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of capital assets		(5,345)		(12,582)
Collection of notes receivable		2,150		7,106
Business acquisitions, net of cash acquired		516		0
Purchases of intangible assets		(27)		(900)
Distributions from investments		0		1,048
Cash paid for short-term investment		0		(3,400)
Proceeds from disposal of short-term investments		0		3,400
Proceeds from business divestiture		500		0
Net cash used in investing activities		(2,206)		(5,328)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds (payments) from equity transactions		(79)		0
Proceeds from financing (refer to Note 14 for related party financing)		27,121		25,000
Deferred financing costs paid		(500)		(511)
Repayment of debt		(913)		(1,084)
Capital distributions - non-controlling interests		(3,968)		(5,534)
Net cash provided by financing activities		21,661		17,871
Net increase (decrease) in cash, cash equivalents, restricted cash, and cash held for sale		726		(17,930)
Cash, cash equivalents, and restricted cash - Beginning of period		24,067		44,501
Cash, cash equivalents, and restricted cash - End of period		24,793		26,571
RECONCILIATION OF CASH FLOW INFORMATION:
Cash and cash equivalents		15,142		26,476
Restricted cash		9,651		95
Total cash, cash equivalents, restricted cash, and cash held for sale at end of period		24,793		26,571
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest paid - non-lease		19,266		12,730
Income taxes paid		5,933		21,742
OTHER NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capital assets not yet paid for		5,040		6,242
Non-cash proceeds from business divestiture		0		7,850
Non-cash proceeds from finance lease		0		5,785
Cumulative effect of change in accounting principle for current expected credit losses, net of tax		121		0
NCI adjustments for changes in ownership		$ (14)		$ 0

[1] Presentation of September 30, 2022 figures have been revised, refer to Note 2 for further discussion.

XML

NATURE OF OPERATIONS

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NATURE OF OPERATIONS

Acreage Holdings, Inc. (the “Company”, “Pubco” or “Acreage”) is a vertically integrated, multi-state operator in the United States (“U.S.”) cannabis industry. The Company’s operations include (i) cultivating and processing cannabis plants, (ii) manufacturing branded consumer products, (iii) distributing cannabis flower and manufactured products, and (iv) retailing cannabis products to patients and consumers. The Company’s products appeal to medical and adult recreational use customers through brand strategies intended to build trust and loyalty.

The Company’s Class E subordinate voting shares (“Fixed Shares”) and Class D subordinate voting shares (“Floating Shares”) are listed on the Canadian Securities Exchange under the symbols “ACRG.A.U” and “ACRG.B.U”, respectively, quoted on the OTCQX under the symbols “ACRHF” and “ACRDF”, respectively, and traded on the Frankfurt Stock Exchange under the symbols “0VZ1” and “0VZ2”, respectively.

High Street Capital Partners, LLC (“HSCP”) was formed on April 29, 2014. The Company became the indirect parent of HSCP on November 14, 2018 in connection with the reverse takeover (“RTO”) transaction described below.

The Company’s principal place of business is located at 366 Madison Ave, 14th floor, New York, New York in the U.S. The Company’s registered and records office address is Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia in Canada.

The RTO transaction

On September 21, 2018, the Company, HSCP, HSCP Merger Corp. (a wholly-owned subsidiary of the Company), Acreage Finco B.C. Ltd. (a special purpose corporation) (“Finco”), Acreage Holdings America, Inc. (“USCo”) and Acreage Holdings WC, Inc. (“USCo2”) entered into a business combination agreement (the “Business Combination Agreement”) whereby the parties thereto agreed to combine their respective businesses, which would result in the RTO of Pubco by the security holders of HSCP, which was deemed to be the accounting acquiror. On November 14, 2018, the parties to the Business Combination Agreement completed the RTO.

Canopy Growth Corporation transaction

On June 27, 2019, the Company and Canopy Growth Corporation (“Canopy Growth” or “CGC”) implemented the Prior Plan of Arrangement (as defined in Note 13) contemplated by the Original Arrangement Agreement (as defined in Note 13). Pursuant to the Prior Plan of Arrangement, Canopy Growth was granted an option to acquire all of the issued and outstanding shares of the Company in exchange for the payment of 0.5818 of a common share in the capital of Canopy Growth for each Class A subordinate voting share (each, a “SVS”) held (with the Class B proportionate voting shares (the “PVS”) and Class C multiple voting shares (the “MVS”) being automatically converted to SVS immediately prior to consummation of the Acquisition (as defined in Note 13), which original exchange ratio was subject to adjustment in accordance with the Original Arrangement Agreement. Canopy Growth was required to exercise the option upon a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and, subject to the satisfaction or waiver of certain closing conditions set out in the Original Arrangement Agreement, Canopy Growth was required to acquire all of the issued and outstanding SVS (following the mandatory conversion of the PVS and MVS into SVS).

On June 24, 2020, Canopy Growth and the Company entered into an agreement to, among other things, amend the terms of the Original Arrangement Agreement and the terms of the Prior Plan of Arrangement (the “Amended Arrangement”). On September 16, 2020, the Company’s shareholders voted in favor of a special resolution authorizing and approving the terms of, among other things, the Amended Arrangement. Subsequently, on September 18, 2020, the Company obtained a final order from the Supreme Court of British Columbia approving the Amended Arrangement, and on September 23, 2020 the Company and Canopy Growth entered into the Amending Agreement (as defined in Note 13) and implemented the Amended Arrangement. Pursuant to the Amended Arrangement, the Company’s articles were amended to create the Fixed Shares, the Floating Shares and the Class F multiple voting shares (the “Fixed Multiple Shares”), and each outstanding SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share, each outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and each outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share. Pursuant to the Amended Arrangement, Canopy Growth was granted the option to acquire all of the issued and outstanding Fixed Shares on the basis of 0.3048 (the “Fixed Exchange Ratio”) of a common share of Canopy Growth (each, a “Canopy Share”) for each Fixed Share held at the time of the acquisition of the Fixed Shares (the “Acquisition” or “Acquisition Time”), subject to adjustment in accordance with the terms of the Amended Arrangement (the “Canopy Call Option”), which Canopy Growth is

required to exercise upon the occurrence, or waiver (at the discretion of Canopy Growth), of a change in federal laws in the United States to permit the general cultivation, distribution and possession of marijuana (as defined in the relevant legislation) or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event” and the date on which the Triggering Event occurs, the “Triggering Event Date”). Refer to Note 13 for further discussion.

Pursuant to the implementation of the Amended Arrangement, on September 23, 2020, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 to Universal Hemp, LLC, an affiliate of the Company. The debenture bears interest at a rate of 6.1% per annum. Refer to Note 10 for further discussion.

On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. On March 15, 2023, the Company received the required approval of the holders of Floating Shares in connection with the Floating Share Arrangement at its special meeting of holders of Floating Shares. On March 21, 2023, the Corporation obtained a final order form from the Supreme Court of British Columbia approving the Floating Share Arrangement. Upon the satisfaction or waiver of all other conditions set out in the Floating Share Arrangement Agreement, which the parties continue to work towards, the parties will complete the Floating Share Arrangement. Refer to Note 13 for further discussion.

XML

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation and going concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other period.

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of September 30, 2023, as well as a net loss and negative cash flow from operating activities for the nine months ended September 30, 2023. Additionally, subsequent to quarter end the Company was temporarily in default of the Universal Hemp 6.1% Loan. Refer to Note 10 for further discussion. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, and (iv) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company’s need to raise additional capital on an immediate basis.

These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023, as filed with the Securities and Exchange Commission (the “2022 Form 10-K”).

Use of estimates

Preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the dates presented and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include the fair value of assets acquired and liabilities assumed in business combinations, assumptions relating to equity-based compensation expense, estimated useful lives for property, plant and equipment and intangible assets, the valuation allowance against deferred tax assets and the assessment of potential charges on goodwill, intangible assets and investments in equity and notes receivable.

Emerging growth company

The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.

Functional and presentation currency

The unaudited condensed consolidated financial statements and the accompanying notes are expressed in U.S. dollars. Financial metrics are presented in thousands. Other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.

Basis of consolidation

The Company’s unaudited condensed consolidated financial statements include the accounts of Acreage, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in business entities in which Acreage lacks control but is able to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations.

Non-controlling interests (“NCI”)

Non-controlling interests represent ownership interests in consolidated subsidiaries by parties that are not shareholders of Pubco. They are shown as a component of Total equity in the Unaudited Condensed Consolidated Statements of Financial Position, and the share of loss attributable to non-controlling interests is shown as a component of Net loss in the Unaudited Condensed Consolidated Statements of Operations. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.

Cash and cash equivalents

The Company defines cash equivalents as highly liquid investments held for the purpose of meeting short-term cash commitments that are readily convertible into known amounts of cash, with original maturities of three months or less. The Company maintains cash with various U.S. banks and credit unions with balances in excess of the Federal Deposit Insurance Corporation and National Credit Union Share Insurance Fund limits, respectively. The failure of a bank or credit union where the Company has significant deposits could result in a loss of a portion of such cash balances in excess of the insured limit, which could materially and adversely affect the Company’s business, financial condition, results of operations and the market price of the Company’s Fixed Shares and Floating Shares. Cash and cash equivalents belonging to entities the Company has classified as held-for-sale have been reclassified to Assets held-for-sale on the Unaudited Condensed Consolidated Statements of Financial Position. Refer to Note 3 for further discussion.

Restricted cash

Restricted cash represents funds contractually held for specific purposes and, as such, not available for general corporate purposes.

Cash and restricted cash, as presented on the Unaudited Condensed Consolidated Statements of Cash Flows, consists of $15,142 and $9,651 as of September 30, 2023, respectively, and $26,476 and $95 as of September 30, 2022, respectively.

Accounts receivable and notes receivable valuations

The Company reports accounts receivable at their net realizable value, which is management’s best estimate of the cash that will ultimately be received from customers. The Company's notes receivable represent notes due from various third parties. The Company maintains an allowance for expected credit losses to reflect the expected uncollectability of accounts receivable and notes receivable based on historical collection data and specific risks identified among uncollected accounts, as well as management’s expectation of future economic conditions. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the companies receivables and the expected future losses. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Trade accounts receivable and notes receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible. As of September 30, 2023 and December 31, 2022, the Company’s allowance for doubtful accounts was $339 and $953, respectively, all of which relates to the allowance for credit losses over accounts receivable. As of September 30, 2023 and December 31, 2022, the allowance on loans receivable was $15,340 and $14,875, respectively, of which the allowance for credit losses over notes receivable was nil as the receivables were fully reserved for. Refer to Note 6 for further discussion.

Net loss per share

Net loss per share represents the net loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis. Basic and diluted loss per share are the same as of September 30, 2023 and 2022 as the issuance of shares upon conversion, exercise or vesting of outstanding units would be anti-dilutive in each period. There were 51,006 and 47,999 anti-dilutive shares outstanding as of September 30, 2023 and 2022, respectively.

Change in presentation

Note that certain items presented on the nine months ended September 30, 2022, Unaudited Condensed Consolidated Statement of Cash Flows, includes a change in presentation to conform to the current year presentation. There was no impact to our Consolidated Financial Statements as a result of this reclassification.

Accounting Pronouncements Recently Adopted

As of January 1, 2023, the Company adopted Accounting Standards Update (“ASU”) 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which was subsequently revised by ASU 2018-19 and ASU 2020-02. This standard applies to financial assets, measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases and trade accounts receivable. The guidance must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The adoption of ASU 2016-13 did not have a material effect on the Company’s unaudited condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08 - Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The new standard requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers. The ASU will be effective for the Company’s first interim period of fiscal 2024. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company does not anticipate a material impact on the Company’s unaudited condensed consolidated financial statements upon adoption.

XML

ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE

9 Months Ended

Sep. 30, 2023

Business Combination and Asset Acquisition [Abstract]

ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE

ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE

Acquisitions

On January 2, 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine. Under the terms of the agreement, the consideration paid consisted of the settlement of a pre-existing relationship, which included a line-of credit, other advances and the related interest receivable, all totaling $25,160, which were previously recorded in Notes receivable, net on the Statements of Financial Position.

The purchase price allocation is based upon preliminary valuations, estimates and assumptions which are subject to change within the measurement period, generally one year from the acquisition date. The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the capital assets, tangible assets acquired and the residual goodwill resulting from the transaction.

Purchase Price Allocation	Northeast Patients Group
Assets acquired:
Cash and cash equivalents	$	361
Accounts Receivable	25
Inventory	384
Other current assets	173
Capital assets	2,377
Financing lease right-of-use asset	416
Operating lease right-of-use asset	1,279
Goodwill	24,960
Liabilities assumed:
Accounts payable and accrued liabilities	(672)
Taxes payable	(1,112)
Finance lease liability, current	(87)
Finance lease liability, non-current	(459)
Operating lease liability, current	(73)
Operating lease liability, non-current	(1,385)
Notes payable	(11)
Deferred tax liability	(1,016)
Fair value of net assets acquired	$	25,160
Consideration paid:
Settlement of pre-existing relationship	25,160
Total consideration	$	25,160

During the year ended December 31, 2022, the Company did not complete any business acquisitions.

Divestitures

During the three and nine months ended September 30, 2023 management committed to a plan to sell CWG Botanicals, Inc. (“CWG”) as of June 30, 2023. At this point all assets and liabilities were classified as held for sale on the balance sheet and written down to the fair value of the expected sale price. On September 12, 2023 the company effectively sold 100% of its ownership interest in CWG for an aggregate sales price of $500 and recognizing a gain of $47 on the Unaudited Condensed Consolidated Statements of Operations in Other income, net.

During the three and nine months ended September 30, 2022, the Company completed the divestitures of six properties as outlined in the following paragraphs. In February 2021, a subsidiary of the Company entered into a definitive agreement and management services agreement to sell an indoor cultivation facility in Medford, Oregon ("Medford"), and a retail dispensary in Powell, Oregon ("Powell"), for total consideration of $3,000. In March 2022, the total consideration was reduced to $2,000. In April 2022, the Company sold all equity interests in Medford for an aggregate sale price of $2,000 and recognized a gain on sale of $290 for the nine months ended September 30, 2022 which was recorded in Other income, net in the Unaudited Condensed Consolidated Statements of Operations. The aggregate sales price consisted of $750 paid to the Company in February 2021 and $1,250 of promissory notes (refer to Note 6 for further discussion). In conjunction with the sale, the Company closed its dispensary in Powell. Further, the Company derecognized deferred tax liabilities of $375 related to Medford.

In September 2021, a subsidiary of the Company entered into a definitive agreement and management services agreements to sell, upon regulatory approval, four retail dispensaries in Oregon for total consideration of $6,500. In July 2022, the Company executed and closed an amendment to its previously announced asset purchase and services agreement for the sale of its four Oregon retail dispensaries (the “Amended Agreement”). Under the terms of the Amended Agreement, the sale price was reduced to $6,200 and the Company recognized a gain on sale of $3,189 for the nine months ended September 30, 2022 which was recorded in Other income, net in the Unaudited Condensed Consolidated Statements of Operations. The aggregate sales price consisted of a $250 payment previously made at the signing of the Original Agreement, plus an additional $100 in cash at closing. The remaining amount of $5,850 has been satisfied by a 36-month secured promissory note bearing interest at a rate of 12% per annum (the “Note”). Under the terms of the Note, quarterly interest payments commence on January 1, 2023, principal payments of $1,000 are due on January 1, 2024 and January 1, 2025, and the remaining principal is due on January 1, 2026.

Assets Held for Sale

The Company determined certain businesses and assets met the held-for-sale criteria. As such, the related assets and liabilities within these disposal groups were transferred into Assets held-for-sale and Liabilities related to assets held for sale on the Unaudited Condensed Consolidated Statements of Financial Position. As of September 30, 2023 and December 31, 2022, the Company did not have any business or assets that met the held-for-sale criteria.

Previously, the Company determined certain businesses and assets met the held-for-sale criteria. Upon classification of the disposal groups as held for sale, the Company tested each disposal group for impairment and recognized charges of $— and $3,557 within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations related to CWG for three and nine months ended September 30, 2023, respectively.

During the three and nine months ended September 30, 2022, the Company recognized a write down of assets held-for-sale of $— and $874 related to its Oregon operations within Write down of assets held-for-sale on the Unaudited Condensed Consolidated Statements of Operations.

XML

INTANGIBLE ASSETS AND GOODWILL

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL

Intangible assets

The following table details the intangible asset balances by major asset classes:

Intangibles	September 30, 2023		December 31, 2022
Finite-lived intangible assets:
Customer relationships	—		1,000
Total finite-lived intangible assets	—		1,000
Accumulated amortization on finite-lived intangible assets:
Customer relationships	—		(1,000)
Total accumulated amortization on finite-lived intangible assets	—		(1,000)
Finite-lived intangible assets, net	—		—
Indefinite-lived intangible assets
Cannabis licenses	35,124		35,124
Total intangibles, net	$	35,124	$	35,124

During the year ended December 31, 2022, the Company amended the purchase price allocation related to its acquisition of certain Ohio operations based upon final valuations within the measurement period. As a result, $17,000 was re-allocated from Goodwill to Intangible assets, net on the Unaudited Condensed Consolidated Statements of Financial Position.

There was no amortization expense recorded for the three and nine months ended September 30, 2023, respectively. Amortization expense associated with the Company’s intangible assets was $296 and $1,288 for the three and nine months ended September 30, 2022, respectively.

Goodwill

The following table details the changes in the carrying amount of goodwill:

Goodwill	Total
December 31, 2022	$	13,761
Acquisitions	24,960
September 30, 2023	$	38,721

During the nine months ended September 30, 2023, the Company recognized $24,960 of goodwill based on the preliminary purchase price allocation related to the acquisition of Northeast Patients Group. Refer to Note 3 for further discussion.

XML

INVESTMENTS

9 Months Ended

Sep. 30, 2023

Investments [Abstract]

INVESTMENTS

INVESTMENTS

The carrying values of the Company’s investments in the Unaudited Condensed Consolidated Statements of Financial Position as of September 30, 2023 and December 31, 2022 are as follows:

Investments	September 30, 2023		December 31, 2022
Investments held at FV-NI	$	33,176	$	34,046
Total long-term investments	$	33,176	$	34,046

Income from investments, net in the Unaudited Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2023 and 2022 is as follows:

Investment income	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Short-term investments	$	—	$	1	$	—	$	4
Investments held at FV-NI	248		16		228		150
Income from investments, net	$	248	$	17	$	228	$	154

Investments held at FV-NI

The Company has investments in equity of other companies that do not result in significant influence or control. These investments are carried at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.

As further described under the “6.10% Secured debenture due September 2030” in Note 10, on September 23, 2020, a subsidiary of the Company, Universal Hemp, LLC ("Universal Hemp"), was advanced gross proceeds of $50,000 (less transaction costs) pursuant to the terms of a secured debenture. The Company subsequently engaged an investment advisor, which under the investment advisor's sole discretion, on September 28, 2020 invested $34,019 of these proceeds on behalf of Universal Hemp. As a result, Universal Hemp acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the institutional investor holds Class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The Class B units are held by the Investment Advisor as an agent for Universal Hemp.

Universal Hemp, through its investment with the Investment Advisor, was originally determined to hold significant influence in the Investment Partnership in accordance with ASC 810 - Consolidations due to (1) the economic financial interest, and (2) the entitlement to matters as they pertain to ‘Extraordinary Resolution’ items as defined within the Investment Partnership Agreement. As a result, the Company accounted for the investment in the Investment Partnership under the equity method until December 2020. Refer to Note 10 for further discussion. In December 2020, the Company no longer held significant influence due to the removal of the Extraordinary Resolution entitlements and other revisions in the Investment Partnership Agreement. As a result, the Company changed its accounting for the Investment Partnership to recognize the investment at fair value, with gains and losses recognized in the Unaudited Condensed Consolidated Statements of Operations.

XML

NOTES RECEIVABLE, NET

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

NOTES RECEIVABLE, NET

NOTES RECEIVABLE, NET

Notes receivable as of September 30, 2023 and December 31, 2022 consisted of the following:

	September 30, 2023		December 31, 2022
Promissory notes receivable	$	7,062	$	34,088
Line of credit receivable	4,331		5,831
Interest receivable	3,947		4,147
Allowance for notes and interest receivable	(15,340)		(14,875)
Total notes receivable, net	$	—	$	29,191
Less: Notes receivable, current	—		29,191
Notes receivable, non-current	$	—	$	—

Interest income from loans receivable during the three and nine months ended September 30, 2023 was $— and $10, respectively, and during the three and nine months ended September 30, 2022 was $474 and $1,256, respectively.

At each reporting date, the Company applies its judgment to evaluate the collectability of the note receivable and makes a provision based on the assessed amount of expected credit loss. This judgment is based on parameters such as interest rates, market conditions and creditworthiness of the creditor.

The Company determined that the collectability of certain notes receivables is doubtful based on information available. As of September 30, 2023 and December 31, 2022, the Company’s allowance for notes receivable of $15,340 and $14,875, respectively, included $11,393 and $12,041 of principal outstanding and $3,947 and $2,834 of accrued interest, respectively, and represents the full value of such loan balances.

Activity during the nine months ended September 30, 2023

In January 2023, a subsidiary of the Company acquired cultivation, processing and retail operations in Maine from a third party who provided cultivation, manufacturing, processing, distribution and handling, recordkeeping, compliance, and other services to the Company’s operations in Maine and the amounts outstanding under the promissory notes receivable were converted into equity in Northeast Patients Group. Refer to Note 3 for further discussion.

In April 2023, the Company’s subsidiary Prime Alternative Treatment Center Consulting, LLC (“NH-PATCC”) received $1,500 from Prime Alternative Treatment Center, Inc. (“PATC”) in settlement of the principal balance related to a promissory note that was extended to “PATC”.

In May 2023, the Company received a $500 cash payment towards the principal balance on a promissory note receivable from Grown Rogue.

In August 2023, the Company received a $150 cash payment towards the principal balance on a promissory note receivable from Grown Rogue.

Activity during the nine months ended September 30, 2022

In February 2022, the Company received a $5,279 cash payment in full on a line of credit due from Patient Centric Martha’s Vineyard, and subsequently closed the line of credit.

In April 2022, the Company executed and closed its previously announced asset purchase agreement for the sale of Medford and Powell in Oregon. Part of the total consideration was satisfied by a 12-month $1,250 secured promissory note bearing interest at a rate of 12.5% per annum. Refer to Note 3 for further discussion. In August 2022, the secured promissory note was replaced with a $500 secured promissory note bearing interest at a rate of 12.5% per annum and a $750 non-interest bearing secured promissory note, with both secured promissory notes due on May 1, 2023.

In July 2022, the Company executed and closed an amendment to its previously announced asset purchase and services agreement for the sale of its four Oregon retail dispensaries. Part of the total consideration was satisfied by a 36-month $5,850 secured promissory note bearing interest at a rate of 12% per annum. Refer to Note 3 for further discussion.

XML

CAPITAL ASSETS, NET

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

CAPITAL ASSETS, NET

CAPITAL ASSETS, NET

Net property, plant and equipment consisted of:

	September 30, 2023		December 31, 2022
Land	$	9,778	$	9,605
Building	58,524		58,334
Right-of-use asset, finance leases	6,297		5,077
Furniture, fixtures and equipment	40,701		46,811
Leasehold improvements	49,611		6,178
Construction in progress	14,883		34,435
Capital assets, gross	$	179,794	$	160,440
Less: accumulated depreciation and amortization	(42,928)		(27,035)
Capital assets, net	$	136,866	$	133,405

Depreciation of capital assets for the three and nine months ended September 30, 2023 is comprised of $928 and $2,919 of depreciation expense, respectively, and $2,116 and $6,493 that was capitalized to inventory, respectively. Depreciation of capital assets for the three and nine months ended September 30, 2022 is comprised of $751 and $4,731 of depreciation expense, respectively, and $1,963 and $5,679 that was capitalized to inventory, respectively.

During the nine months ended September 30, 2022, the Company determined that it was unable to find a satisfactory buyer for the held-for-sale assets related to its Michigan operations and, as such, these assets were reclassified as held-and-used. This conclusion was considered a triggering event for capital asset impairment testing. Upon assessment, these specific capital assets were not considered to have future economic value. As such, the fair value of the assets was considered to be nil and the Company recognized an impairment charge of $1,907 within Impairments, net on the Unaudited Condensed Consolidated Statements of Operations during the nine months ended September 30, 2022. Refer to Note 3 for further discussion on changes in held-for-sale entities.

XML

LEASES

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

LEASES

LEASES

The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments and accounts for non-lease components separately from leases.

Statements of Financial Position Information	Classification	September 30, 2023		December 31, 2022
Right-of-use assets
Operating	Operating lease right-of-use assets	$	18,699	$	22,443
Finance	Capital assets, net	4,597		4,269
Total right-of-use assets		$	23,296	$	26,712
Lease liabilities
Current
Operating	Operating lease liability, current	$	2,535	$	2,443
Financing	Debt, current	112		1
Non-current
Operating	Operating lease liability, non-current	18,298		21,692
Financing	Debt, non-current	5,846		5,305
Total lease liabilities		$	26,791	$	29,441

		Three Months Ended September 30,				Nine Months Ended September 30,
Statement of Operations Information	Classification	2023		2022		2023		2022
Short-term lease expense	General and administrative	$	102	$	(28)	$	311	$	190
Operating lease expense	General and administrative	1,238		1,221		3,853		3,613
Finance lease expense:
Amortization of right of use asset	Depreciation and amortization	93		63		278		190
Interest expense on lease liabilities	Interest expense	213		314		633		855
Net operating and finance lease cost		$	1,544	$	1,598	$	4,764	$	4,658

		Nine Months Ended September 30,
Statement of Cash Flows Information	Classification	2023		2022
Cash paid for operating leases	Net cash used in operating activities	$	3,871	$	3,390
Cash paid for finance leases - interest	Net cash used in operating activities	$	718	$	843

The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of September 30, 2023:

Maturity of lease liabilities	Operating Leases		Finance Leases
2023	$	1,085	$	228
2024	4,285		923
2025	4,104		946
2026	4,314		969
2027	3,897		992
Thereafter	13,276		11,705
Total lease payments	$	30,961	$	15,763
Less: interest	10,128		9,805
Present value of lease liabilities	$	20,833	$	5,958
Weighted average remaining lease term (years)	8		11
Weighted average discount rate	10%		12%

As of September 30, 2023, there have been no leases entered into that have not yet commenced.

LEASES

LEASES

The Company leases land, buildings, equipment and other capital assets which it plans to use for corporate purposes in addition to the production and sale of cannabis products. Leases with an initial term of 12 months or less are not recorded on the Unaudited Condensed Consolidated Statements of Financial Position and are expensed in the Unaudited Condensed Consolidated Statements of Operations on the straight-line basis over the lease term. The Company does not have any material variable lease payments and accounts for non-lease components separately from leases.

Statements of Financial Position Information	Classification	September 30, 2023		December 31, 2022
Right-of-use assets
Operating	Operating lease right-of-use assets	$	18,699	$	22,443
Finance	Capital assets, net	4,597		4,269
Total right-of-use assets		$	23,296	$	26,712
Lease liabilities
Current
Operating	Operating lease liability, current	$	2,535	$	2,443
Financing	Debt, current	112		1
Non-current
Operating	Operating lease liability, non-current	18,298		21,692
Financing	Debt, non-current	5,846		5,305
Total lease liabilities		$	26,791	$	29,441

		Three Months Ended September 30,				Nine Months Ended September 30,
Statement of Operations Information	Classification	2023		2022		2023		2022
Short-term lease expense	General and administrative	$	102	$	(28)	$	311	$	190
Operating lease expense	General and administrative	1,238		1,221		3,853		3,613
Finance lease expense:
Amortization of right of use asset	Depreciation and amortization	93		63		278		190
Interest expense on lease liabilities	Interest expense	213		314		633		855
Net operating and finance lease cost		$	1,544	$	1,598	$	4,764	$	4,658

		Nine Months Ended September 30,
Statement of Cash Flows Information	Classification	2023		2022
Cash paid for operating leases	Net cash used in operating activities	$	3,871	$	3,390
Cash paid for finance leases - interest	Net cash used in operating activities	$	718	$	843

The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of September 30, 2023:

Maturity of lease liabilities	Operating Leases		Finance Leases
2023	$	1,085	$	228
2024	4,285		923
2025	4,104		946
2026	4,314		969
2027	3,897		992
Thereafter	13,276		11,705
Total lease payments	$	30,961	$	15,763
Less: interest	10,128		9,805
Present value of lease liabilities	$	20,833	$	5,958
Weighted average remaining lease term (years)	8		11
Weighted average discount rate	10%		12%

As of September 30, 2023, there have been no leases entered into that have not yet commenced.

XML

INVENTORY

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

INVENTORY

INVENTORY

The Company’s inventory balance consists of the following:

	September 30, 2023		December 31, 2022
Retail inventory	$	5,305	$	3,255
Wholesale inventory	36,129		35,885
Cultivation inventory	6,491		7,133
Supplies & other	3,125		3,173
Total	$	51,050	$	49,446

Inventory is valued at the lower of cost and net realizable value (“NRV”), defined as estimated selling price in the ordinary course of business, less estimated costs of disposal. During the nine months ended September 30, 2023, the Company analyzed its inventory balances, and recorded wholesale inventory adjustments as a result of (i) having excess or obsolete inventory and (ii) reducing the carrying value to ensure inventory balances are properly recorded at the lower of cost and NRV. The Company recognized $2,103 and $8,824 during the three and nine months ended September 30, 2023, respectively, and $6,286 during the three and nine months ended September 30, 2022 of wholesale inventory adjustments within Cost of goods sold, wholesale on the Unaudited Condensed Consolidated Statements of Operations.

XML

DEBT

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

DEBT

DEBT

The Company’s debt balances consist of the following:

Debt balances	September 30, 2023		December 31, 2022
Financing liability (failed sale-leaseback)	$	15,253	$	15,253
Finance lease liabilities	5,958		5,306
7.50% Loan due April 2026	31,682		31,288
6.10% Secured debenture due September 2030	46,841		46,502
Note due December 2024	2,375		3,167
Prime rate credit facilities due January 2026, as amended	130,989		113,564
Note backed by ERTC	1,640		—
Total debt	$	234,738	$	215,080
Less: current portion of debt	3,336		1,584
Total long-term debt	$	231,402	$	213,496

Scheduled maturities of debt, excluding amortization of discount and issuance costs, are as follows:

2023	$	2,432
2024	1,584
2025	—
2026	173,011
2027	39
Thereafter	71,160
Total payments (excluding amortization of discount and issuance costs)	$	248,226

During the three and nine months ended September 30, 2023, the Company incurred interest expense of $9,207 and $26,143, respectively, and $5,688 and $15,989 during the three and nine months ended September 30, 2022, respectively, on the Unaudited Condensed Consolidated Statements of Operations. Interest expense for the three and nine months ended September 30, 2023 included debt discount amortization of $547 and $1,562, respectively, and amortization of debt issuance costs of $706 and $2,094, respectively. Interest expense for the three and nine months ended September 30, 2022 included debt discount amortization of $381 and $1,132, respectively, and amortization of debt issuance costs of $297 and $849, respectively. As of September 30, 2023 and December 31, 2022, the Company had unamortized discount $5,030 and $6,093, respectively, and debt issuance costs of $8,458 and $10,522, respectively, which is netted against the gross carrying value of long-term debt in Debt, non-current on Unaudited Condensed Unaudited Condensed Consolidated Statements of Financial Position. Additionally, as of September 30, 2023 and December 31, 2022, the Company had accrued interest of $5,676 and $2,575, respectively, within Interest payable on the Unaudited Condensed Consolidated Statements of Financial Position.

Financing liability (failed sales leaseback)

In connection with the Company’s failed sale-leaseback transaction in November 2020, a financing liability was recognized equal to the cash proceeds received. The Company will recognize the cash payments made on the lease as interest expense, and the principal will be de-recognized upon expiration of the lease.

6.10% Secured debenture due September 2030

On September 23, 2020, pursuant to the implementation of the Amended Arrangement (Refer to Note 13 for further discussion), a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture (“6.1% Loan”). In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. An additional $50,000 may be advanced pursuant to the debenture subject to the satisfaction of certain conditions by Universal Hemp. The debenture bears interest at a rate of 6.1% per annum, matures 10 years from the date hereof or such earlier date in accordance with the terms of the debenture and all interest payments made pursuant to the debenture are payable in cash by Universal Hemp. Subsequent to quarter end, Universal Hemp received a reservations of rights letter for

failure to make the annual cash interest payment within 10 business days of September 23, 2023 (October 10, 2023). The parties agreed on November 14, 2023 to waive the default and that the cash interest payment would be satisfied through a partial cash payment of $1,400 by year end 2023, an obligation of Universal Hemp to deliver proceeds from the sale of certain real property held by Universal Hemp and an agreement between the parties to offset potential future expenses that may be payable by Canopy Growth. The debenture is secured by substantially all of the assets of Universal Hemp and its subsidiaries and, further, is not convertible and is not guaranteed by Acreage.

With a portion of the proceeds for the 6.1% Loan received by Universal Hemp, Acreage engaged an Investment Advisor which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp $34,019 on September 28, 2020. As a result, Universal Hemp acquired 34,019 class B units, at $1.00 par value per unit, which represented 100% financial interest in the Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds class A units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Investment Advisor as an agent for Universal Hemp. Upon execution of the limited partnership agreement, $1,019 was distributed to the class A unit holders of the Investment Partnership.

7.50% Loan due April 2026

On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Investor (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note (as described above) and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The loan is unsecured, matures in 3 years and bears interest at a 7.5% annual interest rate. The Lender is controlled by the Institutional Investor. The Investment Partnership is the investor in the Lender. On December 16, 2021, the Company paid an amendment fee of $413 to extend the maturity date from September 28, 2023 to April 2, 2026. The amendment was treated as a debt extinguishment.

Note due December 2024

In November 2020, the Company issued a promissory note with a third party, which is non-interest bearing and payable based on a payment schedule with ten payments in the aggregate amount of $7,750 through December 31, 2024, as a result of a settlement described under the “CanWell Dispute” in Note 13.

Prime rate credit facilities due January 2026, as amended

On December 16, 2021, the Company entered into a $150,000 senior secured credit facility with a syndicate of lenders consisting of a $75,000 initial draw, a $25,000 delayed draw that must be advanced within 12 months and a $50,000 committed accordion facility that is available after December 1, 2022, provided certain financial covenants are met, and with a maturity of January 1, 2026. Upon closing, gross proceeds of $75,000 were drawn (before origination discounts and issuance costs of approximately $4,000 and $1,500, respectively, which were capitalized). In April 2022, the Company drew down on the $25,000 delayed draw. Refer to Note 14 for further discussion of the syndicated related party lender.

The Company obtained a waiver of the financial covenants for the three month periods ended March 31, 2022 and June 30, 2022. This waiver included a $500 waiver fee that was paid to the lenders

On October 24, 2022, the Company amended the senior secured credit facility such that $25,000 of the committed accordion was available for immediate draw by Acreage, which was drawn down in the fourth quarter of 2022, with the remaining $25,000 available from January 1, 2023, provided certain predetermined milestones are achieved. The Company paid an amendment fee of $1,250 to the syndicate of lenders and the amendment was treated as a debt modification.

On April 28, 2023, the Company reached an agreement with the lenders of the Prime rate credit facilities due January 2026 that would allow it to draw a further $15,000 under its current Credit Agreement, but such funds would be maintained in a segregated account until dispersed and be restricted for use to only eligible capital expenditures. As part of this agreement, the Company agreed to limit the total amounts outstanding under the Credit Agreement to $140,000 and to at all times subsequent to the amendment, maintain collateral (as defined in the Credit Agreement) equal to or greater than the outstanding amount under the Credit Agreement.

The loan is secured by pledged equity interests and substantially all of the assets of the Company. Advances under the facility bear interest at a variable rate of U.S. prime (“Prime”) plus 5.75% per annum, payable monthly in arrears, with a Prime floor of 5.50% plus an additional 1.0% per annum until certain collateral assignment agreements are delivered.

The facility has a maturity date of January 1, 2026 and the Company has the option to extend the maturity date to January 1, 2027 prior to January 1, 2024, for a fee equal to 1.0% of the total loan amount. If the Company chooses to extend the maturity date, it will also be required to make monthly installment payments, each of which shall be an amount equal to five percent per year of the outstanding amount of the loan.

The loan is subject to various financial covenants, including (i) a fixed charge coverage ratio and two leverage ratios in respect of all periods beginning on or after December 31, 2023 and (ii) a minimum cash requirement of $9.0 million at each quarter end of the Company. Finally, the Amended Credit Facility includes approval for Canopy USA to acquire control of Acreage without requiring repayment of all amounts outstanding under the Amended Credit Facility, provided certain conditions are satisfied. As of September 30, 2023 the Company was in compliance with all covenants.

ERTC Factoring Agreement

On April 11, 2023, the Company received $12,113 pursuant to a financing agreement with a third-party lender (the “Financing Agreement”), which was included in “Debt, current” as of June 30, 2023. The Company assigned to the lender its interests in Employee Retention Tax Credits (“ERTC”) that it submitted for a claim of approximately $14,251. If the Company does not receive the ERTC, in whole or in part, the Company is required to repay the related portion of the funds received plus 10% interest accrued from the date of the Financing Agreement through the repayment date. The Financing Agreement does not have a stated maturity date and the discount is being accreted to interest expense over an expected term. The Company’s obligations under the Financing Agreement will be satisfied upon receipt of the ERTC or other full repayment. Finally, the Company determined the ERTC did not meet the criteria to record as a receivable as of June 30, 2023 due to the uncertain nature of such claims.

During the three and nine months ended September 30, 2023, the Company received $10,472 of the ERTC claims which was remitted to the lender per the terms of the Financing Agreement, extinguishing an equal portion of the debt included in “Debt, current” as of September 30, 2023.

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS

The table below details the change in Pubco shares outstanding by class for the nine months ended September 30, 2023:

Shareholders’ Equity	Fixed Shares	Floating Shares	Fixed Shares Held in Treasury	Floating Shares Held in Treasury	Fixed Multiple Shares	Total Shares Outstanding
December 31, 2022	79,047	34,114	(589)	(253)	118	112,437
Issuances	1,626	1,902	—	—	—	3,528
September 30, 2023	80,673	36,016	(589)	(253)	118	115,965

Warrants

A summary of the warrants activity outstanding is as follows:

Warrants	Fixed Shares	Floating Shares
December 31, 2022	5,817	2,524
Expired	—	—
September 30, 2023	5,817	2,524

The exercise price of each Fixed Share warrants ranged from $3.15 to $4.00, respectively, and the exercise price of each Floating Share warrants ranged from $3.01 to $4.00, respectively. The warrants are exercisable for a period of 4 years. The weighted-average remaining contractual life of the warrants outstanding is approximately 1.3 years. There was no aggregate intrinsic value for warrants outstanding as of September 30, 2023.

Non-controlling interests - convertible units

The Company has NCIs in consolidated subsidiaries USCo2 and HSCP. The non-voting shares of USCo2 and HSCP units make up substantially all of the NCI balance as of September 30, 2023 and are convertible for either 0.7 of a Fixed Share and

0.3 of a Floating Share of Pubco or cash, as determined by the Company. Summarized financial information of HSCP is presented below. USCo2 does not have discrete financial information separate from HSCP.

HSCP net asset reconciliation	September 30, 2023			December 31, 2022
Current assets	$	89,448		$	118,193
Non-current assets	261,389			237,665
Current liabilities	(15,172)			(9,141)
Non-current liabilities	(254,751)			(239,525)
Other NCI balances	(726)			(725)
Accumulated equity-settled expenses	(243,182)			(240,760)
Net assets	$	(162,994)		$	(134,293)
HSCP/USCo2 ownership % of HSCP	15.93		%	16.33		%
Net assets allocated to USCo2/HSCP	$	(25,959)		$	(21,930)
Net assets attributable to other NCIs	726			725
Total NCI	$	(25,233)		$	(21,205)

	Three Months Ended September 30,						Nine Months Ended September 30,
HSCP Summarized Statement of Operations	2023			2022			2023			2022
Net loss allocable to HSCP/USCo2	$	(1,521)		$	(16,549)		$	(23,924)		$	(27,589)
HSCP/USCo2 weighted average ownership % of HSCP	15.37		%	16.84		%	16.23		%	16.96		%
Net loss allocated to HSCP/USCo2	$	(234)		$	(2,787)		$	(3,884)		$	(4,679)
Net loss allocated to other NCIs	—			3			(1)			4
Net loss attributable to NCIs	$	(234)		$	(2,784)		$	(3,885)		$	(4,675)

As of September 30, 2023, USCo2’s non-voting shares owned approximately 0.22% of HSCP units. USCo2’s capital structure is comprised of voting shares, all of which are held by the Company, and of non-voting shares held by certain former HSCP members. Certain executive employees and profits interests holders own approximately 16.01% of HSCP non-voting units. The remaining 83.77% interest in HSCP is held by USCo and represents the members’ equity attributable to shareholders of the parent.

A reconciliation of the beginning and ending amounts of convertible units is as follows:

Convertible Units	September 30, 2023	December 31, 2022
Beginning balance	22,698	23,076
NCI units converted to Pubco	—	(378)
Ending balance	22,698	22,698

XML

EQUITY-BASED COMPENSATION EXPENSE

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

EQUITY-BASED COMPENSATION EXPENSE

EQUITY-BASED COMPENSATION EXPENSE

Amended Arrangement with Canopy Growth

On September 23, 2020, the Company announced the implementation of the Amended Arrangement (as defined in Note 13). Pursuant to the Amended Arrangement, the Company’s articles have been amended to create new Fixed Shares, Floating Shares and Fixed Multiple Shares. Consequently, the Company’s equity-based compensation was modified into new equity awards of the Company. Refer to Note 13 for further discussion.

Equity-based compensation - Plan (Acreage Holdings, Inc. Omnibus Incentive Plan)

In connection with the RTO transaction, the Company’s Board of Directors adopted an Omnibus Incentive Plan, as amended September 23, 2020 (the “Plan”), which permits the issuance of stock options, stock appreciation rights, stock awards, share units, performance shares, performance units and other stock-based awards up to an amount equal to 15% of the issued and outstanding Subordinate Voting Shares of the Company.

Pursuant to the Amended Arrangement, the Company retained the Plan described above, the upper limit of issuances being up to an amount equal to 15% of the issued and outstanding Fixed Shares and Floating Shares of the Company. As of September 30, 2023, the Company had 959 shares authorized and available for grant under the Plan.

Restricted Share Units (“RSUs”)

	Fixed Shares			Floating Shares
Restricted Share Units (Fair value information expressed in whole dollars)	RSUs	Weighted Average Grant Date Fair Value		RSUs	Weighted Average Grant Date Fair Value
Unvested, January 1, 2023	6,324	$	1.80	464	$	6.68
Granted	3,646	$	0.15	7,870	$	0.23
Forfeited	(1,642)	$	0.90	(135)	$	1.15
Vested	(2,201)	$	1.29	(1,973)	$	0.60
Unvested, September 30, 2023	6,127	$	1.24	6,226	$	0.58
Vested and unreleased(1)	40	$	8.52	11	$	17.35
Outstanding, September 30, 2023	6,167	$	1.29	6,237	$	0.61

(1) RSUs that are vested and unreleased represent RSUs that are pending delivery.

RSUs of the Company generally vest over a period of three years and RSUs granted to certain executives vest based on achievement of specific performance conditions. In certain situations for specified individuals, RSUs vest on an accelerated basis on separation. The fair value for RSUs is based on the Company’s share price on the date of the grant. The Company recorded $791 and $2,019 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2023, respectively, and $2,256 and $7,645 during the three and nine months ended September 30, 2022, respectively. The fair value of RSUs vested during the three and nine months ended September 30, 2023 was $890 and $1,489, respectively, and $1,427 and $4,760 during the three and nine months ended September 30, 2022, respectively.

The total weighted average remaining contractual life and aggregate intrinsic value of unvested RSUs as of September 30, 2023 was approximately 0.9 years and $4,612, respectively. Unrecognized compensation expense related to these awards at September 30, 2023 was $10,436 and is expected to be recognized over a weighted average period of approximately 1.0 year.

Stock options

	Fixed Shares			Floating Shares
Stock Options (Exercise price expressed in whole dollars)	Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price
Options outstanding, January 1, 2023	7,337	$	2.75	2,267	$	3.10
Forfeited	(1,875)	$	0.66	(131)	$	3.16
Expired	—	$	—	(35)	$	2.55
Options outstanding, September 30, 2023	5,462	$	3.46	2,101	$	3.10
Options exercisable, September 30, 2023	3,400	$	5.21	2,101	$	3.10

Stock options of the Company generally vest over a period of three years and options granted to certain executives vest based on achievement of specific performance conditions. Stock options of the Company have an expiration period of 5 or 10 years from the date of grant. The weighted average contractual life remaining for Fixed Share options outstanding and exercisable as of September 30, 2023 was approximately 4.3 and 4.7 years, respectively. The weighted average contractual life remaining for Floating Share options outstanding and exercisable as of September 30, 2023 was approximately 6.2 and 6.2 years, respectively. The Company recorded $(46) and $404 as Equity-based compensation expense on Unaudited Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2023 and $300 and $725 during the three and nine months ended September 30, 2022, respectively, in connection with these awards.

As of September 30, 2023, unamortized expense related to stock options totaled $596 and is expected to be recognized over a weighted-average period of approximately 2 years. As of September 30, 2023, the aggregate intrinsic value for unvested options and for vested and exercisable options was nil, respectively.

XML

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Commitments

The Company provides revolving lines of credit to certain of its portfolio companies. As of September 30, 2023, only one revolving line of credit remained outstanding and the maximum obligation under this arrangement was equal to the balance advanced of $4,331. Refer to Note 6 for further discussion).

Prior Plan of Arrangement with Canopy Growth

On June 19, 2019, the shareholders of the Company and of Canopy Growth separately approved the proposed plan of arrangement (the “Prior Plan of Arrangement”) involving the two companies, and on June 21, 2019, the Supreme Court of British Columbia granted a final order approving the Prior Plan of Arrangement. Effective June 27, 2019, the articles of the Company were amended pursuant to the Prior Plan of Arrangement to provide that, upon the occurrence (or waiver by Canopy Growth) of the Triggering Event, subject to the satisfaction of the conditions set out in the arrangement agreement entered into between Acreage and Canopy Growth on April 18, 2019, as amended on May 15, 2019 (the “Original Arrangement Agreement”), Canopy Growth will acquire (the “Acquisition”) all of the issued and outstanding shares in the capital of the Company (each, an “Acreage Share”).

Second Amendment to the Arrangement Agreement with Canopy Growth

On September 23, 2020, Acreage and Canopy Growth entered into an amending agreement (the “Amending Agreement” or “Amended Arrangement”) (and together with the Original Arrangement Agreement and any further amendments thereto, the “Amended Plan of Arrangement”) and the Amended Arrangement became effective at 12:01 a.m. (Vancouver time) (the “Amendment Time”) on September 23, 2020 (the “Amendment Date”). Pursuant to the Amended Plan of Arrangement, Canopy Growth made a cash payment of $37,500 which was delivered to Acreage’s shareholders and certain holders of securities convertible or exchangeable into shares of Acreage. Acreage also completed a capital reorganization (the “Capital Reorganization”) effective as of the Amendment Time whereby: (i) each existing SVS was exchanged for 0.7 of a Fixed Share and 0.3 of a Floating Share; (ii) each issued and outstanding PVS was exchanged for 28 Fixed Shares and 12 Floating Shares; and (iii) each issued and outstanding MVS was exchanged for 0.7 of a Fixed Multiple Share and 0.3 of a Floating Share.

At the Amendment Time, each option, restricted share unit, compensation option, and warrant to acquire existing SVS (each a “Security”) that was outstanding immediately prior to the Amendment Time, was exchanged for a replacement Security to acquire Fixed Shares (a “Fixed Share Replacement Security”) and a replacement Security to acquire Floating Shares (a “Floating Share Replacement Security”) to account for the Capital Reorganization.

Pursuant to the Amended Plan of Arrangement, upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event (the “Triggering Event Date”), Canopy Growth will, subject to the satisfaction or waiver of certain closing conditions set out in the Arrangement Agreement: (i) acquire all of the issued and outstanding Fixed Shares (following the mandatory conversion of the Fixed Multiple Shares into Fixed Shares) on the basis of 0.3048 of a common share of Canopy Growth (each whole common share, a “Canopy Growth Share”) for each Fixed Share held (the “Fixed Exchange Ratio”) at the time of the acquisition of the Fixed Shares (the “Acquisition Time”), subject to adjustment in accordance with the terms of the Amended Plan of Arrangement (the “Canopy Call Option”). The Canopy Call Option will expire 10 years from the Amendment Time.

At the Acquisition Time, on the terms and subject to the conditions of the Amended Plan of Arrangement, each Fixed Share Replacement Security will be exchanged for a replacement Security from Canopy Growth equal to: (i) the number of Fixed Shares that were issuable upon exercise of such Fixed Share Replacement Security immediately prior to the Acquisition Time, multiplied by (ii) the Fixed Exchange Ratio in effect immediately prior to the Acquisition Time (provided that if the foregoing would result in the issuance of a fraction of a Canopy Growth Share, then the number of Canopy Growth Shares to be issued will be rounded down to the nearest whole number).

The Amended Plan of Arrangement provides for, among other things, Amendments to the definition of Purchaser Approved Share Threshold (as defined therein) to change the number of shares of Acreage available to be issued by Acreage without an adjustment in the Fixed Exchange Ratio such that Acreage may issue a maximum of 32,700 shares. Furthermore, Acreage

generally may not issue any equity securities without Canopy Growth’s prior consent. Additionally, the Amended Plan of Arrangement allows for various Canopy Growth rights that extend beyond the Acquisition Date, including, among others: (i) rights to nominate a majority of Acreage’s Board of Directors following the Acquisition Time; (ii) restrictive covenants in respect of the business conduct in favor of Canopy Growth; (iii) termination of non-competition and exclusivity rights granted to Acreage by Canopy Growth in the event that Acreage does not meet certain specified financial targets; (iv) implementation of further restrictions on Acreage’s ability to operate its business in the event that Acreage does not meet certain specified financial targets; and (v) termination of the Amended Plan of Arrangement in the event that Acreage does not meet certain specified financial targets in the trailing 12 month period. Each of the financial targets referred to above is specified in the Amending Agreement and related to the performance of Acreage relative to a business plan for Acreage for each fiscal year ended December 31, 2020 through December 31, 2029 set forth in the Proposal Agreement (the “Initial Business Plan”).

Further, the Amended Plan of Arrangement imposes restrictions on Acreage entering into any contracts in respect of Company Debt if: (i) such contract would be materially inconsistent with market standards for companies operating in the United States cannabis industry; (ii) such contract prohibits a prepayment of the principal amount of such Company Debt; and (iii) such contract would provide for interest payments to be paid through the issuance of securities as opposed to cash, among other restrictions. The Amended Plan of Arrangement also provides for the following: (i) certain financial reporting obligations to Canopy Growth; (ii) certain specified criteria related to any new directors or officers of Acreage, and (iii) a limit to Acreage’s operations to the Identified States (as defined therein).

Third Amendment to the Arrangement Agreement with Canopy Growth

On October 24, 2022, the Company entered into an arrangement agreement (the “Floating Share Agreement”) with Canopy Growth and Canopy USA, LLC (“Canopy USA”), Canopy Growth’s newly-created U.S. domiciled holding company, pursuant to which, subject to approval of the holders of the Class D subordinate voting shares of Acreage (the “Floating Shares”) and the terms and conditions of the Floating Share Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of court-approved plan of arrangement (the “Floating Share Arrangement”) for consideration of 0.4500 of a common share of Canopy Growth (each whole share a “Canopy Share”) in exchange for each Floating Share. A special meeting of the holders of Floating Shares was held on March 15, 2023, where the holders of Floating Shares approved the Floating Share Arrangement (the “Special Meeting”).

Concurrently with entering the Floating Share Agreement, Canopy Growth irrevocably waived its option to acquire the Floating Shares pursuant to the Amended Arrangement.

Subject to the provisions of the Floating Share Agreement, Canopy Growth has agreed to exercise the fixed option pursuant to the Amended Agreement to acquire all outstanding Fixed Shares, representing approximately 70% of the total shares of Acreage as at the date hereof, at a fixed exchange ratio of 0.3048 of a Canopy Share for each Fixed Share.

Acreage expects the Floating Share Arrangement to close upon the satisfaction or waiver of all conditions under the Floating Share Agreement and the Amended Arrangement. It is anticipated that the acquisition by Canopy USA of the Fixed Shares pursuant to the Fixed Option will be completed immediately following closing of the Floating Share Agreement. In the event that Canopy USA exercises the Fixed Option and acquires the Floating Shares pursuant to the Floating Share Arrangement, Acreage will be wholly-owned subsidiary of Canopy USA.

On March 17, May 31, August 31, 2023, and October 31, 2023 Acreage, Canopy and Canopy USA entered into amendments to the Floating Share Arrangement Agreement (collectively, the “FSA Amendments”). Pursuant to the terms of the FSA Amendments, Acreage, Canopy and Canopy USA agreed to multiple extensions to the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement) from its initial date of March 31, 2023 to its current date of December 31, 2023.

Tax Receivable Agreement and Tax Receivable Bonus Plans

The Company is a party to (i) a tax receivable agreement dated November 14, 2018 and subsequently amended (the “Tax Receivable Agreement”) between the Company and certain current and former unit holders of HSCP and (ii) tax receivable bonus plans dated November 14, 2018 and subsequently amended (the “Tax Receivable Bonus Plans”) between the Company and certain directors, officers and consultants of the Company (together the “Tax Receivable Recipients”). Under the Tax Receivable Agreement and the Tax Receivable Bonus Plans, the Company is required to make cash payments to the Tax Receivable Recipients equal to 85% of the tax benefits, if any, that the Company actually realizes, or in certain circumstances is deemed to realize, as a result of (i) the increases in its share of the tax basis of assets of HSCP resulting from any redemptions or exchanges of Units from the HSCP Members, and (ii) certain other tax benefits related to the Company making payments under the Tax Receivable Agreement and the Tax Receivable Bonus Plan. Although the actual timing and amount of any payments that the Company makes to the Tax Receivable Recipients cannot be estimated, it expects those payments will be

significant. Any payments made by the Company to the Tax Receivable Recipients may generally reduce the amount of overall cash flow that might have otherwise been available to it. Payments under the Tax Receivable Agreement are not conditioned on any Tax Receivable Recipient’s continued ownership of Units or our shares after the completion of the RTO. Payments under the Tax Receivable Bonus Plan may, at times, be conditioned on the Tax Receivable Recipient’s continued employment by the Company. As of September 30, 2023, the Company has not made any payments in relation to the Tax Receivable Agreement or the Tax Receivable Bonus Plans.

Concurrently with the execution of the Floating Share Arrangement Agreement, Canopy Growth, Canopy USA, High Street, Acreage Holdings America, Inc. and certain individuals party to the Tax Receivable Agreement, amended the Tax Receivable Agreement in accordance with the Floating Share Agreement. Pursuant to the Floating Share Agreement, Canopy Growth, on behalf of Canopy USA agreed to: (i) issue Canopy Shares with a value of approximately $30,500 to the Tax Receivable Agreement Members in exchange for each such individual executing an assignment of rights agreement assigning such individual’s rights under the Tax Receivable Agreement to Canopy USA, such that following assignment, Canopy USA is the sole member and beneficiary under the Tax Receivable Agreement; and (ii) fund a payment with a value of approximately $19,500 to be made by the Company in Canopy Shares to certain eligible participants pursuant to the Tax Receivable Bonus Plans, as amended on October 24, 2022, both in order to reduce a potential liability of approximately $121,000 under the Tax Receivable Agreement and the Tax Receivable Bonus Plans. In connection with the foregoing, Canopy Growth issued 5,648,927 Canopy Shares on or about November 4, 2022 and 7,102,081 Canopy Shares on or about March 17, 2023 to the Tax Receivable Agreement Members. In addition, the Tax Receivable Agreement Bonuses with an aggregate value of approximately $19,500 in Canopy Shares will be issued by Canopy to certain eligible participants under the Tax Receivable Bonus Plans on the closing of the Floating Share Arrangement or, if the Floating Share Arrangement does not close or is terminated but the Amended Arrangement closes, then on the closing of the acquisition. The Tax Receivable Agreement Bonuses will be paid to recipients to be determined by Kevin Murphy, the administrator of the Tax Receivable Bonus Plans, and may include one or more directors of Acreage and other current and former officers or consultants of Acreage as may be determined by Kevin Murphy. Canopy Growth has also agreed to register the resale of such Canopy Shares under the Securities Act of 1933, as amended.

Debenture

In connection with the implementation of the Amended Arrangement, pursuant to a secured debenture dated September 23, 2020 (the “Debenture”) issued by Universal Hemp, LLC, an affiliate of Acreage that operates solely in the hemp industry in full compliance with all applicable laws (the “Borrower”), to 11065220 Canada Inc., an affiliate of Canopy Growth (the “Lender”), the Lender agreed to provide a loan of up to $100,000 (the “Loan”), $50,000 of which was advanced on the Amendment Date (the “Initial Advance”), and $50,000 of the Loan will be advanced in the event that the following conditions, among others, are satisfied: (a) the Borrower’s EBITDA (as defined in the Debenture) for any 90 day period is greater than or equal to 2.0 times the interest costs associated with the Initial Advance; and (b) the Borrower’s business plan for the 12 months following the applicable 90 day period supports an Interest Coverage Ratio (as defined in the Debenture) of at least 2.00:1. On October 24, 2022, the Debenture was assigned by the Lender to Canopy USA.

The principal amount of the Loan will bear interest from the date of advance, compounded annually, and be payable on each anniversary of the date of the Debenture in cash in U.S. dollars at a rate of 6.1% per annum. The Loan will mature 10 years from the date of the Initial Advance.

The Loan must be used exclusively for U.S. hemp-related operations and on the express condition that such amount will not be used, directly or indirectly, in connection with or for the operation or benefit of any of the Borrower’s affiliates other than subsidiaries of the Borrower exclusively engaged in U.S. hemp-related operations and not directly or indirectly, towards the operation or funding of any activities that are not permissible under applicable law. The Loan proceeds must be segregated in a distinct bank account and detailed records of debits to such distinct bank account will be maintained by the Borrower.

No payment due and payable to the Lender by the Borrower pursuant to the Debenture may be made using funds directly or indirectly derived from any cannabis or cannabis-related operations in the United States, unless and until the Triggering Event Date.

The Debenture includes usual and typical events of default for a financing of this nature, including, without limitation, if: (i) Acreage is in breach or default of any representation or warranty in any material respect pursuant to the Arrangement Agreement; (ii) operations deemed to be non-core must cease within 18 months from the Amendment Date; and (iii) Acreage fails to perform or comply with any covenant or obligation in the Arrangement Agreement which is not remedied within 30 days after written notice is given to the Borrower by the Lender. The Debenture also includes customary representations and warranties, positive covenants and negative covenants of the Borrower.

Advisor fee

In connection with the Prior Plan of Arrangement, the Company entered into an agreement with its financial advisor providing for a fee payment of $7,000 in either cash, Acreage shares or Canopy Growth shares, at the discretion of the Company, upon the successful acquisition of Acreage by Canopy Growth. During the fourth quarter of 2022, the Company amended the terms of the agreement with its financial advisors providing for a fee payment of $3,000 in cash, less a $500 initial payment, and $2,000 in shares of the Company, upon the successful acquisition of Acreage by Canopy Growth.

Surety bonds

The Company has indemnification obligations with respect to surety bonds primarily used as security against non-performance in the amount of $5,000 as of September 30, 2023, for which no liabilities are recorded on the Unaudited Condensed Consolidated Statements of Financial Position.

The Company is subject to other capital commitments and similar obligations. As of September 30, 2023 and 2022, such amounts were not material.

CanWell Settlement

In November 2020, the Company entered into a final confidential settlement agreement with CanWell, LLC for certain outstanding proceedings. As part of that agreement, the Company accrued for $7,750 in Legal settlements, net on the Statements of Operations for the year ended December 31, 2020. In connection with this settlement agreement, the Company issued a promissory note in the amount of $7,750 to CanWell, which is non-interest bearing and is payable in periodic payments through December 31, 2024. Through September 30, 2023, the Company has paid $5,375 of the promissory note.

Contingencies

The Company’s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company’s applicable subsidiaries ceasing operations. While management of the Company believes that the Company’s subsidiaries are in compliance with applicable local and state regulations as of September 30, 2023, cannabis regulations continue to evolve and are subject to differing interpretations. As a result, the Company’s subsidiaries may be subject to regulatory fines, penalties, or restrictions in the future.

The Company and its subsidiaries may be, from time to time, subject to various administrative, regulatory and other legal proceedings arising in the ordinary course of business. Contingent liabilities associated with legal proceedings are recorded when a liability is probable, and the contingent liability can be reasonably estimated.

New York outstanding litigation

On November 2, 2018, EPMMNY LLC (“EPMMNY”) filed a complaint in the Supreme Court of the State of New York, County of New York, asserting claims against 16 defendants, including NYCANNA, Impire State Holdings LLC (“Impire”), NY Medicinal Research & Caring, LLC (“NYMRC”) (each, a wholly owned subsidiary of High Street) and High Street. The Index Number for the action is 655480/2018. EPMMNY alleges that it was wrongfully deprived of a minority equity interest and management role in NYCANNA by its former partner, New Amsterdam Distributors, LLC (“New Amsterdam”), which attempted to directly or indirectly sell or transfer EPMMNY’s alleged interest in NYCANNA to other entities in 2016 and 2017, including Impire, NYMRC and High Street.

EPMMNY alleges that it is entitled to the value of its alleged minority interest in NYCANNA or minority ownership in NYCANNA. EPMMNY also alleges that certain defendants misused its alleged intellectual property and/or services, improperly solicited its employees, and aided and abetted or participated in the transfer of equity and/or business opportunities from EPMMNY.

High Street, along with the other Defendants, filed motions to dismiss on April 1, 2019. The motions were fully briefed and submitted to the Court as of July 18, 2019, and oral argument was heard on September 6, 2019. Following a hearing held during April 2022, in ruling on one dismissal argument advanced by several Defendants, the Court ruled that Plaintiff had the capacity to bring this action on behalf of EPMMNY. On July 13, 2023, the Court ruled on the remaining dismissal arguments, granting the vast majority of them. As part of its ruling, the Court dismissed without prejudice every claim against NYCANNA, Impire,

NYMRC, and High Street, except the claims for unjust enrichment and quantum meruit (which also were permitted to proceed against other Defendants). The only other claim that the Court did not dismiss was for breach of contract against New Amsterdam.

On July 24, 2023, EPMMNY moved for leave to file a proposed amended complaint. The proposed amended complaint names several defendants, including NYCANNA, Impire, NYMRC, High Street, and Kevin Murphy, and contains similar allegations to those in the original complaint. High Street intends to oppose the motion for leave to amend and,if necessary, move to dismiss the new complaint.

High Street intends to continue vigorously defend this action, which the Company firmly believes is without merit. High Street also believes it is entitled to full indemnity from the claims asserted against it by EPMMNY pursuant to the purchase agreement pertaining to its acquisition of NYCANNA and personal guarantee by the largest shareholders of the seller.

Health Circle, Inc. litigation

On April 13, 2023, Health Circle, Inc., a licensed cannabis dispensary operator in Massachusetts, initiated a civil action against the Company and MA RMD SVCS, LLC in Plymouth County, Massachusetts for alleged breaches of that certain Revolving Line of Credit, dated October 31, 2017, by and between Health Circle, Inc. and MA RMD SVCS, LLC (the “HCI Credit Agreement”) and certain torts. High Street has filed a second civil action against Michael Westort, individually, in the Business Litigation Section, located in Boston, MA, predicated upon that certain Membership Interest Purchase Agreement, dated June 30, 2018, by and between Mr. Westort and High Street. The Company has moved to partially dismiss the complaint in Plymouth County, and the court has scheduled a hearing on February 1, 2024 to hear argument on this motion. The Company is assessing the amended complaint, and will ultimately file counterclaims against Health Circle, Inc. based on the outstanding debt under the HCI Credit Agreement. High Street intends to vigorously defend against this action, which the Company believes is without merit, and to pursue its claims against Mr. Westort and Health Circle, Inc.

Alfred’s Finest, Inc. arbitration

On June 22, 2023, Alfred’s Finest, Inc. (“AFI”) filed a demand for arbitration relating to that certain Asset Purchase Agreement, dated June 24, 2021, by and between Alfred’s Finest, Inc., Robert M. Andrews, Jr and The Botanist, Inc., a wholly owned subsidiary of High Street, and the Company (the “AFI APA”). The AFI APA provided for the payment of $2,000 to AFI upon closing and an additional $3,000 payable on or before the 18-month anniversary of the closing date. Pursuant to its termination rights provided under the APA, the Company sent a notice of termination of the AFI APA on June 29, 2022 before the closing occurred. AFI alleges that the Company breached the terms of the APA and claims that the notice of termination sent by the Company has no basis in the language of the AFI APA. AFI is seeking relief from the Company consisting of specific performance of the AFI APA and recovery of its damages, including arbitration fees and costs. The Company believes the plain language of the AFI APA supports its position and intends to vigorously defend this action, which the Company believes is without merit. The Company has filed a counterclaim against AFI for breach of the AFI APA based on AFI’s failure to act in good faith as required by the AFI APA.

On June 28, 2023, in response to AFI’s demand for arbitration, the Company asserted its right under the AFI APA to submit the dispute to mediation before it proceeds to arbitration. The parties are in the process of scheduling the mediation and identifying a mediator.

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2023

Related Party Transactions [Abstract]

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

Transactions with related parties are entered into in the normal course of business and are measured at the amount established and agreed to by the parties.

6.10% Secured debenture due September 2030

As disclosed in Note 10, “6.10% Secured debenture due September 2030”, on September 23, 2020, pursuant to the implementation of the Amended Arrangement, a subsidiary of Canopy Growth advanced gross proceeds of $50,000 (less transaction costs of approximately $4,025) to Universal Hemp, an affiliate of the Company, pursuant to the terms of a secured debenture. In accordance with the terms of the debenture, the funds cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. Acreage then engaged an investment advisor (the “Investment Advisor”) which, under the Investment Advisor’s sole discretion, invested on behalf of Universal Hemp, $34,019 of the proceeds on September 28, 2020. During the three and nine months ended September 30, 2023, the Company incurred interest expense attributable to the 6.10% Secured debenture due September 2030 of $763 and $2,289, respectively.

As a result of the transaction described above, Universal Hemp, a subsidiary of the Company, acquired 34,019 class B units, at $1 par value per unit, which represented 100% financial interest in an Investment Partnership, a Canada-based limited partnership. An affiliate of the Institutional Investor holds Class A Units of the Investment Partnership. The general partner of the Investment Partnership is also an affiliate of the Institutional Investor. The class B units are held by the Institutional Investor as agent for Universal Hemp. On September 28, 2020, the Company received gross proceeds of $33,000 (less transaction costs of approximately $959) from an affiliate of the Institutional Lender (the “Lender”) and used a portion of the proceeds of this loan to retire its short-term $11,000 convertible note and its short-term note aggregating approximately $18,000 in October 2020, with the remainder being used for working capital purposes. The Lender is controlled by the Institutional Lender. The Investment Partnership is the investor in the Lender.

Prime rate credit facilities due January 2026, as amended

On December 16, 2021, the Company entered into the Prime rate credit facilities due January 2026 with a syndicate of lenders, including Viridescent Realty Trust, Inc. (“Viridescent”), an entity controlled by Kevin Murphy. Refer to Note 10 for further discussion. On October 24, 2022, the Company amended these credit facilities and the Company paid an amendment fee of $1,250 to the lenders, with $375 paid to Viridescent. On April 28, 2023, the Company and the lenders further amended the Prime rate credit facilities. Refer to Note 10 for further discussion.

Viridescent has committed $42,000 of the $140,000 drawn down under the Credit Facility, with third-party syndicated affiliates committing the additional $98,000. During the three and nine months ended September 30, 2023, the Company incurred interest expense attributable to Viridescent of $1,522 and $4,212, respectively. The loan is secured by first-lien mortgages on Acreage’s wholly owned real estate and other commercial security interests. A third-party syndicate served as Administrative Agent for the transaction.

XML

REPORTABLE SEGMENTS	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
REPORTABLE SEGMENTS	REPORTABLE SEGMENTSThe Company prepares its segment reporting on the same basis that its Chief Operating Decision Maker manages the business, and makes operating decisions. The Company operates under one operating segment, which is its only reportable segment: the production and sale of cannabis products. The Company’s measure of segment performance is net income, and derives its revenue primarily from the sale of cannabis products, as well as related management or consulting services which were not material in all periods presented. All of the Company’s operations are located in the United States.

XML

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

EARNINGS PER SHARE

EARNINGS PER SHARE

Basic earnings per share are computed by dividing net loss attributable to common shareholders of the Company by the weighted average number of outstanding shares for the period. Diluted earnings per share are calculated based on the weighted number of outstanding common shares plus the dilutive effect of stock options and warrants, as if they were exercised, and restricted stock units and profits interests, as if they vested and NCI convertible units, as if they converted.

Basic and diluted loss per share is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Net loss attributable to common shareholders of the Company	$	(7,625)	$	(22,214)	$	(38,371)	$	(44,837)
Weighted average shares outstanding - basic	114,171		111,200		113,181		108,795
Effect of dilutive securities	—		—		—		—
Weighted average shares - diluted	114,171		111,200		113,181		108,795
Net loss per share attributable to common shareholders of the Company - basic	$	(0.07)	$	(0.20)	$	(0.34)	$	(0.41)
Net loss per share attributable to common shareholders of the Company - diluted	$	(0.07)	$	(0.20)	$	(0.34)	$	(0.41)

During the nine months ended September 30, 2023, 5,817 Fixed warrants, 2,524 Floating warrants, 6,167 Fixed Share RSUs, 6,237 Floating Share RSUs, 5,462 Fixed Share stock options, 2,101 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive. During the nine months ended September 30, 2022, 5,817 Fixed warrants, 2,524 Floating warrants, 6,786 Fixed Share RSUs, 534 Floating Share RSUs, 7,337 Fixed Share stock options, 2,303 Floating Share stock options and 22,698 NCI convertible units were excluded from the calculation of net loss per share attributable to common shareholders of the Company - diluted, as they were anti-dilutive.

XML

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTSOn October 31, 2023, Acreage, Canopy and Canopy USA entered into a fourth amendment to the Floating Share Arrangement Agreement (the “Floating Share Amendment”). Pursuant to the terms of the Floating Share Amendment, Acreage, Canopy and Canopy USA agreed to amend the Exercise Outside Date from October 31, 2023, to December 31, 2023.

XML

SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Basis of presentation and going concern

Basis of presentation and going concern

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments consisting only of normal recurring adjustments necessary for a fair presentation have been reflected in these unaudited condensed consolidated financial statements. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2023, or any other period.

As reflected in the unaudited condensed consolidated financial statements, the Company had an accumulated deficit as of September 30, 2023, as well as a net loss and negative cash flow from operating activities for the nine months ended September 30, 2023. Additionally, subsequent to quarter end the Company was temporarily in default of the Universal Hemp 6.1% Loan. Refer to Note 10 for further discussion. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance of these financial statements.

However, management believes that substantial doubt about the Company’s ability to meet its obligations for the next twelve months from the date these financial statements are issued, can be mitigated by, but not limited to, (i) expected long-term sales growth from the Company’s consolidated operations, (ii) latitude as to the timing and amount of certain operating expenses as well as capital expenditures, (iii) expense reduction plans that have already been put in place to improve the Company’s results, and (iv) access to the U.S. and Canadian public equity markets.

If the Company is unable to raise additional capital whenever necessary, it may be forced to decelerate or curtail its footprint build-out or other operational activities until such time as additional capital becomes available. Such limitation of the Company’s activities would allow it to slow its rate of spending and extend its use of cash until additional capital is raised. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur at any time within the next twelve months or thereafter which could increase the Company’s need to raise additional capital on an immediate basis.

These interim unaudited condensed consolidated financial statements and notes thereto should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, dated May 1, 2023, as filed with the Securities and Exchange Commission (the “2022 Form 10-K”).

Use of estimates

Use of estimates

Preparation of financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities as of the dates presented and the reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates. Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include the fair value of assets acquired and liabilities assumed in business combinations, assumptions relating to equity-based compensation expense, estimated useful lives for property, plant and equipment and intangible assets, the valuation allowance against deferred tax assets and the assessment of potential charges on goodwill, intangible assets and investments in equity and notes receivable.

Emerging growth company

Emerging growth company

The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.

Functional and presentation currency

Functional and presentation currency

The unaudited condensed consolidated financial statements and the accompanying notes are expressed in U.S. dollars. Financial metrics are presented in thousands. Other metrics, such as shares outstanding, are presented in thousands unless otherwise noted.

Basis of consolidation

Basis of consolidation

The Company’s unaudited condensed consolidated financial statements include the accounts of Acreage, its subsidiaries and variable interest entities (“VIEs”) where the Company is considered the primary beneficiary, if any, after elimination of intercompany accounts and transactions. Investments in business entities in which Acreage lacks control but is able to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in Loss from investments, net in the Unaudited Condensed Consolidated Statements of Operations.

Non-controlling interests (“NCI”)

Non-controlling interests (“NCI”)

Non-controlling interests represent ownership interests in consolidated subsidiaries by parties that are not shareholders of Pubco. They are shown as a component of Total equity in the Unaudited Condensed Consolidated Statements of Financial Position, and the share of loss attributable to non-controlling interests is shown as a component of Net loss in the Unaudited Condensed Consolidated Statements of Operations. Changes in the parent company’s ownership that do not result in a loss of control are accounted for as equity transactions.

Cash and cash equivalents

Cash and cash equivalents

The Company defines cash equivalents as highly liquid investments held for the purpose of meeting short-term cash commitments that are readily convertible into known amounts of cash, with original maturities of three months or less. The Company maintains cash with various U.S. banks and credit unions with balances in excess of the Federal Deposit Insurance Corporation and National Credit Union Share Insurance Fund limits, respectively. The failure of a bank or credit union where the Company has significant deposits could result in a loss of a portion of such cash balances in excess of the insured limit, which could materially and adversely affect the Company’s business, financial condition, results of operations and the market price of the Company’s Fixed Shares and Floating Shares. Cash and cash equivalents belonging to entities the Company has classified as held-for-sale have been reclassified to Assets held-for-sale on the Unaudited Condensed Consolidated Statements of Financial Position. Refer to Note 3 for further discussion.

Restricted cash

Restricted cashRestricted cash represents funds contractually held for specific purposes and, as such, not available for general corporate purposes.

Accounts receivable and notes receivable valuations

Accounts receivable and notes receivable valuationsThe Company reports accounts receivable at their net realizable value, which is management’s best estimate of the cash that will ultimately be received from customers. The Company's notes receivable represent notes due from various third parties. The Company maintains an allowance for expected credit losses to reflect the expected uncollectability of accounts receivable and notes receivable based on historical collection data and specific risks identified among uncollected accounts, as well as management’s expectation of future economic conditions. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the companies receivables and the expected future losses. If current or expected future economic trends, events, or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is adjusted accordingly. Trade accounts receivable and notes receivable are written off after exhaustive collection efforts occur and the receivable is deemed uncollectible.

Net loss per share

Net loss per shareNet loss per share represents the net loss attributable to shareholders divided by the weighted average number of shares outstanding during the period on an as converted basis. Basic and diluted loss per share are the same as of September 30, 2023 and 2022 as the issuance of shares upon conversion, exercise or vesting of outstanding units would be anti-dilutive in each period.

Accounting Pronouncements Recently Adopted and Accounting Pronouncements Not Yet Adopted

Accounting Pronouncements Recently Adopted

As of January 1, 2023, the Company adopted Accounting Standards Update (“ASU”) 2016-13 - Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which was subsequently revised by ASU 2018-19 and ASU 2020-02. This standard applies to financial assets, measured at amortized cost, including loans, held-to-maturity debt securities, net investments in leases and trade accounts receivable. The guidance must be adopted using a modified retrospective transition method through a cumulative-effect adjustment to retained earnings in the period of adoption. The adoption of ASU 2016-13 did not have a material effect on the Company’s unaudited condensed consolidated financial statements.

Accounting Pronouncements Not Yet Adopted

In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08 - Business Combinations (Topic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The new standard improves the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The new standard requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers. The ASU will be effective for the Company’s first interim period of fiscal 2024. The standard should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company does not anticipate a material impact on the Company’s unaudited condensed consolidated financial statements upon adoption.

XML

ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE (Tables)

9 Months Ended

Sep. 30, 2023

Business Combination and Asset Acquisition [Abstract]

Schedule of Purchase Price Allocations

The primary areas of the purchase price allocation that are not yet finalized relate to the valuation of the capital assets, tangible assets acquired and the residual goodwill resulting from the transaction.

Purchase Price Allocation	Northeast Patients Group
Assets acquired:
Cash and cash equivalents	$	361
Accounts Receivable	25
Inventory	384
Other current assets	173
Capital assets	2,377
Financing lease right-of-use asset	416
Operating lease right-of-use asset	1,279
Goodwill	24,960
Liabilities assumed:
Accounts payable and accrued liabilities	(672)
Taxes payable	(1,112)
Finance lease liability, current	(87)
Finance lease liability, non-current	(459)
Operating lease liability, current	(73)
Operating lease liability, non-current	(1,385)
Notes payable	(11)
Deferred tax liability	(1,016)
Fair value of net assets acquired	$	25,160
Consideration paid:
Settlement of pre-existing relationship	25,160
Total consideration	$	25,160

XML

INTANGIBLE ASSETS AND GOODWILL (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

The following table details the intangible asset balances by major asset classes:

Intangibles	September 30, 2023		December 31, 2022
Finite-lived intangible assets:
Customer relationships	—		1,000
Total finite-lived intangible assets	—		1,000
Accumulated amortization on finite-lived intangible assets:
Customer relationships	—		(1,000)
Total accumulated amortization on finite-lived intangible assets	—		(1,000)
Finite-lived intangible assets, net	—		—
Indefinite-lived intangible assets
Cannabis licenses	35,124		35,124
Total intangibles, net	$	35,124	$	35,124

Schedule of Goodwill

The following table details the changes in the carrying amount of goodwill:

Goodwill	Total
December 31, 2022	$	13,761
Acquisitions	24,960
September 30, 2023	$	38,721

XML

INVESTMENTS (Tables)

9 Months Ended

Sep. 30, 2023

Investments [Abstract]

Schedule of Investments

The carrying values of the Company’s investments in the Unaudited Condensed Consolidated Statements of Financial Position as of September 30, 2023 and December 31, 2022 are as follows:

Investments	September 30, 2023		December 31, 2022
Investments held at FV-NI	$	33,176	$	34,046
Total long-term investments	$	33,176	$	34,046

Schedule of Investment Income (Loss)

Income from investments, net in the Unaudited Condensed Consolidated Statements of Operations during the three and nine months ended September 30, 2023 and 2022 is as follows:

Investment income	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Short-term investments	$	—	$	1	$	—	$	4
Investments held at FV-NI	248		16		228		150
Income from investments, net	$	248	$	17	$	228	$	154

XML

NOTES RECEIVABLE, NET (Tables)

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

Schedule of Notes Receivable

Notes receivable as of September 30, 2023 and December 31, 2022 consisted of the following:

	September 30, 2023		December 31, 2022
Promissory notes receivable	$	7,062	$	34,088
Line of credit receivable	4,331		5,831
Interest receivable	3,947		4,147
Allowance for notes and interest receivable	(15,340)		(14,875)
Total notes receivable, net	$	—	$	29,191
Less: Notes receivable, current	—		29,191
Notes receivable, non-current	$	—	$	—

XML

CAPITAL ASSETS, NET (Tables)

9 Months Ended

Sep. 30, 2023

Property, Plant and Equipment [Abstract]

Schedule of Capital Assets, net

Net property, plant and equipment consisted of:

	September 30, 2023		December 31, 2022
Land	$	9,778	$	9,605
Building	58,524		58,334
Right-of-use asset, finance leases	6,297		5,077
Furniture, fixtures and equipment	40,701		46,811
Leasehold improvements	49,611		6,178
Construction in progress	14,883		34,435
Capital assets, gross	$	179,794	$	160,440
Less: accumulated depreciation and amortization	(42,928)		(27,035)
Capital assets, net	$	136,866	$	133,405

XML

LEASES (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Schedule of Lease Cost

Statements of Financial Position Information	Classification	September 30, 2023		December 31, 2022
Right-of-use assets
Operating	Operating lease right-of-use assets	$	18,699	$	22,443
Finance	Capital assets, net	4,597		4,269
Total right-of-use assets		$	23,296	$	26,712
Lease liabilities
Current
Operating	Operating lease liability, current	$	2,535	$	2,443
Financing	Debt, current	112		1
Non-current
Operating	Operating lease liability, non-current	18,298		21,692
Financing	Debt, non-current	5,846		5,305
Total lease liabilities		$	26,791	$	29,441

		Three Months Ended September 30,				Nine Months Ended September 30,
Statement of Operations Information	Classification	2023		2022		2023		2022
Short-term lease expense	General and administrative	$	102	$	(28)	$	311	$	190
Operating lease expense	General and administrative	1,238		1,221		3,853		3,613
Finance lease expense:
Amortization of right of use asset	Depreciation and amortization	93		63		278		190
Interest expense on lease liabilities	Interest expense	213		314		633		855
Net operating and finance lease cost		$	1,544	$	1,598	$	4,764	$	4,658

		Nine Months Ended September 30,
Statement of Cash Flows Information	Classification	2023		2022
Cash paid for operating leases	Net cash used in operating activities	$	3,871	$	3,390
Cash paid for finance leases - interest	Net cash used in operating activities	$	718	$	843

Schedule of Operating Lease, Liability, Maturity

The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of September 30, 2023:

Maturity of lease liabilities	Operating Leases		Finance Leases
2023	$	1,085	$	228
2024	4,285		923
2025	4,104		946
2026	4,314		969
2027	3,897		992
Thereafter	13,276		11,705
Total lease payments	$	30,961	$	15,763
Less: interest	10,128		9,805
Present value of lease liabilities	$	20,833	$	5,958
Weighted average remaining lease term (years)	8		11
Weighted average discount rate	10%		12%

Schedule of Finance Lease, Liability, Maturity

The following represents the Company’s future minimum payments required under existing leases with initial terms of one year or more as of September 30, 2023:

Maturity of lease liabilities	Operating Leases		Finance Leases
2023	$	1,085	$	228
2024	4,285		923
2025	4,104		946
2026	4,314		969
2027	3,897		992
Thereafter	13,276		11,705
Total lease payments	$	30,961	$	15,763
Less: interest	10,128		9,805
Present value of lease liabilities	$	20,833	$	5,958
Weighted average remaining lease term (years)	8		11
Weighted average discount rate	10%		12%

XML

INVENTORY (Tables)

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

The Company’s inventory balance consists of the following:

	September 30, 2023		December 31, 2022
Retail inventory	$	5,305	$	3,255
Wholesale inventory	36,129		35,885
Cultivation inventory	6,491		7,133
Supplies & other	3,125		3,173
Total	$	51,050	$	49,446

XML

DEBT (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Debt

The Company’s debt balances consist of the following:

Debt balances	September 30, 2023		December 31, 2022
Financing liability (failed sale-leaseback)	$	15,253	$	15,253
Finance lease liabilities	5,958		5,306
7.50% Loan due April 2026	31,682		31,288
6.10% Secured debenture due September 2030	46,841		46,502
Note due December 2024	2,375		3,167
Prime rate credit facilities due January 2026, as amended	130,989		113,564
Note backed by ERTC	1,640		—
Total debt	$	234,738	$	215,080
Less: current portion of debt	3,336		1,584
Total long-term debt	$	231,402	$	213,496

Schedule of Maturities of Debt

Scheduled maturities of debt, excluding amortization of discount and issuance costs, are as follows:

2023	$	2,432
2024	1,584
2025	—
2026	173,011
2027	39
Thereafter	71,160
Total payments (excluding amortization of discount and issuance costs)	$	248,226

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of Stock by Class

The table below details the change in Pubco shares outstanding by class for the nine months ended September 30, 2023:

Shareholders’ Equity	Fixed Shares	Floating Shares	Fixed Shares Held in Treasury	Floating Shares Held in Treasury	Fixed Multiple Shares	Total Shares Outstanding
December 31, 2022	79,047	34,114	(589)	(253)	118	112,437
Issuances	1,626	1,902	—	—	—	3,528
September 30, 2023	80,673	36,016	(589)	(253)	118	115,965

Schedule of Warrants

A summary of the warrants activity outstanding is as follows:

Warrants	Fixed Shares	Floating Shares
December 31, 2022	5,817	2,524
Expired	—	—
September 30, 2023	5,817	2,524

Schedule of Summarized Financial Information

Summarized financial information of HSCP is presented below. USCo2 does not have discrete financial information separate from HSCP.

HSCP net asset reconciliation	September 30, 2023			December 31, 2022
Current assets	$	89,448		$	118,193
Non-current assets	261,389			237,665
Current liabilities	(15,172)			(9,141)
Non-current liabilities	(254,751)			(239,525)
Other NCI balances	(726)			(725)
Accumulated equity-settled expenses	(243,182)			(240,760)
Net assets	$	(162,994)		$	(134,293)
HSCP/USCo2 ownership % of HSCP	15.93		%	16.33		%
Net assets allocated to USCo2/HSCP	$	(25,959)		$	(21,930)
Net assets attributable to other NCIs	726			725
Total NCI	$	(25,233)		$	(21,205)

	Three Months Ended September 30,						Nine Months Ended September 30,
HSCP Summarized Statement of Operations	2023			2022			2023			2022
Net loss allocable to HSCP/USCo2	$	(1,521)		$	(16,549)		$	(23,924)		$	(27,589)
HSCP/USCo2 weighted average ownership % of HSCP	15.37		%	16.84		%	16.23		%	16.96		%
Net loss allocated to HSCP/USCo2	$	(234)		$	(2,787)		$	(3,884)		$	(4,679)
Net loss allocated to other NCIs	—			3			(1)			4
Net loss attributable to NCIs	$	(234)		$	(2,784)		$	(3,885)		$	(4,675)

Schedule of Conversions of Stock

A reconciliation of the beginning and ending amounts of convertible units is as follows:

Convertible Units	September 30, 2023	December 31, 2022
Beginning balance	22,698	23,076
NCI units converted to Pubco	—	(378)
Ending balance	22,698	22,698

XML

EQUITY-BASED COMPENSATION EXPENSE (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Restricted Stock and Restricted Stock Unit, Activity

Restricted Share Units (“RSUs”)

	Fixed Shares			Floating Shares
Restricted Share Units (Fair value information expressed in whole dollars)	RSUs	Weighted Average Grant Date Fair Value		RSUs	Weighted Average Grant Date Fair Value
Unvested, January 1, 2023	6,324	$	1.80	464	$	6.68
Granted	3,646	$	0.15	7,870	$	0.23
Forfeited	(1,642)	$	0.90	(135)	$	1.15
Vested	(2,201)	$	1.29	(1,973)	$	0.60
Unvested, September 30, 2023	6,127	$	1.24	6,226	$	0.58
Vested and unreleased(1)	40	$	8.52	11	$	17.35
Outstanding, September 30, 2023	6,167	$	1.29	6,237	$	0.61

(1) RSUs that are vested and unreleased represent RSUs that are pending delivery.

Schedule of Option Activity

Stock options

	Fixed Shares			Floating Shares
Stock Options (Exercise price expressed in whole dollars)	Options	Weighted Average Exercise Price		Options	Weighted Average Exercise Price
Options outstanding, January 1, 2023	7,337	$	2.75	2,267	$	3.10
Forfeited	(1,875)	$	0.66	(131)	$	3.16
Expired	—	$	—	(35)	$	2.55
Options outstanding, September 30, 2023	5,462	$	3.46	2,101	$	3.10
Options exercisable, September 30, 2023	3,400	$	5.21	2,101	$	3.10

XML

EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

Basic and diluted loss per share is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Net loss attributable to common shareholders of the Company	$	(7,625)	$	(22,214)	$	(38,371)	$	(44,837)
Weighted average shares outstanding - basic	114,171		111,200		113,181		108,795
Effect of dilutive securities	—		—		—		—
Weighted average shares - diluted	114,171		111,200		113,181		108,795
Net loss per share attributable to common shareholders of the Company - basic	$	(0.07)	$	(0.20)	$	(0.34)	$	(0.41)
Net loss per share attributable to common shareholders of the Company - diluted	$	(0.07)	$	(0.20)	$	(0.34)	$	(0.41)

XML

NATURE OF OPERATIONS (Details) $ in Thousands	Oct. 24, 2022 Rate	Sep. 23, 2020 USD ($) shares	Jun. 27, 2019	Sep. 30, 2023
Class of Stock [Line Items]
Share conversion (as percent)			0.5818
Entity reorganization, fixed exchange ratio		0.3048
6.10% Secured debenture due September 2030
Class of Stock [Line Items]
Interest rate (as percent)				6.10%
6.10% Secured debenture due September 2030 | Universal Hemp
Class of Stock [Line Items]
Interest rate (as percent)				6.10%
Acreage Holdings | Canopy Growth and Canopy USA, LLC
Class of Stock [Line Items]
Consideration of common share (in shares) | Rate	45.00%
Universal Hemp | Canopy Growth | Canopy Growth | Debenture | Universal Hemp
Class of Stock [Line Items]
Debenture amount, amount advanced | $		$ 50,000
Fixed Shares
Class of Stock [Line Items]
Percent of share - canopy reorganization		0.7
Floating Shares
Class of Stock [Line Items]
Percent of share - canopy reorganization		0.3
PVS, Fixed Shares
Class of Stock [Line Items]
Canopy reorganization, shares exchanged (in shares)		28
PVS, Floating Shares
Class of Stock [Line Items]
Canopy reorganization, shares exchanged (in shares)		12
Fixed Multiple Share
Class of Stock [Line Items]
Percent of share - canopy reorganization		0.7
Floating Multiple Share
Class of Stock [Line Items]
Percent of share - canopy reorganization		0.3

XML

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Nov. 14, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 15,142	$ 26,476		$ 24,067
Restricted cash	9,651	$ 95		0
Allowance for credit losses, accounts receivable	339			953
Allowance for notes and interest receivable	15,340			$ 14,875
Allowance for credit losses over notes receivable	$ 0
Antidilutive shares (in shares)	51,006	47,999
6.10% Secured debenture due September 2030
Debt Instrument [Line Items]
Interest rate (as percent)	6.10%
6.10% Secured debenture due September 2030 | Universal Hemp
Debt Instrument [Line Items]
Interest rate (as percent)	6.10%
6.10% Secured debenture due September 2030 | Universal Hemp | Subsequent Event
Debt Instrument [Line Items]
Interest rate (as percent)			6.10%

XML

ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE - Narrative (Details)			1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 12, 2023 USD ($)	Jan. 02, 2023 USD ($)	Jul. 31, 2022 USD ($) dispensary	Sep. 30, 2021 USD ($) dispensary	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($) divestiture	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($) divestiture	Dec. 31, 2022 business	Apr. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Feb. 28, 2021 USD ($)
Business Acquisition [Line Items]
Number of businesses acquired | business									0
Gain (loss) on disposal							$ 47,000	$ 3,490,000
Number of divestitures | divestiture						6		6
Deferred tax (income) expense							16,000	$ (889,000)
Write down of assets held-for-sale					$ 0	$ 0	$ 3,557,000	874,000
Discontinued Operations, Disposed of by Sale | CWG
Business Acquisition [Line Items]
Ownership interest (as percent)	100.00%
Oregon
Business Acquisition [Line Items]
Number of dispensaries to be sold | dispensary			4
Oregon | Held-for-sale
Business Acquisition [Line Items]
Gain (loss) on disposal								3,189,000
Aggregate sales price			$ 6,200,000	$ 6,500,000
Number of dispensaries to be sold | dispensary				4
Cash consideration			100,000	$ 250,000
Remaining balance to acquire businesses			$ 5,850,000
Promissory note term			36 months
Promissory note stated interest rate (as percent)			12.00%
Annual principal payments			$ 1,000,000
CWG | Discontinued Operations, Disposed of by Sale
Business Acquisition [Line Items]
Gain (loss) on disposal	$ 47,000
Aggregate sales price	$ 500,000
Medford Cultivation and Processing Facility | Discontinued Operations, Disposed of by Sale
Business Acquisition [Line Items]
Gain (loss) on disposal								290,000
Aggregate sales price										$ 2,000,000		$ 3,000,000
Deferred tax (income) expense								$ 375,000
Medford Cultivation and Processing Facility | Held-for-sale
Business Acquisition [Line Items]
Aggregate sales price											$ 2,000,000
Medford Cultivation and Processing Facility | Disposed of by Sale, Additional Cash
Business Acquisition [Line Items]
Aggregate sales price												750,000
Medford Cultivation and Processing Facility | Disposed of by Sale, Promissory Note
Business Acquisition [Line Items]
Aggregate sales price												$ 1,250,000
Northeast Patients Group
Business Acquisition [Line Items]
Total consideration		$ 25,160,000

XML

ACQUISITIONS, DIVESTITURES AND ASSETS HELD FOR SALE - Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands	Jan. 02, 2023	Sep. 30, 2023	Dec. 31, 2022
Purchase Price Allocation
Goodwill		$ 38,721	$ 13,761
Northeast Patients Group
Purchase Price Allocation
Cash and cash equivalents	$ 361
Accounts Receivable	25
Inventory	384
Other current assets	173
Capital assets	2,377
Financing lease right-of-use asset	416
Operating lease right-of-use asset	1,279
Goodwill	24,960
Accounts payable and accrued liabilities	(672)
Taxes payable	(1,112)
Finance lease liability, current	(87)
Finance lease liability, non-current	(459)
Operating lease liability, current	(73)
Operating lease liability, non-current	(1,385)
Notes payable	(11)
Deferred tax liability	(1,016)
Fair value of net assets acquired	25,160
Consideration paid:
Settlement of pre-existing relationship	25,160
Total consideration	$ 25,160

XML

INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total finite-lived intangible assets	$ 0	$ 1,000
Total accumulated amortization on finite-lived intangible assets	0	(1,000)
Finite-lived intangible assets, net	0	0
Indefinite-lived intangible assets	35,124	35,124
Total intangibles, net	35,124	35,124
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Total finite-lived intangible assets	0	1,000
Total accumulated amortization on finite-lived intangible assets	$ 0	$ (1,000)

XML

INTANGIBLE ASSETS AND GOODWILL - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill re-allocated					$ 17,000
Intangible assets, adjustments					$ 17,000
Amortization of intangible assets	$ 0	$ 296	$ 0	$ 1,288
Acquisitions			$ 24,960

XML

INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 13,761
Acquisitions	24,960
Goodwill, ending balance	$ 38,721

XML

INVESTMENTS - Schedule of Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Investments [Abstract]
Investments held at FV-NI	$ 33,176	$ 34,046
Total long-term investments	$ 33,176	$ 34,046

XML

INVESTMENTS - Schedule of Investment Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net Investment Income [Line Items]
Income from investments, net	$ 248	$ 17	$ 228	$ 154
Short-term investments
Net Investment Income [Line Items]
Income from investments, net	0	1	0	4
Investments held at FV-NI
Net Investment Income [Line Items]
Income from investments, net	$ 248	$ 16	$ 228	$ 150

XML

INVESTMENTS - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Sep. 28, 2020	Sep. 23, 2020	Sep. 30, 2023
Subsidiary or Equity Method Investee [Line Items]
Proceeds from secured debenture		$ 50,000
Amount invested	$ 34,019
Universal Hemp | Investment Partnership
Subsidiary or Equity Method Investee [Line Items]
Financial interest in the investment partnership (as percent)	100.00%
Universal Hemp | Investment Partnership | Investment Partnership
Subsidiary or Equity Method Investee [Line Items]
Financial interest in the investment partnership (as percent)	100.00%
Universal Hemp | Class B Units | Investment Partnership
Subsidiary or Equity Method Investee [Line Items]
Number of shares acquired (in shares)	34,019
Par value (in USD per share)	$ 1
Universal Hemp | Class B Units | Investment Partnership | Investment Partnership
Subsidiary or Equity Method Investee [Line Items]
Financial interest in the investment partnership (as percent)	100.00%
6.10% Secured debenture due September 2030
Subsidiary or Equity Method Investee [Line Items]
Interest rate (as percent)		6.10%	6.10%

XML

NOTES RECEIVABLE, NET - Schedule of Notes Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest receivable	$ 3,947	$ 4,147
Allowance for notes and interest receivable	(15,340)	(14,875)
Total notes receivable, net	0	29,191
Less: Notes receivable, current	0	29,191
Notes receivable, non-current	0	0
Promissory notes receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Principal outstanding	7,062	34,088
Line of credit receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Principal outstanding	$ 4,331	$ 5,831

XML

NOTES RECEIVABLE, NET - Narrative (Details) $ in Thousands	1 Months Ended							3 Months Ended		9 Months Ended
	Aug. 31, 2023 USD ($)	May 31, 2023 USD ($)	Apr. 30, 2023 USD ($)	Jul. 31, 2022 USD ($) dispensary	Apr. 30, 2022 USD ($)	Feb. 28, 2022 USD ($)	Sep. 30, 2021 dispensary	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Aug. 31, 2022 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest income from loans receivable								$ 0	$ 474	$ 10	$ 1,256
Allowance for notes and interest receivable								15,340		15,340		$ 14,875
Oregon
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of dispensaries to be sold | dispensary				4
Oregon | Held-for-sale
Accounts, Notes, Loans and Financing Receivable [Line Items]
Promissory note term				36 months
Remaining balance to acquire businesses				$ 5,850
Promissory note stated interest rate (as percent)				12.00%
Number of dispensaries to be sold | dispensary							4
Grown Rogue
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collection of notes receivable	$ 150	$ 500
Patient Centric Martha's Vineyard
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collection of notes receivable						$ 5,279
Prime Alternative Treatment Center Consulting, LLC (“NH-PATCC”) | Prime Alternative Treatment Center, Inc. ("PATC")
Accounts, Notes, Loans and Financing Receivable [Line Items]
Collection of notes receivable			$ 1,500
Principal
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for notes and interest receivable								11,393		11,393		12,041
Accrued Interest
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for notes and interest receivable								$ 3,947		$ 3,947		$ 2,834
Interest Bearing Notes Receivable | Oregon
Accounts, Notes, Loans and Financing Receivable [Line Items]
Promissory note term					12 months
Remaining balance to acquire businesses					$ 1,250								$ 500
Promissory note stated interest rate (as percent)					12.50%								12.50%
Non-Interest Bearing Notes Receivable | Oregon
Accounts, Notes, Loans and Financing Receivable [Line Items]
Non - interest secured promissory note													$ 750

XML

CAPITAL ASSETS, NET - Schedule of Capital Assets, net (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Right-of-use asset, finance leases	$ 6,297	$ 5,077
Capital assets, gross	179,794	160,440
Less: accumulated depreciation and amortization	(42,928)	(27,035)
Capital assets, net	136,866	133,405
Land
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	9,778	9,605
Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	58,524	58,334
Furniture, fixtures and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	40,701	46,811
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	49,611	6,178
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 14,883	$ 34,435

XML

CAPITAL ASSETS, NET - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 928,000	$ 751,000	$ 2,919,000	$ 4,731,000
Depreciation capitalized to inventory	2,116,000	1,963,000	6,493,000	5,679,000
Assets	$ 355,784,000		$ 355,784,000		$ 360,573,000
Assets related to Michigan Operations
Property, Plant and Equipment [Line Items]
Assets		$ 0		0
Impairment charge				$ 1,907,000

XML

LEASES - Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Right-of-use assets
Operating	$ 18,699	$ 22,443
Finance	4,597	4,269
Total right-of-use assets	$ 23,296	$ 26,712
Finance lease, right-of-use asset, statement of financial position	Capital assets, net	Capital assets, net
Lease liabilities
Operating lease liability, current	$ 2,535	$ 2,443
Finance lease liability, current	112	1
Operating lease liability, non-current	18,298	21,692
Finance lease liability, noncurrent	5,846	5,305
Total lease liabilities	$ 26,791	$ 29,441
Finance lease, liability, current, statement of financial position, extensible list	Debt, current	Debt, current
Finance lease, liability, non-current, statement of financial position, extensible list	Debt, non-current	Debt, non-current

XML

LEASES - Income Statement Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Short-term lease expense	$ 102	$ (28)	$ 311	$ 190
Operating lease expense	1,238	1,221	3,853	3,613
Amortization of right of use asset	93	63	278	190
Interest expense on lease liabilities	213	314	633	855
Net operating and finance lease cost	$ 1,544	$ 1,598	$ 4,764	$ 4,658

XML

LEASES - Cash Flow Statement Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Cash paid for operating leases	$ 3,871	$ 3,390
Cash paid for finance leases - interest	$ 718	$ 843

XML

LEASES - Lease Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Operating Leases
2023	$ 1,085
2024	4,285
2025	4,104
2026	4,314
2027	3,897
Thereafter	13,276
Total lease payments	30,961
Less: interest	10,128
Present value of lease liabilities	$ 20,833
Weighted average remaining lease term (years)	8 years
Weighted average discount rate	10.00%
Finance Leases
2023	$ 228
2024	923
2025	946
2026	969
2027	992
Thereafter	11,705
Total lease payments	15,763
Less: interest	9,805
Present value of lease liabilities	$ 5,958	$ 5,306
Weighted average remaining lease term (years)	11 years
Weighted average discount rate	12.00%

XML

LEASES - Narrative (Details)	Sep. 30, 2023 lease
Leases [Abstract]
Number of leases not yet commenced	0

XML

INVENTORY - Schedule of Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Retail inventory	$ 5,305	$ 3,255
Wholesale inventory	36,129	35,885
Cultivation inventory	6,491	7,133
Supplies & other	3,125	3,173
Total	$ 51,050	$ 49,446

XML

INVENTORY - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventory write-down	$ 2,103	$ 6,286	$ 8,824	$ 6,286

XML

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 28, 2020
Debt Instrument [Line Items]
Financing liability (failed sale-leaseback)	$ 15,253	$ 15,253
Finance lease liabilities	5,958	5,306
Total debt	234,738	215,080
Less: current portion of debt	3,336	1,584
Total long-term debt	$ 231,402	213,496
7.50% Loan due April 2026
Debt Instrument [Line Items]
Interest rate (as percent)	7.50%		7.50%
Loans	$ 31,682	31,288
6.10% Secured debenture due September 2030
Debt Instrument [Line Items]
Interest rate (as percent)	6.10%
Loans	$ 46,841	46,502
Note due December 2024
Debt Instrument [Line Items]
Loans	2,375	3,167
Prime rate credit facilities due January 2026, as amended
Debt Instrument [Line Items]
Loans	130,989	113,564
Note backed by ERTC
Debt Instrument [Line Items]
Loans	$ 1,640	$ 0

XML

DEBT - Schedule of Maturities of Debt (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Debt Disclosure [Abstract]
2023	$ 2,432
2024	1,584
2025	0
2026	173,011
2027	39
Thereafter	71,160
Total payments (excluding amortization of discount and issuance costs)	$ 248,226

XML

DEBT - Narrative (Details) $ / shares in Units, shares in Thousands						1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 11, 2023 USD ($)	Oct. 24, 2022 USD ($)	Dec. 16, 2021 USD ($) leverage_ratio	Sep. 28, 2020 USD ($) $ / shares shares	Sep. 23, 2020 USD ($)	Apr. 30, 2022 USD ($)	Nov. 30, 2020 USD ($) payment	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Nov. 14, 2023	Apr. 28, 2023 USD ($)	Jan. 01, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Interest expense								$ 9,207,000	$ 5,688,000	$ 26,143,000	$ 15,989,000
Debt discount amortization								547,000	381,000	1,562,000	1,132,000
Amortization of debt issuance costs								706,000	$ 297,000	2,094,000	$ 849,000
Unamortized discounts								5,030,000		5,030,000					$ 6,093,000
Debt issuance costs								8,458,000		8,458,000					10,522,000
Interest payable								$ 5,676,000		$ 5,676,000					$ 2,575,000
Amount invested				$ 34,019,000
Repayment of short-term debt				$ 18,000,000
Amendment fee			$ 413,000
Number of debt payments | payment							10
Amended Credit Facility
Debt Instrument [Line Items]
Fee amount		$ 1,250,000
Amount available for immediate draw		$ 25,000											$ 140,000
Additional borrowing capacity													$ 15,000
Maturity extension option fee (percent)		1.00%
Maturity extension option, periodic payment fee (percent)		5.00%
Amended Credit Facility | Prime
Debt Instrument [Line Items]
Variable rate (as percent)		5.75%
Prime floor (as percent)		5.50%
CanWell Settlement
Debt Instrument [Line Items]
Accrued loss contingency loss							$ 7,750,000
Universal Hemp | Investment Partnership
Debt Instrument [Line Items]
Financial interest in the investment partnership (as percent)				100.00%
Universal Hemp | Universal Hemp
Debt Instrument [Line Items]
Amount invested				$ 34,019,000
Universal Hemp | Canopy Growth | Canopy Growth | Debenture | Universal Hemp
Debt Instrument [Line Items]
Debenture amount, amount advanced					$ 50,000,000
Debt issuance costs					4,025,000
11065220 Canada Inc | Canopy Growth | Canopy Growth
Debt Instrument [Line Items]
Face amount					$ 100,000,000
11065220 Canada Inc | Canopy Growth | Canopy Growth | Debenture
Debt Instrument [Line Items]
Interest rate (as percent)					6.10%
Debenture amount, amount advanced					$ 50,000,000
Debenture amount, amount to be advanced					$ 50,000,000
Debt term (in years)					10 years
Investment Partnership | Universal Hemp | Investment Partnership
Debt Instrument [Line Items]
Financial interest in the investment partnership (as percent)				100.00%
Investment Partnership | Universal Hemp | Class B Units
Debt Instrument [Line Items]
Number of shares acquired (in shares) | shares				34,019
Par value (in USD per share) | $ / shares				$ 1
Investment Partnership | Universal Hemp | Class B Units | Investment Partnership
Debt Instrument [Line Items]
Financial interest in the investment partnership (as percent)				100.00%
Investment Partnership | Universal Hemp | Class A Units
Debt Instrument [Line Items]
Amount invested				$ 1,019,000
6.10% Secured debenture due September 2030
Debt Instrument [Line Items]
Interest rate (as percent)					6.10%			6.10%		6.10%
6.10% Secured debenture due September 2030
Debt Instrument [Line Items]
Interest rate (as percent)								6.10%		6.10%
6.10% Secured debenture due September 2030 | Universal Hemp
Debt Instrument [Line Items]
Interest rate (as percent)								6.10%		6.10%
6.10% Secured debenture due September 2030 | Universal Hemp | Subsequent Event
Debt Instrument [Line Items]
Interest rate (as percent)												6.10%
7.50% Loan due April 2026
Debt Instrument [Line Items]
Interest rate (as percent)				7.50%				7.50%		7.50%
Debenture amount, amount advanced				$ 33,000,000
Debt issuance costs				$ 959,000
Debt term (in years)				3 years
Securities Purchase Agreement | Convertible Debt
Debt Instrument [Line Items]
Repayment of short-term debt				$ 11,000,000
Prime rate credit facilities due January 2026, as amended
Debt Instrument [Line Items]
Unamortized discounts			4,000,000
Debt issuance costs			1,500,000
Face amount			150,000,000
Proceeds from issuance of debt			75,000,000
Fee amount			$ 500,000
Number of leverage ratios | leverage_ratio			2
Minimum cash requirement			$ 9,000,000
Prime rate credit facilities due January 2026, as amended | Amended Credit Facility | Prime
Debt Instrument [Line Items]
Variable rate (as percent)		1.00%
Prime Rate Credit Facilities Due January 2026, Initial Draw
Debt Instrument [Line Items]
Face amount			75,000,000
Prime Rate Credit Facilities Due January 2026, Delayed Draw
Debt Instrument [Line Items]
Face amount			$ 25,000,000
Proceeds from delayed draw facility						$ 25,000,000
Delayed draw, term for issuance (in months)			12 months
Prime Rate Credit Facilities Due January 2026, Committed Accordion Facility
Debt Instrument [Line Items]
Face amount			$ 50,000,000
Line of credit facility, remaining borrowing capacity														$ 25,000
Note backed by ERTC | ERTC Factoring Agreement
Debt Instrument [Line Items]
Interest rate (as percent)	10.00%
Proceeds from sale of finance receivables	$ 12,113,000
Interest in employee retention tax credit assigned to the lender	$ 14,251,000
Proceeds from ERTC claims								$ 10,472,000		$ 10,472,000

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Stock by Class (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2023 shares
Class Of Stock [Roll Forward]
Common stock, outstanding, beginning (in shares)	112,437
Treasury stock, beginning (in shares)	(842)
Common stock, outstanding, ending (in shares)	115,965
Treasury stock, ending (in shares)	(842)
Fixed Shares | Pubco
Class Of Stock [Roll Forward]
Common stock, outstanding, beginning (in shares)	79,047
Issuances (in shares)	1,626
Common stock, outstanding, ending (in shares)	80,673
Floating Shares | Pubco
Class Of Stock [Roll Forward]
Common stock, outstanding, beginning (in shares)	34,114
Issuances (in shares)	1,902
Common stock, outstanding, ending (in shares)	36,016
Fixed Shares Held in Treasury | Pubco
Class Of Stock [Roll Forward]
Treasury stock, beginning (in shares)	(589)
Issuances (in shares)	0
Treasury stock, ending (in shares)	(589)
Floating Shares Held in Treasury | Pubco
Class Of Stock [Roll Forward]
Treasury stock, beginning (in shares)	(253)
Issuances (in shares)	0
Treasury stock, ending (in shares)	(253)
Fixed Multiple Shares | Pubco
Class Of Stock [Roll Forward]
Common stock, outstanding, beginning (in shares)	118
Issuances (in shares)	0
Common stock, outstanding, ending (in shares)	118
Total Shares Outstanding | Pubco
Class Of Stock [Roll Forward]
Common stock, outstanding, beginning (in shares)	112,437
Issuances (in shares)	3,528
Common stock, outstanding, ending (in shares)	115,965

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Warrants (Details) shares in Thousands	9 Months Ended
	Sep. 30, 2023 shares
Fixed Shares
Class Of Warrant Or Right [Roll Forward]
Beginning balance (in shares)	5,817
Expired (in shares)	0
Ending balance (in shares)	5,817
Floating Shares
Class Of Warrant Or Right [Roll Forward]
Beginning balance (in shares)	2,524
Expired (in shares)	0
Ending balance (in shares)	2,524

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Warrants (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares
Class of Warrant or Right [Line Items]
Warrants term (in years)	4 years
Warrant contractual weighted average life remaining (in years)	1 year 3 months 18 days
Aggregate intrinsic value | $	$ 0
Fixed Shares | Minimum
Class of Warrant or Right [Line Items]
Exercise price (in USD per share)	$ 3.15
Fixed Shares | Maximum
Class of Warrant or Right [Line Items]
Exercise price (in USD per share)	4.00
Floating Shares | Minimum
Class of Warrant or Right [Line Items]
Exercise price (in USD per share)	3.01
Floating Shares | Maximum
Class of Warrant or Right [Line Items]
Exercise price (in USD per share)	$ 4.00

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Non-Controlling Interests - Convertible Units (Details)	Sep. 30, 2023
Equity [Abstract]
USCo2 conversion, fixed share	0.7
USCo2 conversion, floating share	0.3
USCo2 Ownership of HSCP (as percent)	0.22%
HSCP ownership by LLC members (as percent)	16.01%
HSCP owned by Pubco (as percent)	83.77%

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Summarized Financial Information (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Subsidiary-specific information [Line Items]
Current assets	$ 89,679	$ 118,193
Non-current assets	266,105	242,380
Current liabilities	(96,667)	(72,333)
Non-current liabilities	(263,315)	(248,061)
Total NCI	(25,233)	(21,205)
HSCP LLC
Subsidiary-specific information [Line Items]
Current assets	89,448	118,193
Non-current assets	261,389	237,665
Current liabilities	(15,172)	(9,141)
Non-current liabilities	(254,751)	(239,525)
Other NCI balances	(726)	(725)
Accumulated equity-settled expenses	(243,182)	(240,760)
Net assets	(162,994)	(134,293)
Net assets allocated to USCo2/HSCP	(25,959)	(21,930)
Net assets attributable to other NCIs	$ 726	$ 725
HSCP LLC | HSCP/USCo2
Subsidiary-specific information [Line Items]
HSCP/USCo2 ownership % of HSCP	15.93%	16.33%

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Noncontrolling Interest, P&L Allocation (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Subsidiary-specific information [Line Items]
Net loss allocable to HSCP/USCo2	$ (7,859)	$ (18,240)	$ (16,157)	$ (24,998)	$ (10,603)	$ (13,911)	$ (42,256)	$ (49,512)
Net loss attributable to NCIs	(234)			(2,784)			(3,885)	(4,675)
HSCP LLC
Subsidiary-specific information [Line Items]
Net loss allocable to HSCP/USCo2	$ (1,521)			$ (16,549)			$ (23,924)	$ (27,589)
HSCP/USCo2 weighted average ownership % of HSCP	15.37%			16.84%			16.23%	16.96%
Net loss allocated to HSCP/USCo2	$ (234)			$ (2,787)			$ (3,884)	$ (4,679)
Net loss allocated to other NCIs	$ 0			$ 3			$ (1)	$ 4

XML

SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTERESTS - Schedule of Conversions by Stock (Details) - shares shares in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Convertible Units Outstanding [Roll Forward]
Beginning balance	22,698	23,076
NCI units converted to Pubco	0	(378)
Ending balance	22,698	22,698

XML

EQUITY-BASED COMPENSATION EXPENSE - Expense by Plan (Details) - Equity-based compensation - Plan shares in Thousands	9 Months Ended
	Sep. 30, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock	15.00%
Shares available for grant (in shares)	959

XML

EQUITY-BASED COMPENSATION EXPENSE - Schedule of Restricted Stock and Restricted Stock Unit, Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restricted Stock Units, Fixed
RSUs
Beginning Balance (in shares)			6,324
Granted (in shares)			3,646
Forfeited (in shares)			(1,642)
Vested (in shares)			(2,201)
Ending Balance (in shares)	6,127		6,127
Vested and unreleased (in shares)	40		40
Outstanding (in shares)	6,167		6,167
Weighted Average Grant Date Fair Value
Beginning Balance (in USD per share)			$ 1.80
Granted (in USD per share)			0.15
Forfeited (in USD per share)			0.90
Vested (in USD per share)			1.29
Ending Balance (in USD per share)	$ 1.24		1.24
Vested and unreleased (in USD per share)	8.52		8.52
Outstanding (in USD per share)	$ 1.29		$ 1.29
Restricted Stock Units, Floating
RSUs
Beginning Balance (in shares)			464
Granted (in shares)			7,870
Forfeited (in shares)			(135)
Vested (in shares)			(1,973)
Ending Balance (in shares)	6,226		6,226
Vested and unreleased (in shares)	11		11
Outstanding (in shares)	6,237		6,237
Weighted Average Grant Date Fair Value
Beginning Balance (in USD per share)			$ 6.68
Granted (in USD per share)			0.23
Forfeited (in USD per share)			1.15
Vested (in USD per share)			0.60
Ending Balance (in USD per share)	$ 0.58		0.58
Vested and unreleased (in USD per share)	17.35		17.35
Outstanding (in USD per share)	$ 0.61		$ 0.61
Restricted Stock Units (RSUs)
Weighted Average Grant Date Fair Value
Requisite service period (in years)			3 years
Equity-based compensation expense	$ 791	$ 2,256	$ 2,019	$ 7,645
Fair value	890	$ 1,427	$ 1,489	$ 4,760
Weighted average remaining contractual term (in years)			10 months 24 days
Aggregate intrinsic value, outstanding	4,612		$ 4,612
Unrecognized compensation expense	$ 10,436		$ 10,436
Unrecognized compensation expense, period (in years)			1 year

XML

EQUITY-BASED COMPENSATION EXPENSE - Schedule of Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Weighted Average Exercise Price
Weighted average remaining contractual term (in years)			4 years 3 months 18 days
Weighted average remaining contractual term, exercisable (in years)			4 years 8 months 12 days
Cost not yet recognized	$ 596		$ 596
Fixed Shares
Options
Beginning balance (in shares)			7,337
Forfeited (in shares)			(1,875)
Expired (in shares)			0
Ending balance (in shares)	5,462		5,462
Exercisable (in shares)	3,400		3,400
Weighted Average Exercise Price
Beginning balance (in USD per share)			$ 2.75
Forfeited (in USD per share)			0.66
Expired (in USD per share)			0
Ending balance (in USD per share)	$ 3.46		3.46
Exercisable (in USD per share)	$ 5.21		$ 5.21
Aggregate intrinsic value for options outstanding	$ 0		$ 0
Floating Shares
Options
Beginning balance (in shares)			2,267
Forfeited (in shares)			(131)
Expired (in shares)			(35)
Ending balance (in shares)	2,101		2,101
Exercisable (in shares)	2,101		2,101
Weighted Average Exercise Price
Beginning balance (in USD per share)			$ 3.10
Forfeited (in USD per share)			3.16
Expired (in USD per share)			2.55
Ending balance (in USD per share)	$ 3.10		3.10
Exercisable (in USD per share)	$ 3.10		$ 3.10
Options
Weighted Average Exercise Price
Vesting period (in years)			3 years
Weighted average remaining contractual term (in years)			6 years 2 months 12 days
Weighted average remaining contractual term, exercisable (in years)			6 years 2 months 12 days
Equity-based compensation expense	$ (46)	$ 300	$ 404	$ 725
Unrecognized compensation expense, period (in years)			2 years
Options | Minimum
Weighted Average Exercise Price
Expiration period (in years)			5 years
Options | Maximum
Weighted Average Exercise Price
Expiration period (in years)			10 years

XML

COMMITMENTS AND CONTINGENCIES - Commitments and Prior Plan of Arrangement with Canopy Growth (Details) $ in Thousands	Sep. 30, 2023 USD ($) line_of_credit	Jun. 19, 2019 company
Commitments and Contingencies Disclosure [Abstract]
Number of lines of credit | line_of_credit	1
Credit facility amount	$ 4,331
Credit facility	$ 4,331
Number of companies involved In agreement | company		2

XML

COMMITMENTS AND CONTINGENCIES - Second Amendment to the Arrangement Agreement (Details) $ in Thousands	Sep. 23, 2020 USD ($) shares
Business Acquisition [Line Items]
Cash payment | $	$ 37,500
Fixed shares percent - canopy reorganization	0.3048
Expiration period - canopy reorganization	10 years
Canopy Growth
Business Acquisition [Line Items]
Maximum number of shares allowed for issuance under agreement (in shares)	32,700,000
Fixed Shares
Business Acquisition [Line Items]
Percent of share - canopy reorganization	0.7
Floating Shares
Business Acquisition [Line Items]
Percent of share - canopy reorganization	0.3
PVS, Fixed Shares
Business Acquisition [Line Items]
Canopy reorganization, shares exchanged (in shares)	28
PVS, Floating Shares
Business Acquisition [Line Items]
Canopy reorganization, shares exchanged (in shares)	12
Fixed Multiple Share
Business Acquisition [Line Items]
Percent of share - canopy reorganization	0.7
Floating Multiple Share
Business Acquisition [Line Items]
Percent of share - canopy reorganization	0.3

XML

COMMITMENTS AND CONTINGENCIES - Third Amendment to the Arrangement Agreement with Canopy Growth (Details) - Acreage Holdings - Canopy Growth and Canopy USA, LLC	Oct. 24, 2022 Rate
Loss Contingencies [Line Items]
Consideration of common share (in shares)	45.00%
Amended Credit Facility
Loss Contingencies [Line Items]
Consideration of common share (in shares)	30.48%
Percentage of voting interests acquired (as percent)	70.00%

XML

COMMITMENTS AND CONTINGENCIES - Tax Receivable Agreement and Tax Receivable Bonus Plans (Details) - Canopy Growth Corporation - USD ($) $ in Thousands	Mar. 17, 2023	Nov. 04, 2022	Oct. 24, 2022
Certain Current or Former Unit Holders Of HSCP | Canopy Growth and Canopy USA, LLC
Loss Contingencies [Line Items]
Value of Canopy shares issuable under the agreement			$ 30,500
Certain Directors, Officers or Consultants of Acreage | High Street Capital Partners, LLC (“HSCP”)
Loss Contingencies [Line Items]
Value of Canopy shares issuable under the agreement			19,500
Potential liability			121,000
Certain Holders | High Street Capital Partners, LLC (“HSCP”) | Tax Receivable Agreement
Loss Contingencies [Line Items]
TRA, number of shares issued (in shares)	7,102,081	5,648,927
Certain Eligible Participants | Canopy Growth and Canopy USA, LLC
Loss Contingencies [Line Items]
TRA final payment issuable			$ 19,500

XML

COMMITMENTS AND CONTINGENCIES - Debenture (Details) - 11065220 Canada Inc - Canopy Growth - Canopy Growth	Sep. 23, 2020 USD ($)
Business Acquisition [Line Items]
Face amount	$ 100,000,000
Debenture
Business Acquisition [Line Items]
Debenture amount, amount advanced	50,000,000
Debenture amount, amount to be advanced	$ 50,000,000
EBITDA ratio measurement period	90 days
Interest coverage ratio	2.0
Interest rate (as percent)	6.10%
Debt term (in years)	10 years
Period non-core divestitures are completed	18 months
Remediation period upon receipt of written notice	30 days

XML

COMMITMENTS AND CONTINGENCIES - Advisor Fee (Details) - USD ($) $ in Thousands		3 Months Ended
	Jun. 19, 2019	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Advisor fee	$ 7,000	$ 3,000
Intial payment of advisor		500
Payment to advisor in share value		$ 2,000

XML

COMMITMENTS AND CONTINGENCIES - Surety Bonds (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Indemnification obligation, surety bonds	$ 5,000

XML

COMMITMENTS AND CONTINGENCIES - Canwell Settlement (Details) - CanWell Settlement - USD ($) $ in Thousands	1 Months Ended	35 Months Ended
	Nov. 30, 2020	Sep. 30, 2023
Loss Contingencies [Line Items]
Accrued loss contingency loss	$ 7,750
Repayments of promissory note		$ 5,375

XML

COMMITMENTS AND CONTINGENCIES - New York Outstanding Litigation and Lease Dispute (Details)	Nov. 02, 2018 defendant
New York Outstanding Litigation
Loss Contingencies [Line Items]
Number of defendants	16

XML

COMMITMENTS AND CONTINGENCIES - Alfred’s Finest, Inc. Arbitration (Details) - Alfred’s Finest, Inc $ in Thousands	Jun. 22, 2023 USD ($)
Loss Contingencies [Line Items]
Proceed to settlement payment	$ 2,000
Litigation settlement, additional amount awarded to payment	$ 3,000

XML

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			3 Months Ended		9 Months Ended
	Sep. 28, 2020	Sep. 23, 2020	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Oct. 24, 2022	Dec. 16, 2021
Related Party Transaction [Line Items]
Amount invested	$ 34,019
Interest expense			$ 9,207	$ 5,688	$ 26,143	$ 15,989
Repayment of short-term debt	$ 18,000
Amended Credit Facility
Related Party Transaction [Line Items]
Fee amount							$ 1,250
Universal Hemp | Investment Partnership
Related Party Transaction [Line Items]
Financial interest in the investment partnership (as percent)	100.00%
Universal Hemp | Investment Partnership | MB Melody LP | Class B Units
Related Party Transaction [Line Items]
Number of shares acquired (in shares)	34,019
Par value (in USD per share)	$ 1
Universal Hemp | Universal Hemp
Related Party Transaction [Line Items]
Amount invested	$ 34,019
Universal Hemp | Canopy Growth | Canopy Growth | Debenture | Universal Hemp
Related Party Transaction [Line Items]
Debenture amount, amount advanced		$ 50,000
Debt issuance costs		$ 4,025
Viridescent Realty Trust, Inc | Amended Credit Facility
Related Party Transaction [Line Items]
Fee amount							$ 375
6.10% Secured debenture due September 2030
Related Party Transaction [Line Items]
Interest rate (as percent)		6.10%	6.10%		6.10%
6.10% Secured debenture due September 2030 | Related Party
Related Party Transaction [Line Items]
Interest expense			$ 763		$ 2,289
7.50% Loan due April 2026
Related Party Transaction [Line Items]
Interest rate (as percent)	7.50%		7.50%		7.50%
Debenture amount, amount advanced	$ 33,000
Debt issuance costs	959
Securities Purchase Agreement | Convertible Debt
Related Party Transaction [Line Items]
Repayment of short-term debt	$ 11,000
Prime rate credit facilities due January 2026, as amended
Related Party Transaction [Line Items]
Fee amount								$ 500
Prime rate credit facilities due January 2026, as amended | Viridescent Realty Trust, Inc
Related Party Transaction [Line Items]
Debt instrument, committed amount								42,000
Prime rate credit facilities due January 2026, as amended | Viridescent Realty Trust, Inc | Related Party
Related Party Transaction [Line Items]
Interest expense			$ 1,522		$ 4,212
Prime rate credit facilities due January 2026, as amended | Third-Party Syndicated Affiliates
Related Party Transaction [Line Items]
Debt instrument, committed amount								98,000
Prime Rate Credit Facilities Due January 2026, Initial Draw | Viridescent Realty Trust, Inc
Related Party Transaction [Line Items]
Debt instrument, committed amount								$ 140,000

XML

REPORTABLE SEGMENTS (Details)	9 Months Ended
	Sep. 30, 2023 segment
Segment Reporting [Abstract]
Number of reportable segments	1

XML

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss attributable to common shareholders of the Company	$ (7,625)	$ (22,214)	$ (38,371)	$ (44,837)
Weighted average shares outstanding - basic (in share)	114,171	111,200	113,181	108,795
Effect of dilutive securities (in shares)	$ 0	$ 0	$ 0	$ 0
Weighted average shares - diluted (in shares)	114,171	111,200	113,181	108,795
Net loss per share attributable to common shareholders of the Company - basic (in USD per share)	$ (0.07)	$ (0.20)	$ (0.34)	$ (0.41)
Net loss per share attributable to common shareholders of the Company - diluted (in USD per share)	$ (0.07)	$ (0.20)	$ (0.34)	$ (0.41)
Antidilutive shares (in shares)			51,006	47,999
Fixed Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			5,817	5,817
Floating Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			2,524	2,524
Fixed Share RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			6,167	6,786
Floating Share RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			6,237	534
Fixed Share Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			5,462	7,337
Floating Share Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			2,101	2,303
NCI Convertible Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)			22,698	22,698